

***3.5.1 Number of Collaborative activities for
research, Faculty exchange, Student
exchange/ internship per year***

**Vishnu Institute of Pharmaceutical Education and Research
Narsapur, Medak District – 502 313, TS**

LIST OF COLLABORATIVE ACTIVITIES

S.No.	Title of the collaborative activity	Name of the collaborating agency with contact details	Name of the participant	Year of collaboration	Duration in days
1	Design and development of a fixed dose combination of three anti-retroviral drugs	Aizant Drug Research Solutions Pvt. Ltd., Sy. No. 172 & 173, Quthbullapur Mandal, Apparel Park Rd, Dulapally, Hyderabad, Telangana 500100	Mr. B. Chandra Siva Naga Raju	2020-2021	264
2	Training in Bioanalytical department	Aizant Drug Research Solutions Pvt. Ltd., Sy. No. 172 & 173, Quthbullapur Mandal, Apparel Park Rd, Dulapally, Hyderabad, Telangana 500100	Ms. Sathoor Harshitha	2020-2021	267
3	Analytical Method development and validation for the simultaneous determination of Ivermectin and Albendazole in active pharmaceutical ingredient and marketed tablet dosage form by RP-HPLC	Sura Labs, S.S. Towers, Dilsukhnagar, Hyderabad - 500060, Telangana, India #9951919887 Email: suralabshyd@gmail.com	Ms. Palugu Sirisha	2020 - 2021	240
4	Development and validation of RP-HPLC method for the simultaneous determination of Niacin and Simvastatin in active pharmaceutical ingredient and combined tablet dosage form	Sura Labs, S.S. Towers, Dilsukhnagar, Hyderabad - 500060, Telangana, India #9951919887 Email: suralabshyd@gmail.com	Ms. M. Sushmitha	2020 - 2021	240
5	Simultaneous estimation of Indacaterol and	Sura Labs, S.S. Towers, Dilsukhnagar, Hyderabad -	Ms. CH. Sanjuna	2020 - 2021	240

	Glycopyrrolate in pure and marketed tablet form by using RP-HPLC	500060, Telangana, India #9951919887 Email: suralabshvd@gmail.com			
6	3D-printing technology in pharmaceutical dosage forms: Advantages and challenges	KL (Deemed to be University)Green Fields, Vaddeswaram, Andhra Pradesh 522502	Dr. K. Vanitha	2020-2021	90
7	Effects of different monosaccharides on thermal stability of phycobiliproteins from <i>Oscillatoria</i> sp. (BTA-170): Analysis of kinetics, thermodynamics, colour and antioxidant properties	NIT, Agarthala	Dr. K. Vanitha	2020-2021	90
8	Nutritional impact of foods made from spirulina on children of selected anganwadis of siddipet district in telangana state in India	Sukrutha Organics, Punjagutta, Hyderabad	Dr. K. Vanitha	2019-2020	90
9	Development of nitric oxide releasing quinoline derivatives as inhibitors of doxorubicin resistance in cancer cells	BogaR Laboratories Peddapuram - Rayabhupalapatnam Rd, Andhra Pradesh 533437	Dr. VVS Rajendra Prasad	2019 - 2020	365
10	ELISA testing for biological samples	Chemiloids Life Sciences Auto Nagar 7th Line, Auto Nagar, Vijayawada, Andhra Pradesh 520007	Dr. VVS Rajendra Prasad	2019 - 2020	365
11	Simultaneous Estimation of New Analytical Method Development And Validation of Dolutegravir And	Sura Labs, S.S. Towers, Dilsukhnagar, Hyderabad - 500060, Telangana, India #9951919887 Email:	Ms. Afreen Khanam	2019 - 2020	520

	Lamivudine By High Performance Liquid Chromatography	suralabshyd@gmail.com			
12	Simultaneous Determination Of Darunavir And Cobicistat In Bulk Form And Combined Marketed Formulation By Using Reverse Phase - Hplc Method	Sura Labs, S.S. Towers, Dilsukhnagar, Hyderabad - 500060, Telangana, India #9951919887 Email: suralabshyd@gmail.com	Ms. Chaplala Umarani	2019 - 2020	520
13	Development Of A New Analytical Method And Validation Of Lornoxicam And Thiocolchicoside In Pure Form And Pharmaceutical Formulation	Sura Labs, S.S. Towers, Dilsukhnagar, Hyderabad - 500060, Telangana, India #9951919887 Email: suralabshyd@gmail.com	Ms. Anusha Woododi	2019 - 2020	520
14	Method Development And Validation Of A Rp-Hplc For The Simultaneous Estimation Of Alogliptin And Pioglitazone In Bulk And Marketed Pharmaceutical Dosage Form	Sura Labs, S.S. Towers, Dilsukhnagar, Hyderabad - 500060, Telangana, India #9951919887 Email: suralabshyd@gmail.com	Ms. Farheen Sulthana	2019 - 2020	520
15	Simultaneous Estimation Of Escitalopram And Clonazepam In Pure Form And Marketed Pharmaceutical Dosage Form By Using Reverse Phase - Hplc Method	Sura Labs, S.S. Towers, Dilsukhnagar, Hyderabad - 500060, Telangana, India #9951919887 Email: suralabshyd@gmail.com	Ms. Methari Mamatha	2019 - 2020	520
16	A New Analytical Method Development Andvalidation For The Quantitative Determinationsitagliptin By	Sura Labs, S.S. Towers, Dilsukhnagar, Hyderabad - 500060, Telangana, India #9951919887 Email:	Ms. R. Manasa	2019 - 2020	520

	Using Reverse Phase-Hplc combined Marketed Pharmaceutical Dosage Form and Simvastatin In Bulk Form And	suralabshyd@gmail.com			
17	A New Rp-Hplc Method And It's Validation For The Analysis of Artesunate And Mefloquine In Bulk And Pharmaceutical Dosage Form As Per Ich Guidelines	Sura Labs, S.S. Towers, Dilsukhnagar, Hyderabad - 500060, Telangana, India #9951919887 Email: suralabshyd@gmail.com	Ms. Nazma Begum	2019 - 2020	520
18	Development And Validation of A Simple And Novel Rp-Hplc Method For Simultaneous determination of Levodopa And Carbidopa In Bulk Form And Pharmaceutical Dosage Form According To Ich Guidelines	Sura Labs, S.S. Towers, Dilsukhnagar, Hyderabad - 500060, Telangana, India #9951919887 Email: suralabshyd@gmail.com	Ms. P. Bhavana	2019 - 2020	520
19	Analytical Method Development And Method Validation Of Stability Indicating Related Substances By Rp-Hplc For Levomilnacipran Pellets	Pellet Pharma Plot No: 8&9, EPIP-TSIIC, Pashamylaram, Telangana 502327	Ms. Ch. Shailaja	2019 - 2020	304
20	Formulation Development and Invitro Evaluation of Esomeprazole Magnesium Trihydrate Capsule	Pellet Pharma Plot No: 8&9, EPIP-TSIIC, Pashamylaram, Telangana 502327	Ms. Yarlagadda Navya	2019 - 2020	304
21	Method Development And Validation For The Estimation Of Solifenacin Succinate In Bulk And	Hetero labs Shapur Nagar, Bonthapalle, Telangana 500043	Ms. Yerva Girisha Reddy	2019 - 2020	162

	Tablet Dosage Form By RP-HPLC				
22	Manufacturing assistance	Granules India Ltd., Jinnaram Rd, Bonthapalle, Telangana 500043	Dr. A. Ramesh	2018-2019	60
23	SMT Training	Dr Reddys Labs Miyapur - Janapriya West City Rd, Jaya Prakash Narayan Nagar, Miyapur, Telangana 500049	Dr. A. Ramesh	2018-2019	45
24	Phytochemical screening and evaluation of acute oral toxicity on Sandhivaataari gutika	Dept. of Ayush, Hyderabad	Dr. A. Ramesh	2018-2019	365
25	Formulation and Evaluation of Paliperidone sustained release tablets	Sura Labs, S.S. Towers, Dilsukhnagar, Hyderabad - 500060, Telangana, India #9951919887 Email: suralabshyd@gmail.com	Ms. G.Sandhya	2018-2019	217
26	Formulation and Invitro Evaluation of Mirabegron Extended Release Tablets	Sura Labs, S.S. Towers, Dilsukhnagar, Hyderabad - 500060, Telangana, India #9951919887 Email: suralabshyd@gmail.com	Ms. K.A.Rajeswari	2018-2019	217
27	Formulation, Characterisation and Evaluation of Controlled Release Matrix Tablets of Felodipine	Sura Labs, S.S. Towers, Dilsukhnagar, Hyderabad - 500060, Telangana, India #9951919887 Email: suralabshyd@gmail.com	Ms. M.Harika	2018-2019	217
28	Formulation Development and Invitro Evaluation of Perampanel Immediate Release Tablets	Sura Labs, S.S. Towers, Dilsukhnagar, Hyderabad - 500060, Telangana, India #9951919887 Email: suralabshyd@gmail.com	Ms. M.Vennela	2018-2019	217
29	Formulation Development	Sura Labs, S.S. Towers,	Mr. P.Sravan	2018-2019	260


	and In Vitro Characterization of Sustained Release Matrix Tablets of Granisetron	Dilsukhnagar, Hyderabad - 500060, Telangana, India #9951919887 Email: suralabshyd@gmail.com	kumar		
30	Formulation and Evaluation of Sustained Release Matrix Tablets of Pioglitazone Hydrochloride	Sura Labs, S.S. Towers, Dilsukhnagar, Hyderabad - 500060, Telangana, India #9951919887 Email: suralabshyd@gmail.com	Ms. Sara Begum	2018-2019	217
31	Formulation Design and Invitro Evaluation of Candesartan Cilexetil Buccal Patches by Solvent Casting Method	Chandra labs173, Plot No. 10, 5-5-35, Prashanti Nagar, IDA, Kukatpally, Hyderabad, Telangana 500072	Ms. T.Veena	2018-2019	181
32	Formulation And Evaluation Of Oral Disintegrating Tablets of Nimodipine	Active Pharma LabsOpp: R.S.Brothers, Door No 202, 2nd Floor, Raja Enclave Bhagyanagar Colony, Kukatpally Housing Board Colony, Hyderabad, Telangana 500072	Ms. Syed.Shahabaz	2017 - 2018	180
33	Harmonization Of Excepients Using Different Pharmacopoeias	Dr Reddys Labs Miyapur - Janapriya West City Rd, Jaya Prakash Narayan Nagar, Miyapur, Telangana 500049	Ms. G.Sneha	2017 - 2018	185
34	SMT Training	Dr Reddys Labs Miyapur - Janapriya West City Rd, Jaya Prakash Narayan Nagar, Miyapur, Telangana 500049	Dr. A. Ramesh	2017-2018	45
35	Identification of pharmacophore of quinazolines to target lung cancer	Incozen Therapeutics Pvt Limited13th Floor, Manjeera Corporate, Trinity, K P H B Phase 3, Kukatpally, Hyderabad, Telangana 500072	Dr. VVS Rajendra Prasad	2017-2018	365

36	4-Anilino Quinazolines as potent EGFR Inhibitors	BogaR Laboratories Peddapuram - Rayabhupalapatnam Rd, Andhra Pradesh 533437	Dr. VVS Rajendra Prasad	2017-2018	365
37	Stability studies of Sulphamethaxazole and Ciprofloxacin tablets	Aizant Pharma Hyderabad Sy. No. 172 & 173, Quthbullapur Mandal, Apparel Park Rd, Dulapally, Hyderabad, Telangana 500100	Dr. K. Vanitha	2017-2018	365
38	Formulation and evaluation of sustained release tablets of glibenclamide using natural polymers(Guar gum)	Sura Labs, S.S. Towers, Dilsukhnagar, Hyderabad - 500060, Telangana, India #9951919887 Email: suralabshyd@gmail.com	Ms. D.Chandi priya goud	2017-2018	236
39	development and validation of a Reverse Phase HPLC method for simultaneous determination of Cilnidipine & Chlorthalidone in pure and pharmaceutical dosage form	Sura Labs, S.S. Towers, Dilsukhnagar, Hyderabad - 500060, Telangana, India #9951919887 Email: suralabshyd@gmail.com	Ms. G. Flawrence	2017-2018	207
40	RP-HPLC method development and validation for simultaneous estimation of cefuroxime and clavulanic acid in pure and pharmaceutical dosage form	Sura Labs, S.S. Towers, Dilsukhnagar, Hyderabad - 500060, Telangana, India #9951919887 Email: suralabshyd@gmail.com	Ms. D. Jhansi	2017-2018	207
41	Development and validation of A RP-HPLC-PDA method for simultaneous determination of trithioparamethoxyphenyleprone and chlorpheniramine maleate in pure and pharmaceutical dosage form	Sura Labs, S.S. Towers, Dilsukhnagar, Hyderabad - 500060, Telangana, India #9951919887 Email: suralabshyd@gmail.com	Ms. G.Laxmi prasanna	2017-2018	207
42	Formulation and Evaluation	Active Pharma Labs Opp:	Ms. K.Deekshitha	2017-2018	182

	of Chlorthalidone and Nifedipine as Bilayer Tablets	R.S.Brothers, Door No 202, 2nd Floor, Raja Enclave Bhagyanagar Colony, Kukatpally Housing Board Colony, Hyderabad, Telangana 500072			
43	Formulation and Evaluation of Amlodipine and Enalapril Bilayered Tablets	Active Pharma LabsOpp: R.S.Brothers, Door No 202, 2nd Floor, Raja Enclave Bhagyanagar Colony, Kukatpally Housing Board Colony, Hyderabad, Telangana 500072	Ms. L.Tejaswini	2017-2018	181
44	Formulation and Evaluation of Atazavir Nanospeheres Drug Delivery System for Enhancing Its Oral Bioavaliability and Efficacy	Active Pharma LabsOpp: R.S.Brothers, Door No 202, 2nd Floor, Raja Enclave Bhagyanagar Colony, Kukatpally Housing Board Colony, Hyderabad, Telangana 500072	Ms. M.Durga bhavani	2017-2018	181
45	Development and validation of stability indicating HPLC method for the simultaneous estimation of acetaminophen, dextromethorphan and doxylamine succinate in pharmaceutical dosage form	AurobindoSy. No. 313 Hyderabad, Bachupally, Telangana 500090	Ms. B.Prashanthi	2017-2018	182
46	Self Manageble Team (SMT) Training	Dr Reddys Labs Miyapur - Janapriya West City Rd, Jaya Prakash Narayan Nagar, Miyapur, Telangana 500049	Dr. A. Ramesh	2016 - 2017	45
47	Formulation of Potassium Chloride mg and mg extended release tablets	Suraksha Pharma 8-3-898/5, Road Number 8, Nagarjuna Nagar colony, Ameerpet, Hyderabad, Telangana 500073	Dr. S. Dinesh mohan	2016 - 2017	365

48	Synthesis of Telmesartan	Everest organics Ltd C9MR+VR6, Doctor's Colony, Madhapur, Telangana 500033	Mr. D. Appaji	2016 - 2017	365
49	Phytochemical Screening and in vitro antimicrobial antihelminthic analgesic and antiinflammatory activities of different extracts of polyherbal formulation named as RASONA PINDA	Dept. of Ayush, Hyderabad	Dr. SVVNSM Lakshmi	2016- 2017	365
50	Formulation And Evaluation of Naratriptan Orodispersible Tablets	Sura Labs, S.S. Towers, Dilsukhnagar, Hyderabad - 500060, Telangana, India #9951919887 Email: suralabshyd@gmail.com	Ms. G.Divya Sneha	2016 - 2017	213
51	Formulation Development And Invitro Evaluation of Famciclovir Microbeads For Sustained Drug Delivery System	Sura Labs, S.S. Towers, Dilsukhnagar, Hyderabad - 500060, Telangana, India #9951919887 Email: suralabshyd@gmail.com	Mr. H. Abilash	2016 - 2017	152
52	Formulation And Evaluation Of Transdermal Patches of Pioglitazone	Active Pharma Labs Opp: R.S.Brothers, Door No 202, 2nd Floor, Raja Enclave Bhagyanagar Colony, Kukatpally Housing Board Colony, Hyderabad, Telangana 500072	Mr. P.Sampath Kumar	2016 - 2017	198




 PRINCIPAL
 Vishnu Institute of Pharmaceutical
 Education & Research
 Vishnupur, Narsapur, Medak Dist - 502313. T.

Date: 7th September 2021

TOWHOMSOEVER IT MAY CONCERN

This is to certify that **Mr. B. Chandra Siva Naga Raju**, Employee code: 40487 has successfully completed his training and Project on **Design and Development of a Fixed Dose Combination of Three Anti-retroviral Drugs** in **Formulation Development Department** from **11th Dec 2020 to 31st Aug 2021**. During the period of his training with us he was found Punctual hardworking and inquisitive.

We have paid Rs, 10000/- in his training period.

We wish him all the success in his future endeavors.

For Aizant Drug Research Solutions Pvt. Ltd



Authorized Signatory

Aizant Drug Research Solutions Private Limited

Regd. Off : Sy No. 172 & 173, Apparel Park Road, Dulapally Village, Dundigal - Gandimaisamma (M),
Medchal - Malkhajgiri (Dist.), Hyderabad - 500 100.

Tel : 91 40 23792190/91/92, Fax : +91 40 23792223, Web : www.aizant.com

CIN : U24239TG2005PTC048133, E-mail : info@aizant.com

Date: 06 Sep 2021

TO WHOM SO EVER IT MAY CONCERN


This is to certify that **Sathoor Harshitha**, Employee code: 40494 has successfully completed her training in **Bio Analytical Department** from **14th Dec 2020 to 06th Sep 2021**. During the period of her training with us she was found Punctual hardworking and inquisitive.

We have paid Rs. 10,000/- in her training period.

We wish her all the success in her future endeavors.

For Aizant Drug Research Solutions Pvt. Ltd

Authorized Signatory



B.S. Ambesh Babu
Senior Manager – Human Resources

Aizant Drug Research Solutions Private Limited

Regd. Off : Sy No. 172 & 173, Apparel Park Road, Dulapally Village, Dundigal - Gandimaisamma (M),
Medchal - Malkajgiri (Dist.), Hyderabad - 500 100.

Tel : 91 40 23792190/91/92, Fax : +91 40 23792223, Web : www.aizant.com

CIN : U24239TG2005PTC048133, E-mail : info@aizant.com

Date: 07-08-2021.

CERTIFICATE



This is to certify that Miss. P. SIRISHA (HT. No. 19DH1S1208) pursuing her M. Pharmacy in VISHNU INSTITUTE OF PHARMACEUTICAL EDUCATION & RESEARCH has carried out her project work in our Organization entitled "ANALYTICAL METHOD DEVELOPMENT AND VALIDATION FOR THE SIMULTANEOUS DETERMINATION OF IVERMECTIN AND ALBENDAZOLE IN ACTIVE PHARMACEUTICAL INGREDIENT AND MARKETED TABLET DOSAGE FORM BY RP-HPLC" in the department of Pharmaceutical Analysis from 10-DEC-2020 to 07-AUG-2021.

During her tenure she was sincere, hardworking and Punctual in her Project work.

We wish her to success in her future career.



Date: 07-08-2021.

CERTIFICATE



This is to certify that **Miss. M. SUSHMITHA** (HT. No. 19DH1S1203) pursuing her M. Pharmacy in **VISHNU INSTITUTE OF PHARMACEUTICAL EDUCATION & RESEARCH** has carried out her project work in our Organization entitled "**DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD FOR THE SIMULTANEOUS DETERMINATION OF NIACIN AND SIMVASTATIN IN ACTIVE PHARMACEUTICAL INGREDIENT AND COMBINED TABLET DOSAGE FORM**" in the department of Pharmaceutical Analysis from **10-DEC-2020 to 07-AUG-2021**.

During her tenure she was sincere, hardworking and Punctual in her Project work.

We wish her to success in her future career.



Date: 07-08-2021.

CERTIFICATE



This is to certify that Miss. CHILUVERI. SANJANA (HT. No. 19DHIS1202) pursuing her M. Pharmacy in VISHNU INSTITUTE OF PHARMACEUTICAL EDUCATION & RESEARCH has carried out her project work in our Organization entitled "SIMULTANEOUS ESTIMATION OF INDACATEROL AND GLYCOPYRROLATE IN PURE AND MARKETED TABLET FORM BY USING RP-HPLC" in the department of Pharmaceutical Analysis from 10-DEC-2020 to 07-AUG-2021.

During her tenure she was sincere, hardworking and Punctual in her Project work.

We wish her to success in her future career.



See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/348792011>

3D Printing Technology in Pharmaceutical Dosage forms: Advantages and Challenges

Article in *Current Drug Targets* · January 2021

DOI: 10.2174/1389450122666210120142416

CITATION

1

READS

14

6 authors, including:



Prasanna kumar desu

K L University

51 PUBLICATIONS 73 CITATIONS

SEE PROFILE



Balaji Maddiboyina

NRK & KSR Gupta College of Pharmacy

43 PUBLICATIONS 288 CITATIONS

SEE PROFILE



Kondi Vanitha

Vishnu Institute of Pharmaceutical Education & Research

7 PUBLICATIONS 4 CITATIONS

SEE PROFILE



Vikas Jhawar

GD Goenka University Gurgaon

30 PUBLICATIONS 146 CITATIONS

SEE PROFILE

Some of the authors of this publication are also working on these related projects:



Periodontal treatment [View project](#)



Controlled release dosage forms [View project](#)

REVIEW ARTICLE

3D Printing Technology in Pharmaceutical Dosage Forms: Advantages and Challenges

Prasanna Kumar Desu¹, Balaji Maddiboyina², K. Vanitha³, Koteswara Rao GSN¹, R. Anusha⁴ and Vikas Jhawat^{5,*}

¹K L College of Pharmacy, Koneru Lakshmaiah Education Foundation, Vaddeswaram, Andhra Pradesh, India; ²Department of Pharmacy, NRK & KSR Gupta College of Pharmacy, Tenali, Guntur, Andhra Pradesh, India; ³Department of Pharmacy, Vishnu Institute of Pharmaceutical Education and Research, Narsapur, Medak, Telangana, India; ⁴Department of Pharmacy Practice, Nirmala College of Pharmacy, Mangalagiri, Guntur, Andhra Pradesh, India; ⁵Department of Pharmacy, School of Medical & Allied Sciences, GD Goenka University, Gurgaon, India

Abstract: Three Dimensional (3D) printing is a promising method for quick prototyping and manufacturing of any material. It is similar to photocopy or printing, where the new materials are formed on layers (3D) like their mother component. Following its growth and advancement in the 1980s, its application in pharmaceuticals is still limited. It has become one of the most innovative and influential tools serving as a technology for developing dosage forms from the last decade. The potential of 3D printing to produce drugs for precise measurement customized to specific patients' needs has shown the possibility of developing personalized medicines to novel dosage forms. The breakthrough allows the clear perception of the dosage structures on different shapes, sizes, surfaces and the associated challenges in delivering them by using such designed conditions. There are different difficulties related to the correct utilization of 3D imprinting in the pharmaceuticals, which have a strong impact on the scope of this technology. Recent advancements in the field of 3D printing technology used in the pharmaceutical industry mainly focused on different techniques for the fabrication of different dosage forms. The Food and Drug Administration's (FDA) recent approval of the first 3D prescription highlights possibilities for 3D printing innovation in the field of pharmaceutical drug supply. This analysis assesses 3D printing advancement possibilities, particularly in the area of custom prescriptions. This technology can be regarded as the future produced on demand, low-cost solid dosage forms and helps minimize side effects due to overdose.

ARTICLE HISTORY

Received: November 06, 2020
Revised: February 03, 2021
Accepted: February 17, 2021

DOI:
10.2174/1389450122666210120142416

Keywords: 3D Printing, Fused Deposition Molding, Inkjet Printing, Stereolithography, Personalized Medication.

1. INTRODUCTION

Three Dimensional Printing (3DP) has become one of the most innovative developments in the area of pharmaceuticals. The development of drug delivery has increased dramatically over the last decade [1]. The 3D print refers to a different approach for fabricating solid objects, known as the additive manufacturing process. In 3D printing, successive similar layers of the mother component are formed using sophisticated control systems [2]. 3DP is now one of the fastest-developing technologies in the creative and engineering industries, expanding its application [3]. International Standard Organization (ISO) describes 3D technology as manufacturing items by depositing a printed head, Nozzle, or other printer technology content [4]. The 3D model is used for the preparation of parts by layer in materials connection in this technique. 3DP is also used in the latest drug delivery method for viable tablet growth. The tablets were thus

produced to satisfy regulatory tests and commercial tablet standards [5].

In the last decade, the focus was on developing patient-driven medicines that remained a novel type of dosage form [6]. The vital progress of personalized drug communications is used to drive interest in custom devices combined with the expansion of technological innovation. For example, the generation of small, exclusively selected doses and custom prosthesis meets the patient's anatomical needs. Inside numerous disclosures brought into the pharmaceutical and biomedical market, 3DP is the foremost progressive and compelling. This strategy has a versatile instrument of tangible assembling of various gadgets. It is an advancement to create new dosage formulations, engineering tissues and organs, and model diseases. The use of 3D printers has increased significantly in the last decade. Global sales of consumer printers have increased by more than 33% [7]. Various 3DP technologies were found to generate the most common, distinct, and modern solid dosage types [8, 9]. Additional production is a subset of quick prototyping, involving techniques for the fast development of models and prototypes, but now it is a scalable production process [10]. 3D

*Address correspondence to this author at the Department of Pharmacy, School of Medical & Allied Sciences, GD Goenka University, Gurgaon, India; Tel: +91-9729216101; E-mail: jhawat231287@gmail.com

printers and other additive manufacturing technologies have increased steadily over the last thirty years in the engineering industries across biomedical applications [11]. The utilization of those technologies for improving drug delivery systems has been investigated and more recently realized with the FDA approval of the 3D printed or dispersible tablet. Moreover, supporting the skills of 3D printing to fabricate complex and customized dosage forms is also exploited [12]. The advantages of utilizing additive production technology for drug delivery means the ability to track the spatial dispersal of an active pharmaceutical ingredient (API) accurately within a dosage form, creates complicated geometries, stores modest API numbers, reduces rapidly growing variability [13]. The pharmaceutical industry can reduce traditionally complex, lent, and expensive supply chains, minimize the production and stock waste, and allow individual methodizing methods with no significant amounts to be generated [14]. 3D printing has also quickly developed and revolutionized the healthcare sector [15]. The medical applications of 3DP include customized prosthetics, body tissue, manufacture of organs, dental modeling, pharmaceutical research on the forms of medicinal dosage, delivery of medicines, and discovery [16]. The principle behind a 3D printer is similar to a regular printer [17, 18]. The 3D printer is a horizontally moving extruder that moves on a double axis, allowing it, on the x-y level, to move back and forth to form the object base [19]. Both axes are fixed to the printer ends. The only difference is that the 3D printer is based on the z-axis to generate the layers above the object vertically [20]. The extruder remains at the top and only moves in Two Dimensional (2D) while printing the first layer. The base containing the substratum decreases in height to allow for the next layer. The cycle is repeated in computerized formulation until the object is layer by layer built [21]. This method is known as the development of additives, Rapid Prototyping (RP), or solid freeform (SFF) technology. For printing various controlled chemicals, interconnected porosity and specific porous scaffold forms are employed by 3D printers. These graphics are biologically degradable and are ideal for supplying drugs [22]. This technique allows some of the highly complex structures containing live cells to become more frequent and accessible in cancer treatment [23].

2. HISTORY OF 3D PRINTING

3DP covers a wide variety of processes and techniques, providing a full assortment of manufacturing capabilities in various materials for parts and goods. The principles of 3DP processing by layer compared with conventional production methods that involve subtractive processes or molding processes are the same [24]. 3DP applications emerge almost daily, and as these technologies continue to penetrate the industrial, manufacturing, and consumer sectors more broadly and more profoundly, they will only grow. Many well-known experts in this technology field believe that the true potential of 3D printing has only just started to appear [25]. The 3D Printing industry, a credible 3D print media outlet, brings new perspectives, process innovations, and applications as they arise in this exciting field [26]. This review arti-

cle aims to provide the 3DP industry with a comprehensive backgrounder on 3D printing [27].

The early 3D printer technology known as RP technology was the first technology to become apparent in the late 1980s [28]. Initially, the processes were designed to create prototypes for product development as a fast and cost-efficient method [16].

The 3D printers concentrated on improving the design and functional prototyping of prototypes, which were designed expressly as office-orientated and economically efficient devices, the prelude to today's mobile computers. However, all the contrivances for industrial applications were also widely used. On the lower end of the market, a mid-range price war today, with rapidly improving print accuracy, speed, and materials, emerged. In 2007, 3D systems had the first \$10,000 system in the industry, but this never really reached the mark, partly because of the system itself and certain other factors. The Holy Grail would then have a 3D printer less than \$5000 - many business experts, consumers, and commentators saw the catalyst for opening 3D pressing technology for a broader audience [32]. The organization went wrong during the launch and it came to nothing. With the IP 3D Systems acquired from Desktop Factory and its information, Cathy Lewis, in 2008, and everything was slightly lost. "Dr. Bowyer invented an open-source, self-replicative, 3D printer idea of RepRap in 2004" and the following years. In particular, Vik Oliver and Rhys Jones used the elimination of the 3D printer technology to refine and create prototypes. The shooting started in 2007, and this early development in open-source 3D printing became more apparent.

Nonetheless, the first commercially available, kit-based 3D printer based on RepRap was not released until January 2009 [33]. In April of the same year, the creators of MakerBot Industries were very interested in creating RepRap until, after significant investment, they abandoned the open-source philosophy. A host of similar film printers have grown since 2009 and continues to do so with marginal unique selling points (USPs). The fascinating dichotomy here is that while RepRap's trend has created a whole new business field for entry-level 3D printers, RepRap's ethos culture is about using open sources for 3D printing and keeping marketing under control! 2012 marked the beginning of market entry for alternative 3D printing processes. In 1984, Charles Hull first created the technology for the printing of digital 3D physical objects. He called the process a "stereolithography and, in 1986, secured a patent". Stereolithography systems were popular in the late 1980s, but related technologies, such as fused deposition machines and selective laser sintering, were introduced. The process, called "3-dimensional printing techniques," was patented by the Massachusetts Institute of technology in 1993, was close to inking-jet technology used in 2D printers. Three primary devices, Stratasys "Genisys," 3D Systems "Actua 2100," and Z Corporation's "Z402" were launched in 1996. In the first high definition 3D printer on the market, Z Corp. released an interruptive Spectrum Z50 in 2005. The launch of an open-source project called Riprap, to create a free 3D printer, was another advance in 3D printing in 2006.




Fig. (1). History of 3D printing in pharmaceutical dosage forms.

3D printed pyramid-shaped tablets, for example, can become famous as a quick-acting treatment method, and that drugs are released quicker than standard dosage forms. The US FDA launched Spritam, the world's first 3D drug, to treat epileptic seizures in adults and infants. The drug developed with the patented Zip Dose technology of Aprexia Pharmaceuticals based on current 3DP analysis to create materials for quick melting. The technology would play a crucial role in advancing small volumes, custom pharmaceutical medical innovations, and making dosage formats more versatile. A move forward could encourage physicians to improve care upon request by creating personalized dose schemes in clinics and pharmacies. Further, patients can utilize customized medicine with various colours, tastes, and forms to improve adherence. Fig. (1) demonstrates the most impressive improvement in the field of pharmaceuticals by 3DP.

3. 3D PRINTING MATERIALS

The technology would play a crucial role in advancing small quantities, custom pharmaceutical innovations, and making dosage formats more versatile. A move forward could encourage physicians to improve care upon request by creating personalized dose schemes in clinics and pharmacies [34]. Nylon or polyamide plastics (powder or filament form) commonly used in fused deposition printing. The 3DP technology was proved reliable for robust, versatile, and durable plastic materials. It is naturally white, but it can be coloured-pre- or post-printed [35]. This material (in powder format) can also be mixed with powdered aluminium to produce another regular 3D printer for sintering aluminide [36]. Another common 3D-printing material, Acrylonitrile Butadi-

ene Styrene (ABS), is commonly used in filament form in 3D input stages of fused deposition machines. It comes in several colours and is especially strong in plastic. ABS can be collected from a variety of non-owned sources in the form of a filament. Polylactic acid is a biodegradable plastic material and became popular for 3D printing [37]. Polylactic acid can be used for stereolithography and the fused deposition machine cycle in the resin format. It is available in various colours, including transparent, proven useful in some 3D printing applications. It is not as durable or versatile as ABS. However, Lay wood is a 3D printing medium designed specifically for 3D extrusion printing at the entry-level. The wood or polymer combination is available in filament form [38].

In the industrial 3D printing sector, an increasing number of metals and metal composites are used. Aluminium and cobalt products are two of the most popular materials used in 3D printing. Stainless steel is one of the strongest and most used metals in 3D printing in powder for sintering, melting, and eating. It is, of course, silver, but it can be plated with other materials to give a bronze or gold effect [39]. The organization's business model is radically different from that of other 3D printing firms, which allows a system to obtain an average cost, but emphasizes a readily available cost-effective supply of material that can be bought on the market. 3D printed paper models are safe, eco-friendly, easy to recycle, and do not require post-processing. A tremendous amount of research is conducted into the potential of 3D printing biomaterials for a host of medical (and other) applications. Various leading organizations improve live tissue, including human transplant systems and external body substitute tissue printing [40].

4. THE PRINTING CYCLE

3D printing is a simple, highly automated process [41]. The air inside the printer warms initially to create an ideal 3D printing operating environment. The machine immediately fills the building chamber with a powder coating of one ounce (3.18 mm) to make it simple to remove the components. The computer can also perform an automated head alignment routine. This procedure consists of a template printing onto the material, electronic eye reading of the template, and subsequent aligning of its imprint heads [42].

Printing—once the pre-build routine is complete, the printer immediately begins printing the layers created in the “ZPrint” software. This machine stores powder in the machine's back from the trigger, spreading the thin layer of 0.004 inches (0.1 mm) over the building platform forward. The print carriage is then moving over that sheet, depositing binder in the template for the first slice sent from “ZPrint” (and various inks for the colour model). Within that cross-section, the binder consolidates the powder and leaves the remaining powder dry to be recycled. The piston lowers under the chamber and prepares for the next layer, lowering the pulverizing bed by 0.004 inches.

Depowering or recycling—when finished, the model is suspended in powder to cure. The unit automatically extracts most powder from the model at the end of the curing operation by applying vacuum and vibration pressure to the building chamber base. Pneumatically, the loose powder is transferred through the device and collected into the hopper for further use. Any powder filling, removal, and recycling system require an airborne particle-containing device supporting a closed-loop system with constant negative pressure. 3D printing works when the user clicks “3D Print,” warms the printer and fills the building chamber with building content. The printer begins making a pattern and deposits a powder film. The print wagon travels in the first slice pattern through this sheet that deposits binder (and colour inks). Through cross-section, the binder solidifies the material, allowing the remaining material to be recycled dry. The piston lowers the powder pad and prepares for the next layer after each layer below the building chamber. The process goes on to the completion of the pattern. The cycle continues until the model is complete. After completion, the model is suspended in powder to cure. At the end of curing time, the machine automatically vacuums most of the powder from around the model and recycles it for subsequent builds.

If all powder traces of the components are removed, they can be used in post-process treatment to strengthen further or improve the finish. This process is called infiltration, and it can be decided if or how to infiltrate by using the model. All is free, clean, fast, and efficient to infiltrate our items. Infiltrates are secondary resin material, usually drizzled or broken onto the model sheet. This infiltrate fills the microscopic pockets of the model, screens its surface, improves colour saturation, and improves the model's mechanical characteristics [43].

5. ADDITIVE MANUFACTURING TECHNOLOGIES

5.1. Laser-Based Writing Systems

It works on the principle of photo-polymerization, which releases free radicals after interaction with UV light from a photoinitiator [44]. Photo-polymerization requires ultraviolet or other reliable sources of light for exposure of liquid resins to polymerization reactions. The main restriction of this technique is the need for photopolymerizable raw materials, which are relatively rare in pharmaceutical production. The uncured content is chemically distinct from the printed product and may also contain functional groups plausibility of structural warnings to genotoxicity—the residual Resin, which poses a toxicology risk.

5.1.1. Stereolithography

The enterprise in the late 1980s was stereolithography (Fig. 2) as a reliable free-form production technology [45]. The stereolithography technique involves the curing of photosensitive materials to create 3D artifacts (photo-polymerization) [46]. SLA uses the digital mirroring tool for scanning a concentrated ultraviolet (UV) layer over a photopolymerizable liquid, causing a photopolymer to gel in an exposed area; the chemical reaction is initiated [47]. The whole layer of the object is assembled repeatedly by this method. However, this method poses a health risk in the form of possible carcinogenic resins. It is also a long process [48]. The SLA presses consist of an ultraviolet light pulse, such as a laser that transfers energy to a liquid resin [49].

A UV lamp, XYZ point, shutter, lens, and computer are used in this device. To create a 3D microstructure, thin cross-sectional spliced forms of the final product are constructed using the transparent Z-stage UV beam based on photopolymers. They are lined up to build the real 3D layers [50]. The lifting step slips to another liquid pitch layer's tallness when a layer setting starts the technology again before the assembly of the 3D product finished layer-by-layer [51]. The thickness of the deposits here depends on the strength of the UV light that discloses tar [52].

5.1.2. Continuous Layer Interface Production

This is a technical advancement in terms of printing speed [53]. However, the process comprises the non-layered development of the 3D structure. The Resin tank is containing oxygen that allows photo-polymerization more straightforward and guaranteed [54]. It is similar to jetting material where a powder bed is not needed [55]. There is no need for a powder pad. Inkjet solidifies the masses by the drop-in method to form the structures [55]: molten waxes, UV resins, and complex multi-component fluids used as jetted materials. For jetting and rapid solidification, the whole kit should be formulated [56]. Wang *et al.* used the stereolithography for fabricating 4-aminosalicylic acid and paracetamol-loaded tablets for modified-drug release characteristics using polyethylene glycol diacrylate a resin and diphenyl (2,4,6-trimethyl benzoyl) phosphine oxide (DPPO) as a photoinitiator. Tablets with different quantities of polyethylene

glycol 300 (PEG 300) were successfully printed, and an improvement in the content of PEG300 revealed a 10-hour improvement in drug release studies [25].




Fig. (2). A representation of stereolithography printer. (A higher resolution / colour version of this figure is available in the electronic copy of the article).

5.2. Powder Based 3D Printing

This technique uses powder jetting or a powder bed to spread thin layers of powder simultaneously with the aid of inkjet printers [57]. The tint (binders and APIs, or binders) is distributed over a 2-dimensional powder bed to create the finished product in layer after layer [58]. It is simpler for this technology to be adapted to pharmaceutical production than other technologies, as powder and binder solutions are commonly used in the pharmaceutical industry [59]. This approach often has its inconveniences. To remove solvent residues, additional drying is required. During printing, excess powder builds up and contributes to wastage. Also, because of the porous powder structure, the drug delivery system's mechanical strength is reduced [60]. This approach can be used for the manufacturing of Orodispersible dosage forms in the pharmaceutical industry.

5.3. Nozzle-Based Deposition Systems

Nozzle-based systems (Fig. 3) comprise pre-3D printing blending of medicines, polymers, and other solids [61]. Dust is passed through which the three-dimensional object starts, layer by layer. In the case of the type of material used, there are three styles of printing: inkjet printing, fused deposition manufacturing with melted parts, and micro-assisted pressing syringes without using molten materials [62].

5.3.1. Inkjet Printing

This technique begins with a similar method of a personal computer (PC) operating inkjet printing—custom drug treatment [63]. The ink supplants with a pharmaceutical system containing medicines and ordinary paper with edible

sheets called substrates was adjusted for pharmaceutical application [64]. Dose modifications by modifying the number of layers in the printed zone area. The drug and excipients are formulated in such a way that they can print on a rich substratum as microdots [65]. Warm inkjet printers and piezoelectric inkjet printers are the two significant print styles used under inkjet printing [66]. Two kinds of techniques are implemented in print-based inkjet frameworks: Continuous inkjet printing (CIP) and Drop-on-Demand Printing (DOD) [67].




Fig. (3). A representation of nozzle based 3D printer. (A higher resolution / colour version of this figure is available in the electronic copy of the article).

The liquid ink is guided through an aperture with a diameter of 50-80 μm to produce a continuous flow of ink while printing continually [68]. The fluid flows and breaks down at a certain speed and scales with a piezoelectric crystal at regular intervals. Electrostatic regulates the formation of the 3D object. To reduce electrostatic repulsion, the droplets are filled and separated by "guard droplets." The induced electrostatic field leads the loads to the substratum [69].

The drop-on-demand technique includes several heads and contains two types of translators, a thermal head or piezoelectric crystal. The thermal head is only limited to gases, and the piezoelectric cuts a wide variety of fluids [70]. The thermal head often reaches temperatures to 300°C, which means it will cause degradation of bioactive compounds due to high vapour pressure. This limitation of the use of thermal heads in drug use [71]. The piezoelectric crystal changes quickly, but this can lead to a sudden change in volume [72]. All heads can produce drops between 10 and 50 μm , equivalent to an amount between 1 and 70 pL. Due to their ability to work at room temperature using less volatile and compliance fluid, Piezoelectric Printing Technology is best suited to design medicines [71].




Fig. (4). A representation of fused deposition modeling 3D printer. (A higher resolution / colour version of this figure is available in the electronic copy of the article).

5.3.1.1. Inkjet Printing Ideal for Minimal Doses of the Therapeutic Agent

For the multi-layer print in a specific region, it is challenging to formulate higher doses through this technology in the form of a longer drying time. The rising part to address this problem would also increase the dosage type size. So, by using this technology, unique dosage forms are manufactured in the pharmaceutical industry [73].

5.3.2. Fused Deposition Modelling

In this technique, extrude a thermoplastic filament into a semi-solid layer by layer fusion filament *via* a high-temperature nozzle shown in Fig. (4) [74]. The item consists of layers of molten or blocked thermoplastic filaments extruded to different directions by computer software from the printer [75]. The material is then heated just above its softening point, extracted by a piston, and layer by layer is deposited and solidified in a second. Due to this fused filament, drug loading is also called filament incubation, and poor filling of medicines can reduce its use to lower dose medicines [76]. Xuyu Chai *et al.* used 3D modeling for fusion deposition to prepare to float intragastric domperidone tablets [77]. Using hot-melt extrusion, the medication is inserted in Hydroxypropyl Cellulose (HPC) filament. The filaments have then been printed in select tablets with modification of shell numbers and penetration estimates. Skowrya *et al.* have shown that the fusion deposition can be modeled in printing Polyvinyl Alcohol (PVA) filaments up to 24 hours after oral administration, with prolonged drug release of prednisolone [78]. The ability for extended-release fused deposition modeling has been demonstrated for 5-Aminosalicylic acid (5-ASA) or 4-ASA. A significant limitation on the use of the fused deposition model is that the high temperature required for operations (~220°C) may degrade the potential of fusion deposition modeling for extended-release to a significant number of pharmaceutical excipients and active drugs. Pi-

etrzak *et al.* bridged 3D extrusion technology to expand the variety of polymers that can be adapted for fused deposition modeling and increase the loading of drugs [79]. They showed that theophylline cells based on cellulosic or methacrylic polymer filaments could be printed immediately and extensively, with 50% of the drug loading. For processing to be possible, materials must have excellent rheological properties. Such properties are determined by the dust diameter, pressure drop, feeding rate, *etc.*, which are related to the thermal properties of feed materials such as thermal conduction, density, or glass transition temperature.

5.3.3. Pressure-Assisted Microsyringe Technology

This technology employs a syringe extruder, which uses a pressure piston to deposit viscous material. These deposits in the default geometry layer by layer [80]. The main parameters which determine the robustness of the article are viscosity, viscoelasticity, and apparent elastic limits. Advantage: continuously flows and works at room temperature. Disadvantage: the use of solvents could threaten the health and degrade the active ingredient of pharmaceuticals [81].

5.4. Semi-Solid Extrusion 3D Printing

Extrude semi-solids into a substance through the moving stage layer by layer. This technique uses a syringe tool head to inject layer after layer of semi-solid material. The semi-solid gel or paste is a polymer and solvent mixture in a ratio that makes the semi-circular consistency ideal for printing [82]. Okwuosa *et al.* manufactured tablets for immediate release through 3D printing to provide a powerful tool for personalizing the dosage type on demand. They also reported using pharmaceutically approved and soluble polymer in the manufacture of patient-sized tablets at a relatively low temperature (110°C). This work confirms that Fused Deposition Modeling (FDM) 3D can be used in a broader range of temperatures for immediate releases when needed. The material

used should be in gel or paste form, as the method requires extrusion. During drying, the deformation can be induced or decreased. If the dosage layers are not sufficiently hardened, the following layers cannot be borne in weight during printing, causing the supply collapse [83].

6. DESIGN OF VARIOUS DRUG DELIVERY SYSTEMS USING 3D PRINTERS

3D printing techniques are used in the production of several dosage forms, from the immediate release to the distribution of the osmotic drug, such as conventional manufacturing technology. Below are some recent attempts to develop different types of oral dosage by 3D print.

6.1. Immediate-Release Tablets

For immediate release of the pill, a drug filament and a hydrophilic polymer are prepared with or without plasticizers. The widely used hydrophilic polymers can be picked like povidone, hydroxypropyl-methylcellulose, or newly used graffiti polymers like Soluplus[®]. These filaments are fed to an instant release tablet using an FDM-based 3D printer [26]. Okwuosa *et al.* manufactured polyvinyl-pyrrolidone, triethyl citrate as a plasticizer, and talc as a filler tablet at ratios of 10%, 50%, 12.5%, and 27.5% wt., for direct releasing of theophylline and dipyridamole. More than 90% of the drug was dissolved in 30 minutes, showing the usefulness of 3D printing, informing the immediate-release tablet for both drugs with a 10% load [83].

6.2. Orodispersible Films

Jamróz *et al.* manufactured Orodispersible aripiprazole films using polyvinyl alcohol as a polymer through FDM-based 3DP technology. The decay time for placebo tablets was 43.00 ± 1.00 s as opposed to 27.50 ± 4.23 s. In contrast, to cast films, the conversion of Aripiprazole into morphine and a high surface of printed films showed more substantial dissolution; however, the mechanical characteristics of coiled films were negligible. 3D films were printed better because of their permanent foundation [84].

6.3. Floating Drug Delivery System (FDDS)

Chai *et al.* developed floating drug delivery systems by FDM-based 3DP [20]. FDM 3D printers' critical parameters are shells and infills, which describe the outline shape and structure of the object's emotional support. At least one shell is required to print an item, and extra shots add strength and weight to the body but take more time and material to print. Likewise, the infill rate is another parameter that can be adjusted from 0% to 100% to generate the entity from a hollow structure to a solid structure. In this study, the optimized 0.77 g/cm^3 tablet configuration with its two shells and 0% infill had dissolution capabilities above 10 hours, while the more than 20 percent coated shells had densities above 0.9 g/cm^3 , which caused them to sink in less than 1 hour. The sample was more than 10 hours after dissolution. Dissolution tablets over 12 hours, and no significant effects were observed in the number of coats or the infill stage [77].

6.4. Monolithic Sustained-Release Tablets

Sustainable release tablets of 5-ASA manufactured with medicinal filled filaments of Polyvinyl Alcohol. Filaments were produced by loading drugs from their ethanolic solutions on the market, all available polyvinyl alcohol filaments. The dissolution in the Auto pH System controlled bicarbonate buffer tablets 5-ASA (pH 6.8) showed a 100% release over four hours in tablets with an infill rate of 90 percent. Reduced infill percentage increased the manufacture of goods. During the preparation of the tablet, 50% of 4-ASA degraded to PVA filament due to high extrusion (210°C). Consequently, thermolabile medication this approach cannot be appropriate. A lower extrusion temperature alternative polymer can help to minimize product degradation due to temperatures [85].

6.5. Pulsatile Drug Release Tablets

ChronoCap[®] is a pulsatile delivery system based on capsular design. Capsules with various densities fabricated using hydrophilic polymers with a technique for molding injections, which creates different degrees with a time lag [86]. Through 3D HPC filament printing, such capsular devices are possible too. Melochhi *et al.* studied the behaviour of these 3D print and injection molding capsular devices [87]. It was reported that a lag was seen in 3D printed applications before the drug was released in the targeted area. Also, morphological changes corresponded to the technique of injection molding. The work also revealed that 3DP could be used instead of using traditional injection molding technology.

6.6. Bilayer Tablets

Khaled *et al.* prepared two-layered guaifenesin tablets using 3D printing to equate them to the bi-layer tablet brand--Mucinex[®], which is available on the market. The two-layered tablet was created with immediate release and a continuous release layer. Immediate-release layer (IR) is printed with microcrystalline cellulose (MCC) as a diluent and sodium starch glycolate (SSG) as a super disintegrant polymer. They were sustaining release layers printed with Hydroxypropyl Methylcellulose (HPMC 2208) and poly (acrylic acid) (PAA) polymers. 3DP tablets with two printing heads were used to make the tablets. Formulation of 14% w/w of hydrophilic polymer HPMC 2208 with 2% as binder showed a dissolution profile faster than but not significantly different from that of Mucinex[®]. Increased dissolution of HPMC 2208 showed a decrease due to the formation of a thicker hydration gel barrier that reduces drug release [88].

6.7. Multi-Active Solid Dosage Forms

Shaban *et al.* fabricated a tablet that contains nifedipine, captopril, and glipizide using room temperature extrusion-based 3D printing with separate controlled release profiles [89]. The same research group has recorded a single tablet that immediately releases aspirin and hydrochlorothiazide and continues to release atenolol, pravastatin, and ramipril *via* extruder processes [26].




Fig. (5). Application of 3DP in the area of pharmaceutical sciences. (A higher resolution / colour version of this figure is available in the electronic copy of the article).

6.8. Fast-Disintegrating Tablets

Yu *et al.* prepared a rapidly disintegrating tablet having loosely bound powder in the core area of the printed binder system. Three phases of printing created the hollow core area by printing binder solutions: a rugged circular area for a basis, various ring layers for a cave, and a solid circular area to be finally covered. There were just 21.8 s with a hardness of 54.5 N/cm² during the disintegration [90].

6.9. Nano Capsule-Based Formulation

3D-equipped printed tablets were developed by Gazzaniga *et al.* with a Nano capsule deflazacort 138 nm particle size. They were using the commonly used FDM. In filaments Poly (ti-caprolactone) (PCL) and Eudragit RL100, they are channeling agents with or without mannitol. Subsequently, tables were soaking into a particular volume (2 ml per unit) and dry for 24 hours at 30 degrees C for polymer nanoparticles. For 24-hour drinking of the bottle, up to 0.62% of the drug load was reached [91].

6.10. Transdermal Delivery Systems

It can be useful to prevent first-pass metabolism or pH-mediated degradation or to facilitate the smooth administration of patients with chronic diseases like diabetes. 3D printing techniques can easily be used layer by layer to produce multi-layered transdermal film patches; for a manufacturer's transdermal pharmaceutical microneedles, 3D technology offers a unique advantage. The micro-adhesives are typically less than 500 mm high and will penetrate the corneal stratum (10-15 mm) to provide active agents [92]. The insert forces of 0.1 to 3.0 n were measured, and the use of 150 mm microneedles with 26-gage needle controls showed little to no discomfort; these needles should not be enough for the

epidermis but should not be too difficult to cause pain and irritation [93]. Biodegradable polymers are preferred for the manufacture of needles if the tip breaks and is impregnated in the skin. The size, nature, and number of microneedles render making and painting a complicated geometry but suited to 3D printing techniques [93].

Boehm *et al.* The preparation of drug-loaded micro-needles used two additive fabrication processes. SL has been used to manufacture polymers, biodegradables polymers, and inkjets, used as an active agent for the model for the quantum dot needles [94]. Boehm *et al.* later applied stereo and inkjet techniques for generating amphotericin B packed, miconazole-laden antimicrobial-clogging micro-needles and demonstrated adequate transdermal resistance [95]. There have been some improvements in the surface and structure in micro-needles caused by printing of the ink wetting of the micro-needles, covered by a quantum dot and amphotericin B solutions. The deposition focused on the end of the needle than on the needle top, and the Miconazole tests had less influence on the structure of microneedle [96].

7. PHARMACEUTICAL APPLICATIONS FOR 3D PRINTING

3DP pharmaceutical applications are fast expanding, and health care should revolutionize. 3DP technologies implemented in pharmaceutical research and development. The advantages of 3DP include accurate control of the droplet size and dose, high reproductivity, and complex drug-release profiles to produce dosage forms. The technology of 3DP facilitates the standardization, accessibility, and feasibility of complex drug manufacturing processes. In the development of personalized medicine, 3DP technology is also a powerful resource. The applications of 3DP are listed in Fig. (5).

7.1. Personalized Medicine

The aim of the medicines' development should be to enhance effectiveness and decrease the risk of adverse reactions. The objective is to produce personalized drugs with 3D printing. Oral tablets are the most common type of medication because of their simpler manufacturing, pain relief, exact dosage, and strong patient adherence. However, there is no workable way of manufacturing customized, solid dosage forms like tablets regularly. Oral tablets are usually produced by well-known methods, such as grinding, milling, and dry and wet granulation through pumping or molding ingredients into tablets [101]. These steps can lead to problems, such as degradation of drugs and changes in shape, which can lead to formulation problems or batch failures.

Moreover, these conventional methods of manufacturing are ineffective for personalized medicines. It reduces the ability to create custom dosage forms with highly complex geometries, new drug release profiles, and longer-run stability to create custom dosage shapes [77]. Clients who are known to have pharmacology or are using medicines with limited therapeutic indices may benefit from personalized 3D drug prints. Pharmacists may evaluate the pharmacogenetic patient profile and other factors such as age, breed, and sex to determine an optimal dose of medication. An automated 3D printing system is used to print and dispense personalized medicines. The dosage could be further modified based on the clinical response, if appropriate. Customized drugs may also be made with entirely new formulae such as multi-active combinations or complex written multi-layer or multi-reservoir tablets, such as multiple active ingredients. Patients with many chronic illnesses could have their medication printed at the point of care in a single multi-dose form. Patients will theoretically boost patient compliance with a precise, customized dosage of several medicines in one tablet.

7.2. Complex Drug-Release Profiles

The creation of drugs with complex drug release profiles is one of the most researched applications in 3D printers. Traditional dosage shapes are mostly made from a homogeneous combination of active and inactive ingredients and are mostly limited to a specific pharmaceutical discharge profile [48]. However, in layers typically 200 micrometres thick, 3D printers can print binder onto the powder bed of a matrix to make a barrier between the active ingredients easier to release controlled drugs. 3D-printed dosage shapes can also develop into complex and porous geometries with various medications, surrounded by barrier-modifying layers [84].

7.3. Orodispersible High-Dose Medications

3DP allows the manufacturing of High-Dose medicines Orodispersible (up to 1000 mg) without compression or conventional molding. With the use of an aqueous fluid, the 3D printer stitches various layers of pulverized medicines, creating a porous, water-soluble matrix that quickly breaks with a sip of liquid [103].

7.4. Unique Dosage Forms

Unique dosage forms produced by using “injection-based 3D processing of medicines” and inkjet printers are used to spray medicine formulation and binders onto a substratum in tiny droplets at exact speeds, movements, and sizes. Cellulose, coated or uncoated paper, micropores, glass scaffolding, metal alloys, and potato starch films are among the most common substrates in use [104]. This technique has been further developed by spraying uniform “black” droplets on the liquid film encapsulating the material and forming microparticles and nanoparticles. These matrices are suitable for the supply of small hydrophobic molecules and growth factors. In the “powder-based 3D drug development,” the inkjet printer head sprays the “ink” on the powder-based base. If the ink reaches the powder, it will harden and produce a solid, layer by layer dosage shape. The ink may also contain active ingredients, binders, and other inactive ingredients. After the 3D-printed dosage form is dry, the solid object is removed from the surrounding powder substratum. It also enables the creation of unlimited forms of dosage that are likely to challenge traditional drug manufacture. A significant number of novel dosing forms were already being used by 3D printers, including microcapsules, synthetic extracellular hyaluronic matrices, paper-printed micro-antibiotic designs, and bioplasm scrapers, nanosuspensions, and multi-layered drug delivery systems [97].

7.5. Drugs with Complex Geometries

In dry conditions, the shape is used to prepare medicinal tablets in various uncommon forms that are difficult to manufacture by conventional methods. Pharmacy Scientists and FabRx, Inc. University College London (UCL). Scholars - Researchers Five tablets, each of which has a distinctly different design, [*i.e.*, the ring/donut], were designed in their study using auto Computer-Aided Design (CAD) software — the cube, pyramid, cylinder, sphere, and torus. The device used to produce tablets of stable surface (275 mm²), the volume ratio of surface area (1:1), or weight (500 mg). However, each type has been preserved in all cases by its length, width, and height ratio. Each tablet was finally published with a “MakerBot Replicator 2X Desktop 3D Printer,” using a drug-infused filament. The dissolution testing of each pill was performed after printing the tablets [90]. The drug release rates in the pyramids were found to be the highest, followed by the torus, cubes, body, and finally, the ring, where the tablets' surface area continuously held. The pyramid tablet and the low cylinder limit are directly associated with the tablet surface/volume ratio. This led the researchers to believe that a tablet's geometric form influences its profile of the release of drugs [105].

7.6. Increased Cost Efficiency

The essential advantage of 3D printing is the ability to manufacture low-cost products. The traditional method of medication is not as cost-effective as 3D printing technologies because the conventional method uses a large number of processes such as mixing, frying, dry or wet granulation,

compression, molding, *etc.* For instance, a 10 mg pharmaceutical tablet may probably be custom-made as a 1 mg tablet on request. Some medicine may also be printed in a more cost-effective and easier-to-use dosage format [106].

7.7. Enhanced Productivity

In 3D printing, the conventional process of drug processing uses different methods, including mixing, grinding, dry or wet granulation, compaction, or molding that makes it time-consuming, is much faster than the traditional process. Other qualities like solving, precise, reliable, and repeatable 3D printing technologies improve as well as speed [107].

7.8. Environment-friendly

3D printing technology appears to have more sustainable benefits than conventional medicines that require vast quantities of pill manufacturers [107].

8. REGULATORY CONSIDERATIONS

A further significant obstacle to the widespread pharmaceutical use of 3D printing is the safeguarding of regulatory approvals. Until then, the approval of the FDA has been given to only one dosage form printed by Aprelia pharmaceuticals. However, meeting more demanding regulatory requirements from the FDA could represent an obstacle to the availability of large-scale 3D printing medicines [97]. Their similarity sells these products to conventional medical devices under the new FDA rules. Despite over a decade of 3D printing technology developed over 150 licensed medical devices, the application for the manufacture of medicines is still in its infancy. The USFDA has taken the first 3d print pharmaceutical-Spiritam[®] significant steps forward with the approval [12].

The research and review unit at the USFDA's CDER Pharmaceutical Quality Unit focuses on outstanding problems relating to the implementation of this technology. To create regulations for printed 3D products, several unanswered questions about the CMC (Chemistry, Manufacture, and Control) and clinical aspects must be addressed. CMC problems include a description of critical process parameters, critical and in-process attributes of the material, and finished test requirements for the product [98]. The determination of the connection between geometry and live performance, as well as patient acceptability, the impact on the in-vivo performance of different 3D printer models, and so on, is other challenges. The CDER reviews, in collaboration with the FDA Centre for Devices & Radiological Protection, to ensure the operational quality of the 3D Printers, printer equipment, and intermediate products [99].

8.1. Challenges and Perspectives

The advances in technology in the field of pharmaceuticals continuously improve and offer different possibilities for satisfying the needs of personalized medical treatment. 3DP technology has infinite potential as technical progress continues while manufacturing patient-specific drug delivery devices (DDD) and dosage types. Besides, fast-moving

3D printed DDD work has helped to recognize numerous problems associated with the development and marketing of customized drug delivery systems [100]. *Via* 3DP, prototypes of drug delivery systems have been produced with varying complexity, and it is shown that drug products can be adapted. Patient-specific potential drug delivery is likely to be improved with printing technology. New scientific principles, interdisciplinary research, and established regulatory guidelines would encourage and enhance 3DP perspectives as a choice in the manufacturing of medical products [72]. In the last 35 years, 3DP has been one kind. Its various advantages and its ability to manufacture large, solid doses with high precision and accuracy can revolutionize drug delivery.

3DP can produce robust, variable densities and diffuse dosage forms, complex internal geometries, and several medicinal products. 3DP effectively addresses problems relating to the poor delivery of water-soluble medicines, peptides, active drugs, and multidrug releases. However, difficulties limit 3DP's commercial applications on the market, including the lack of appropriate binders, excipients, and final product pharmacy. If 3DP is successfully combined with a new drug delivery system, further progress in the process is required [101]. 3DP includes a variety of techniques with advantages and open problems each one. The manufacture of drug products was mainly affected by the solidification of powder, extrusion, and stereolithography. The biggest obstacle in using them for custom pharmacologic therapy is likely to be regulatory issues and designing production models to efficiently turn clinical criteria for specific patients into limited amounts of suitable drug products that meet predetermined quality specifications [102]. 3DP developed to address patients' needs as a supporting and potential medicinal tool. It is the product of personalized medicine. It provides many benefits, such as improved cost efficiency and production speed, because rapid prototyping (RP) is possible within minutes. However, there are still significant obstacles to ensuring that the efficacy, protection, and durability of 3D printed drugs are the same as those that the pharmaceutical industry typically manufactures. Due to traditional requirements in the pharmaceutical industry, it is challenging to develop laws, regulations, quality processes, and the safety and implementation of 3D printed medications products by national regulators. National regulatory authorities applying various printing technologies offer potentially customized medicine solutions and adapted dosage forms that meet the requirements of future treatments in particular. Many types of dosage form scenarios are available, including the accurately deposited doses of pharmaceutical substances at the simplest level. Also, computer design provides countless possibilities for creating suitable geometries with a tailor-made purpose and complexity to monitor the release characteristics of one or more drugs. It takes some time to turn these technical advances in the printer industry into improved treatments for patients because challenges exist. However, printing methods are adapting rapidly to build innovative drug delivery systems and cellular functions for human treatments using versatile materials—printing technologies [86].

CONCLUSION

3DP has become a valuable and future resource for the pharmaceutical industry that contributes to customized medicine that meets the need of patients. This analysis demonstrates 3DP technology's versatility that is well-suited for customized/personalized medication when it comes to advanced drug delivery with integrated functionality. Third-party manufacturing revolutionizes the design and composition of pharmaceutical development. However, a significant barrier still exists in ensuring 3D printed pharmaceuticals in the pharmaceutical sector as effective, safe, and stable as traditional medications. Regulators face a unique challenge, given the conventional requirements of the pharmaceutical industry, several obstacles in establishing guidelines, regulations, quality systems, the safety of use, and the use of 3D printed medicines. Initial thoughts on technical aspects related to the process and recommendations for the testing and characterization of devices that involve at least one additive production stage are provided in the FDA Guideline "Technical considerations for additive manufactured devices." Shortly, a 3DP approach was used to produce and develop different new dosing forms. Evolving personalized drugs and optimized dosage release, compacting or preventing drug incompatibilities and biomolecules during the manufacture, and constructing multiple dosage forms for medicines and different dosing forms will be transformed into the new era of 3D printing technologies. While the commercial production of such new dosage forms continues to be challenging.

LIST OF ABBREVIATIONS

3DP	= 3-Dimensional Printing
ABS	= Acrylonitrile Butadiene Styrene
AM	= Additive Manufacturing
API	= Active Pharmaceutical Ingredient
ASA	= Aminosalicyclic Acid
CAD	= Computer-Aided Drug Design
CDER	= Center for Drug Evaluation Research
CIP	= Continuous Inkjet Printing
CMC	= Chemistry Manufacture and Control
DOD	= Drop on Drop
DOS	= Drop on Solid
FDA	= Food and Drug Administration
FDM	= Fused Deposition Modeling
HME	= Hot-melt extrusion
HPMC	= Hydroxypropyl Methylcellulose
IR	= Immediate Release
ISO	= International Organization of Standardization
MCC	= Microcrystalline Cellulose

ODF	= Orodispersible Film
PAA	= Polyacrylic Acid
PC	= Personal Computer
PCL	= Polycaprolactone
PEG	= Polyethylene Glycol
PLA	= Poly Lactic Acid
PVA	= Polyvinyl Alcohol
PVP	= Polyvinylpyrrolidone
R & D	= Research and Development
RP	= Rapid Prototyping
SLA	= Stereolithography
SLM	= Selective Laser Melting
SLS	= Selective Laser Sintering
SSG	= Sodium Starch Glycolate
US	= United States
UV	= Ultra Violet

CONSENT FOR PUBLICATION

Not applicable.

FUNDING

None.

CONFLICT OF INTEREST

The authors have no conflicts of interest, financial or otherwise.

ACKNOWLEDGEMENTS

The authors are very thankful to the management of VIPER, Narsapur, Medak, Telangana for providing facilities for carrying out of this review work and the authority of ICAR- IARI, New Delhi, and NSUT, New Delhi for moral support and encouragement.

REFERENCES

- [1] Khoo ZX, Teoh JEM, Liu Y, *et al.* 3D printing of smart materials: A review on recent progress in 4D printing. *Virtual Phys Prototyp* 2015; 10: 103-22. <http://dx.doi.org/10.1080/17452759.2015.1097054>
- [2] Chua CK, Leong KF, An J. Introduction to rapid prototyping of biomaterials. *Second Edi Rapid Prototyp Biomater Tech Addit Manuf* 2019.
- [3] El Aita I, Ponsar H, Quodbach J. A Critical Review on 3D-printed Dosage Forms. *Curr Pharm Des* 2018; 24(42): 4957-78. <http://dx.doi.org/10.2174/1381612825666181206124206> PMID: 30520369
- [4] Pravin S, Sudhir A. Integration of 3D printing with dosage forms: A new perspective for modern healthcare. *Biomed Pharmacother* 2018; 107: 146-54. <http://dx.doi.org/10.1016/j.biopha.2018.07.167> PMID: 30086461
- [5] Alhnan MA, Okwuosa TC, Sadia M, Wan KW, Ahmed W, Arafat B. Emergence of 3D Printed Dosage Forms: Opportunities and Challenges. *Pharm Res* 2016; 33(8): 1817-32.

- <http://dx.doi.org/10.1007/s11095-016-1933-1> PMID: 27194002
- [6] Norman J, Madurawe RD, Moore CMV, Khan MA, Khairuzzaman A. A new chapter in pharmaceutical manufacturing: 3D-printed drug products. *Adv Drug Deliv Rev* 2017; 108: 39-50. <http://dx.doi.org/10.1016/j.addr.2016.03.001> PMID: 27001902
- [7] Giannitelli SM, Mozetic P, Trombetta M, Rainer A. Combined additive manufacturing approaches in tissue engineering. *Acta Biomater* 2015; 24: 1-11. <http://dx.doi.org/10.1016/j.actbio.2015.06.032> PMID: 26134665
- [8] Schubert C, Langeveld MC, Van , Donoso LA. 2014; Innovations in 3D printing: a 3D overview from optics to organs. 2014; 159-61.
- [9] Kolakovic R, Viitala T, Ihalainen P, Genina N, Peltonen J, Sandler N. Printing technologies in fabrication of drug delivery systems. *Expert Opin Drug Deliv* 2013; 10(12): 1711-23. <http://dx.doi.org/10.1517/17425247.2013.859134> PMID: 24256326
- [10] Günther D, Heymel B, Günther JF, *et al.* Continuous 3D-printing for additive manufacturing. *Rapid Prototyping J* 2014; 20: 320-7. <http://dx.doi.org/10.1108/RPJ-08-2012-0068>
- [11] Boparai KS, Singh R. Development of rapid tooling using fused deposition modeling. *Addit Manuf Emerg Mater* 2018; pp. 251-77.
- [12] Goole J, Amighi K. 3D printing in pharmaceuticals: A new tool for designing customized drug delivery systems. *Int J Pharm* 2016; 499(1-2): 376-94. <http://dx.doi.org/10.1016/j.ijpharm.2015.12.071> PMID: 26757150
- [13] Bansal M, Sharma V, Singh G, *et al.* 3D printing for the future of pharmaceuticals dosage forms. *Int J Appl Pharm* 2018; 10: 1-7. <http://dx.doi.org/10.22159/ijap.2018v10i5.27506>
- [14] Caballero-Aguilar LM, Silva SM, Moulton SE. Three-dimensional printed drug delivery systems. *Eng Drug Deliv Syst* 2020.
- [15] Bhusnure OG, Gholve VS, Sugave BK, Dongre RC, Gore SA, Giram PS. 3D printing and pharmaceutical manufacturing opportunities and challenges. *Int J Bioassays* 2016; 5(1): 4723-38. <http://dx.doi.org/10.21746/ijbio.2016.01.006>
- [16] Acosta-Vélez GF, Wu BM. 3D pharming: direct printing of personalized pharmaceutical tablets. *Polym Sci* 2016; 2(1): 11.
- [17] Kim JJ, Hou L, Huang NF, TKim JJ. Vascularization of three-dimensional engineered tissues for regenerative medicine applications. *Acta Biomater* 2016; 41: 17-26. <http://dx.doi.org/10.1016/j.actbio.2016.06.001> PMID: 27262741
- [18] Ursan ID, Chiu L, Pierce A. Three-dimensional drug printing: a structured review. *J Am Pharm Assoc (2003)* 2013; 53(2): 136-44. <http://dx.doi.org/10.1331/JAPhA.2013.12217> PMID: 23571620
- [19] Bose S, Vahabzadeh S, Bandyopadhyay A. Bone tissue engineering using 3D printing. *Biochem Pharmacol* 2013; 16: 496-504. <http://dx.doi.org/10.1016/j.mattod.2013.11.017>
- [20] Zhang YS, Duchamp M, Oklu R, *et al.* Bioprinting the Cancer Microenvironment Bioprinting the Cancer Microenvironment 2016.
- [21] Mok S, Nizak R, Fu S, *et al.* ScienceDirect from the printer: Potential of three-dimensional printing for orthopaedic applications. 2016; 1-8.
- [22] Jin S, Lee D, Rim T, *et al.* *Acta Biomaterialia* Surface modification of 3D-printed porous scaffolds via mussel-inspired polydopamine and effective immobilization of rhBMP-2 to promote osteogenic differentiation for bone tissue engineering q. *Acta Biomater* 2016; •••: 2-11. <http://dx.doi.org/10.1016/j.actbio.2016.02.006>
- [23] Nelson B. 3-Dimensional bioprinting makes its mark: new tissue and organ printing methods are yielding critical new tools for the laboratory and clinic. *Cancer Cytopathol* 2015; 123(4): 203-4. <http://dx.doi.org/10.1002/cncy.21543> PMID: 25873242
- [24] Daly R, Harrington TS, Martin GD, Hutchings IM. Inkjet printing for pharmaceuticals - A review of research and manufacturing. *Int J Pharm* 2015; 494(2): 554-67. <http://dx.doi.org/10.1016/j.ijpharm.2015.03.017> PMID: 25772419
- [25] Wang J, Goyanes A, Gaisford S, Basit AW. Stereolithographic (S-LA) 3D printing of oral modified-release dosage forms. *Int J Pharm* 2016; 503(1-2): 207-12. <http://dx.doi.org/10.1016/j.ijpharm.2016.03.016> PMID: 26976500
- [26] Khaled SA, Burley JC, Alexander MR, Yang J, Roberts CJ. 3D printing of five-in-one dose combination polypill with defined immediate and sustained release profiles. *J Control Release* 2015; 217: 308-14. <http://dx.doi.org/10.1016/j.jconrel.2015.09.028> PMID: 26390808
- [27] Luxminarayan L, Neha S, Amit V, *et al.* *Asian Journal of Pharmaceutical Research and Development. Asian J Pharm Res Dev* 2017; 5: 1-8.
- [28] Chia HN, Wu BM. Recent advances in 3D printing of biomaterials. *J Biol Eng* 2015; 9: 4. <http://dx.doi.org/10.1186/s13036-015-0001-4> PMID: 25866560
- [29] Surgery M. 3D Printing- The New Frontier in Prosthodontics - A Review.
- [30] Allahham N, Fina F, Marcuta C, *et al.* Selective Laser Sintering 3D Printing of Orally Disintegrating Printlets Containing Ondansetron. 1-13.
- [31] Ikuta K, Maruo S, Hasegawa T, *et al.* Light-drive biomedical micro-tools and biochemical IC chips fabricated by 3D micro/nano stereolithography. *Optomechatronic Micro/Nano Components, Devices. Syst* 2004; 5604: 52.
- [32] Garcia J, Yang Z, Mongrain R, *et al.* 3D printing materials and their use in medical education: a review of current technology and trends for the future. 2017; 1-14.
- [33] Deckard C. History of 3D Printing: The Free Beginner' s Guide. 1992.
- [34] Ngo TD, Kashani A, Imbalzano G, *et al.* Additive manufacturing (3D printing): A review of materials, methods, applications and challenges. *Compos Part B* 2018; 143: 172-96. <http://dx.doi.org/10.1016/j.compositesb.2018.02.012>
- [35] Mostafa KG, Montemagno C, Qureshi AJ. ScienceDirect ScienceDirect Strength to cost ratio analysis of FDM Nylon 12 3D Printed Parts Costing models capacity optimization in industry between used capacity and operational efficiency. *Procedia Manuf* 2018; 26: 753-62. <http://dx.doi.org/10.1016/j.promfg.2018.07.086>
- [36] Parandoush P, Lin D. A review on additive manufacturing of polymer-fiber composites. *Compos Struct* 2017; 182: 36-53. <http://dx.doi.org/10.1016/j.compstruct.2017.08.088>
- [37] Paper C, Manfredi D, Minetola P. About the Use of Recycled or Biodegradable Filaments for Sustainability of 3D Printing About the Use of Recycled or Biodegradable Filaments for Sustainability of 3D Printing State of the Art and Research Opportunities 2017.
- [38] Wimmer R, Steyrer B, Woess J, Koddenberg T, Mundigler N. 3D printing and wood. *Ligno* 2015; 11: 144-9.
- [39] Ribeiro F. 3d printing with metals. *Comput Contr Eng J* 1998; 9: 31-8. <http://dx.doi.org/10.1049/cce:19980108>
- [40] Chia HN, Wu BM. Recent advances in 3D printing of biomaterials. 2015; 1-14.
- [41] Shahrubudin N, Lee TC, Ramlan R. An Overview on 3D Printing Technology: Technological, Materials, and Applications. *Procedia Manufacturing* 2019; 35: 1286-96. <http://dx.doi.org/10.1016/j.promfg.2019.06.089>
- [42] Cerdas F, Juraschek M, Thiede S, Herrmann C. Life cycle assessment of 3D printed products in a distributed manufacturing system. *J Ind Ecol* 2017; 21(S1): S80-93. <http://dx.doi.org/10.1111/jieec.12618>
- [43] Ramya A, Vanapalli SL. 3D printing technologies in various applications. *International Journal of Mechanical Engineering and Technology* 2016; 7(3): 396-409.
- [44] Melchels FPW, Feijen J, Grijpma DW. A review on stereolithography and its applications in biomedical engineering. *Biomaterials* 2010; 31(24): 6121-30. <http://dx.doi.org/10.1016/j.biomaterials.2010.04.050> PMID: 20478613
- [45] Chhaya MP, Poh PSP, Balmayor ER, van Griensven M, Schantz JT, Huttmacher DW. Additive manufacturing in biomedical sciences and the need for definitions and norms. *Expert Rev Med Devices* 2015; 12(5): 537-43. <http://dx.doi.org/10.1586/17434440.2015.1059274> PMID: 26305837
- [46] Li Q, Wen H, Jia D, *et al.* Preparation and investigation of controlled-release glipizide novel oral device with three-dimensional printing. *Int J Pharm* 2017; 525(1): 5-11. <http://dx.doi.org/10.1016/j.ijpharm.2017.03.066> PMID: 28377316

- [47] Mondschein RJ, Kanitkar A, Williams CB, Verbridge SS, Long TE. Polymer structure-property requirements for stereolithographic 3D printing of soft tissue engineering scaffolds. *Biomaterials* 2017; 140: 170-88. <http://dx.doi.org/10.1016/j.biomaterials.2017.06.005> PMID: 28651145
- [48] Martinez PR, Goyanes A, Basit AW, Gaisford S. Influence of Geometry on the Drug Release Profiles of Stereolithographic (SLA) 3D-Printed Tablets. *AAPS PharmSciTech* 2018; 19(8): 3355-61. <http://dx.doi.org/10.1208/s12249-018-1075-3> PMID: 29948979
- [49] He R, Liu W, Wu Z, *et al.* fabrication of complex-shaped zirconia ceramic parts via a DLP- stereolithography-based 3D printing method. *Ceram Int* 2018; 44: 3412-6. <http://dx.doi.org/10.1016/j.ceramint.2017.11.135>
- [50] Xu X, Robles-Martinez P, Madla CM, *et al.* Stereolithography (SLA) 3D printing of an antihypertensive polyprintlet: Case study of an unexpected photopolymer-drug reaction. *Addit Manuf* 2020; 33 <http://dx.doi.org/10.1016/j.addma.2020.101071>
- [51] Manapat JZ, Chen Q, Ye P, *et al.* 3D Printing of Polymer Nanocomposites via Stereolithography. *Macromol Mater Eng* 2017; 302: 1-13. <http://dx.doi.org/10.1002/mame.201600553>
- [52] Hegde M, Meenakshisundaram V, Chartrain N, *et al.* 3D Printing All-Aromatic Polyimides using Mask-Projection Stereolithography: Processing the Nonprocessable. *Adv Mater* 2017; 29(31): 1-7. <http://dx.doi.org/10.1002/adma.201701240> PMID: 28626968
- [53] Januszewicz R, Tumbleston JR, Quintanilla AL, Mecham SJ, DeSimone JM. Layerless fabrication with continuous liquid interface production. *Proc Natl Acad Sci USA* 2016; 113(42): 11703-8. <http://dx.doi.org/10.1073/pnas.1605271113> PMID: 27671641
- [54] Tamil Ponni R, Swamivelmanickam M, Sivakrishnan S. 3D Printing in Pharmaceutical Technology – A Review. *Int J Pharm Investig* 2020; 10: 8-12. <http://dx.doi.org/10.5530/ijpi.2020.1.2>
- [55] Pyo SH, Wang P, Hwang HH, Zhu W, Warner J, Chen S. Continuous optical 3D printing of green aliphatic polyurethanes. *ACS Appl Mater Interfaces* 2017; 9(1): 836-44. <http://dx.doi.org/10.1021/acsami.6b12500> PMID: 27935681
- [56] Yang C, Tian X, Liu T, *et al.* 3D printing for continuous fiber reinforced thermoplastic composites: Mechanism and performance. *Rapid Prototyping J* 2017; 23: 209-15. <http://dx.doi.org/10.1108/RPJ-08-2015-0098>
- [57] Brunello G, Sivoletta S, Meneghello R, *et al.* Powder-based 3D printing for bone tissue engineering. *Biotechnol Adv* 2016; 34(5): 740-53. <http://dx.doi.org/10.1016/j.biotechadv.2016.03.009> PMID: 27086202
- [58] Lille M, Nurmela A, Nordlund E, *et al.* Applicability of protein and fiber-rich food materials in extrusion-based 3D printing. *J Food Eng* 2018; 220: 20-7. <http://dx.doi.org/10.1016/j.jfoodeng.2017.04.034>
- [59] Vantghem G, Boel V, De Corte W. Topology Optimization for 3D-Printed Concrete Structures. *Digit Concr* 2019.
- [60] Xia M, Nematollahi B, Sanjayan JG. Properties of Powder-Based 3D Printed Geopolymers. *3D Concr Print Technol* 2019.
- [61] Goodarzi Hosseinabadi H, Bagheri R, Avila Gray L, *et al.* Plasticity in polymeric honeycombs made by photo-polymerization and nozzle-based 3D-printing. *Polym Test* 2017; 63: 163-7. <http://dx.doi.org/10.1016/j.polymertesting.2017.08.008>
- [62] Zhang B, Seong B, Nguyen VD, *et al.* 3D printing of high-resolution PLA-based structures by hybrid electrohydrodynamic and fused deposition modeling techniques. *J Micromech Microeng* 2016; 26: 25015. <http://dx.doi.org/10.1088/0960-1317/26/2/025015>
- [63] Scoutaris N, Ross S, Douroumis D. Current Trends on Medical and Pharmaceutical Applications of Inkjet Printing Technology. *Pharm Res* 2016; 33(8): 1799-816. <http://dx.doi.org/10.1007/s11095-016-1931-3> PMID: 27174300
- [64] Prasad LK, Smyth H III. 3D Printing technologies for drug delivery: a review. *Drug Dev Ind Pharm* 2016; 42(7): 1019-31. <http://dx.doi.org/10.3109/03639045.2015.1120743> PMID: 26625986
- [65] He Y, Foralosso R, Trindade GF, *et al.* A Reactive Prodrug Ink Formulation Strategy for Inkjet 3D Printing of Controlled Release Dosage Forms and Implants. *Adv Ther* 2020; 1900187 <http://dx.doi.org/10.1002/adtp.201900187>
- [66] 3D Printing Technology in Design of Pharmaceutical Products. *Curr Pharm Des* 2019; 24: 5009-18.
- [67] Gaisford S. 3D printed pharmaceutical products. *3D Print Med* 2017.
- [68] Planchette C, Pichler H, Wimmer-Teubenbacher M, *et al.* Printing medicines as orodispersible dosage forms: Effect of substrate on the printed micro-structure. *Int J Pharm* 2016; 509(1-2): 518-27. <http://dx.doi.org/10.1016/j.ijpharm.2015.10.054> PMID: 26541301
- [69] Khatri P, Shah MK, Vora N. Formulation strategies for solid oral dosage form using 3D printing technology: A mini-review. *J Drug Deliv Sci Technol* 2018; 46: 148-55. <http://dx.doi.org/10.1016/j.jddst.2018.05.009>
- [70] Pandey M, Choudhury H, Fern JLC, *et al.* 3D printing for oral drug delivery: a new tool to customize drug delivery. *Drug Deliv Transl Res* 2020; 10(4): 986-1001. <http://dx.doi.org/10.1007/s13346-020-00737-0> PMID: 32207070
- [71] Pfister A, Landers R, Laib A, *et al.* Biofunctional Rapid Prototyping for Tissue-Engineering Applications: 3D Bioplotting versus 3D Printing. *J Polym Sci A Polym Chem* 2004; 42: 624-38. <http://dx.doi.org/10.1002/pola.10807>
- [72] Sandler N, Preis M. Printed Drug-Delivery Systems for Improved Patient Treatment. *Trends Pharmacol Sci* 2016; 37(12): 1070-80. <http://dx.doi.org/10.1016/j.tips.2016.10.002> PMID: 27992318
- [73] Clark EA, Alexander MR, Irvine DJ, *et al.* 3D printing of tablets using inkjet with UV photoinitiation. *Int J Pharm* 2017; 529(1-2): 523-30. <http://dx.doi.org/10.1016/j.ijpharm.2017.06.085> PMID: 28673860
- [74] Melocchi A, Parietti F, Maroni A, Foppoli A, Gazzaniga A, Zema L. Hot-melt extruded filaments based on pharmaceutical grade polymers for 3D printing by fused deposition modeling. *Int J Pharm* 2016; 509(1-2): 255-63. <http://dx.doi.org/10.1016/j.ijpharm.2016.05.036> PMID: 27215535
- [75] Goyanes A, Wang J, Buanz A, *et al.* 3D Printing of Medicines: Engineering Novel Oral Devices with Unique Design and Drug Release Characteristics. *Mol Pharm* 2015; 12(11): 4077-84. <http://dx.doi.org/10.1021/acs.molpharmaceut.5b00510> PMID: 26473653
- [76] Hoath SD, Harlen OG, Hutchings IM. Jetting behaviour of polymer solutions in drop-on-demand inkjet printing. *J Rheol (NYYN)* 2012; 56: 1109-27. <http://dx.doi.org/10.1122/1.4724331>
- [77] Chai X, Chai H, Wang X, *et al.* Fused deposition modeling (FDM) 3D printed tablets for intragastric floating delivery of domperidone. *Sci Rep* 2017; 7(1): 2829. <http://dx.doi.org/10.1038/s41598-017-03097-x> PMID: 28588251
- [78] Skowrya J, Pietrzak K, Alhnan MA. Fabrication of extended-release patient-tailored prednisolone tablets via fused deposition modelling (FDM) 3D printing. *Eur J Pharm Sci* 2015; 68: 11-7. <http://dx.doi.org/10.1016/j.ejps.2014.11.009> PMID: 25460545
- [79] Pietrzak K, Isreb A, Alhnan MA. A flexible-dose dispenser for immediate and extended release 3D printed tablets. *Eur J Pharm Biopharm* 2015; 96: 380-7. <http://dx.doi.org/10.1016/j.ejpb.2015.07.027> PMID: 26277660
- [80] Tartarisco G, Gallone G, Carpi F, *et al.* Polyurethane unimorph bender microfabricated with Pressure Assisted Microsyringe (PAM) for biomedical applications. *Mater Sci Eng C* 2009; 29: 1835-41. <http://dx.doi.org/10.1016/j.msec.2009.02.017>
- [81] Palo M, Holländer J, Suominen J, Yliruusi J, Sandler N. 3D printed drug delivery devices: perspectives and technical challenges. *Expert Rev Med Devices* 2017; 14(9): 685-96. <http://dx.doi.org/10.1080/17434440.2017.1363647> PMID: 28774216
- [82] Khaleel SA, Alexander MR, Irvine DJ, *et al.* Extrusion 3D Printing of Paracetamol Tablets from a Single Formulation with Tunable Release Profiles Through Control of Tablet Geometry. *AAPS PharmSciTech* 2018; 19(8): 3403-13.

- [83] <http://dx.doi.org/10.1208/s12249-018-1107-z> PMID: 30097806
Okwuosa TC, Stefaniak D, Arafat B, Isreb A, Wan KW, Alhnan MA. A Lower Temperature FDM 3D Printing for the Manufacture of Patient-Specific Immediate Release Tablets. *Pharm Res* 2016; 33(11): 2704-12.
- [84] <http://dx.doi.org/10.1007/s11095-016-1995-0> PMID: 27506424
Jamróz W, Kurek M, Łyszczarz E, et al. 3D printed orodispersible films with Aripiprazole. *Int J Pharm* 2017; 533(2): 413-20.
- [85] <http://dx.doi.org/10.1016/j.ijpharm.2017.05.052> PMID: 28552800
Goyanes A, Buanz ABM, Hatton GB, Gaisford S, Basit AW. 3D printing of modified-release aminosalicylate (4-ASA and 5-ASA) tablets. *Eur J Pharm Biopharm* 2015; 89: 157-62.
- [86] <http://dx.doi.org/10.1016/j.ejpb.2014.12.003> PMID: 25497178
Beck RCR, Chaves PS, Goyanes A, et al. 3D printed tablets loaded with polymeric nanocapsules: An innovative approach to produce customized drug delivery systems. *Int J Pharm* 2017; 528(1-2): 268-79.
- [87] <http://dx.doi.org/10.1016/j.ijpharm.2017.05.074> PMID: 28583328
Melocchi A, Parietti F, Loreti G, et al. 3D printing by fused deposition modeling (FDM) of a swellable/erodible capsular device for oral pulsatile release of drugs. *J Drug Deliv Sci Technol* 2015; 30: 360-7.
- [88] <http://dx.doi.org/10.1016/j.jddst.2015.07.016>
Khaled SA, Burley JC, Alexander MR, Roberts CJ. Desktop 3D printing of controlled release pharmaceutical bilayer tablets. *Int J Pharm* 2014; 461(1-2): 105-11.
- [89] <http://dx.doi.org/10.1016/j.ijpharm.2013.11.021> PMID: 24280018
Khaled SA, Burley JC, Alexander MR, Yang J, Roberts CJ. 3D printing of tablets containing multiple drugs with defined release profiles. *Int J Pharm* 2015; 494(2): 643-50.
- [90] <http://dx.doi.org/10.1016/j.ijpharm.2015.07.067> PMID: 26235921
Yu DG, Branford-White C, Yang YC, Zhu LM, Welbeck EW, Yang XL. A novel fast disintegrating tablet fabricated by three-dimensional printing. *Drug Dev Ind Pharm* 2009; 35(12): 1530-6.
- [91] <http://dx.doi.org/10.3109/03639040903059359> PMID: 19929213
Gazzaniga A, Cerea M, Cozzi A, Foppoli A, Maroni A, Zema L. A novel injection-molded capsular device for oral pulsatile delivery based on swellable/erodible polymers. *AAPS PharmSciTech* 2011; 12(1): 295-303.
- [92] <http://dx.doi.org/10.1208/s12249-011-9581-6> PMID: 21267684
Henry S, McAllister DV, Allen MG, Prausnitz MR. Microfabricated microneedles: a novel approach to transdermal drug delivery. *J Pharm Sci* 1998; 87(8): 922-5.
- [93] <http://dx.doi.org/10.1021/js980042+> PMID: 9687334
Davis SP, Landis BJ, Adams ZH, Allen MG, Prausnitz MR. Insertion of microneedles into skin: measurement and prediction of insertion force and needle fracture force. *J Biomech* 2004; 37(8): 1155-63.
- [94] <http://dx.doi.org/10.1016/j.jbiomech.2003.12.010> PMID: 15212920
Boehm RD, Miller PR, Hayes SL, Monteiro-Riviere NA, Narayan RJ. Modification of microneedles using inkjet printing. *AIP Adv* 2011; 1(2): 22139.
- [95] <http://dx.doi.org/10.1063/1.3602461> PMID: 22125759
Boehm RD, Miller PR, Schell WA, et al. Inkjet printing of amphotericin B onto biodegradable microneedles using piezoelectric inkjet printing. *JOM* 2013; 65: 525-33.
- [96] <http://dx.doi.org/10.1007/s11837-013-0574-7>
Boehm RD, Miller PR, Daniels J, et al. Inkjet printing for pharmaceutical applications. *Mater Today* 2014; 17: 247-52.
- [97] <http://dx.doi.org/10.1016/j.mattod.2014.04.027>
Preis M, Öblom H. 3D-Printed Drugs for Children-Are We Ready Yet? *AAPS PharmSciTech* 2017; 18(2): 303-8.
- [98] <http://dx.doi.org/10.1208/s12249-016-0704-y> PMID: 28078628
Gress DR, Kalafsky RV. Geoforum Geographies of production in 3D: Theoretical and research implications stemming from additive manufacturing. *Geoforum* 2020; 60: 43-52.
- [99] <http://dx.doi.org/10.1016/j.geoforum.2015.01.003>
Morrison RJ, Kashlan KN, Flanagan CL, et al. Review Articles Regulatory Considerations in the Design and Manufacturing of Implantable 3D-Printed Medical Devices. 8
- [100] Manda VR, Kampurath V, Msrk C. 3D Printing and its Effect on Outsourcing: A Study of the Indian Aircraft Industry. 2018; 1-22.
- [101] Moulton SE, Wallace GG. 3-dimensional (3D) fabricated polymer based drug delivery systems. *J Control Release* 2014; 193: 27-34.
- [102] <http://dx.doi.org/10.1016/j.jconrel.2014.07.005> PMID: 25020039
Weller C, Kleer R, Piller FT. Author's Accepted Manuscript. *Intern J Prod Econ* 2015.
- [103] Arafat B, Wojsz M, Isreb A, et al. European Journal of Pharmaceutical Sciences Tablet fragmentation without a disintegrant : A novel design approach for accelerating disintegration and drug release from 3D printed cellulosic tablets. 2018; 118: 191-9.
- [104] <http://dx.doi.org/10.1007/s11095-018-2454-x> PMID: 29998405
Jamróz W, Szafraniec J, Kurek M, Jachowicz R. Szafraniec J, Kurek M, Jachowicz R. 3D printing in Pharmaceutical and medical applications—recent achievements and challenges. *Pharm Res* 2018; 35(9): 176.
- [105] <http://dx.doi.org/10.1016/j.jconrel.2017.06.025> PMID: 28668378
Kyobula M, Adedeji A, Alexander MR, et al. *NU. J Control Release* 2017; •••
- [106] <http://dx.doi.org/10.1016/j.jconrel.2017.06.025> PMID: 28668378
Awad A, Trenfield SJ, Goyanes A, Gaisford S, Basit AW. Reshaping drug development using 3D printing. *Drug Discov Today* 2018; 23(8): 1547-55.
- [107] <http://dx.doi.org/10.1016/j.drudis.2018.05.025> PMID: 29803932
Trenfield SJ, Awad A, Goyanes A, Gaisford S, Basit AW. 3D printing pharmaceuticals: drug development to frontline care. *Trends Pharmacol Sci* 2018; 39(5): 440-51.
- [107] <http://dx.doi.org/10.1016/j.tips.2018.02.006> PMID: 29534837



Effects of different monosaccharides on thermal stability of phycobiliproteins from *Oscillatoria* sp. (BTA-170): Analysis of kinetics, thermodynamics, colour and antioxidant properties

Ramesh Sharma^a, Pinku Chandra Nath^a, Kondi Vanitha^b, Onkar Nath Tiwari^{c,**}, Tarun Kanti Bandyopadhyay^d, Biswanath Bhunia^{a,*}

^a Department of Bio-Engineering, National Institute of Technology, Agartala, 799046, India

^b Department of Pharmaceutics, Vishnu Institute of Pharmaceutical Education and Research, Narsapur, Medak, Telangana, 502313, India

^c Division of Microbiology, ICAR-Indian Agricultural Research Institute, New Delhi, 110012, India

^d Chemical Engineering Department, National Institute of Technology, Agartala, 799046, India

ARTICLE INFO

Keywords:

Oscillatoria sp.
Phycobiliproteins
Antioxidant
Degradation rate
IC₅₀
Monosaccharides

ABSTRACT

Phycobiliproteins (PBP) are natural colourants and antioxidants derived from cyanobacteria. The purity indexes of extracted C-phycoerythrin (C-PC), allophycoerythrin (A-PC), and phycoerythrin (PE) were 0.98–1.23, 0.78–0.096, and 0.85–0.99, respectively. To investigate thermodynamic characteristics, degradation kinetics, colour, and antioxidant capabilities of *Oscillatoria* sp. (BTA-170) extract powder, the PBPs were thermally treated with various monosaccharides such as glucose, fructose, sucrose, and lactose. In comparison to other monosaccharides that can stabilize the degradation of C-PC, A-PC, and PE at higher temperatures, glucose was found to be the most essential supplement. At 85 °C, glucose enhanced the half-life of C-PC from 2.09 to 5.37 h, whereas glucose increased the half-life of A-PC from 4.9 to 13.51 h and PE from 5.57 to 15.77 h. While glucose was added, entropy (S) for C-PC was reduced from –177.82 to –183.25 J/Mol K, for A-PC from –178.24 to –169.61 J/Mol K, and for PE from –176.28 to –170.97 J/Mol K. However, the value of enthalpy (H) was enhanced from 52.37 to 53.20 KJ/Mol, while the values of A-PC and PE were raised from 40.63 to 40.56 KJ/Mol and 40.32 to 41.43 KJ/Mol, respectively. Gibbs free energy (G*) was found in the range of 111.48–118.81 KJ/Mol for C-PC, 94.49–101.28 KJ/Mol for A-PC, and 95.79–102.63 KJ/Mol for PE when glucose was added, showing a higher degree of protein stability. When fructose was added, the ΔE values of PBPs were reduced from 13.31 to 6.62 at 85 °C, with the least amount of colour degradation among the monosaccharides. At 85 °C, glucose reduced the IC₅₀ of PBPs from 30.45 mg/ml to 17.33 mg/ml. The thermal tolerance of monosaccharides for PBPs suggested that they could be a potential source of PBP stabilization in the food industry.

1. Introduction

Food companies had excess synthetic colourant around 1800 BCE, but there was no control over its usage in food goods. Currently, there is a legislative body in place to regulate the use of colourants in food items (Downham & Collins, 2000). The consumer's concern about the safety and health risks associated with the use of synthetic colourants has grown in the last decade. The use of synthetic colourants in food has been questioned due to their harmful impact on human health (Faieta et al., 2020). Simultaneously, the food industry is looking for an

alternate supply of E-numbered chemicals, such as natural additives, to replace them (Khazaei et al., 2014). The Food and Drug Administration (FDA) and the European Food Safety Authority (EFSA) have placed restrictions on the use of synthetic colourants in food, beverages, and confectionary due to their association with cancer cell development or allergic reaction stimulation. Natural colourants are concentrated extracts derived primarily from algae, vegetables, and plants that have vivid colour qualities and have been shown to be beneficial to human health. These pigments, on the other hand, differ from synthetic pigments in that they are extremely susceptible to stress (temperature,

* Corresponding author.

** Corresponding author.

E-mail addresses: rameshdawari156@gmail.com (R. Sharma), nathpinku005@gmail.com (P.C. Nath), vanithakondi@gmail.com (K. Vanitha), ontiwari1968@gmail.com (O.N. Tiwari), tarunkantibandyopadhyay@gmail.com (T.K. Bandyopadhyay), bbhunias@gmail.com (B. Bhunia).

<https://doi.org/10.1016/j.fbio.2021.101354>

Received 21 March 2021; Received in revised form 7 September 2021; Accepted 8 September 2021

Available online 11 September 2021

2212-4292/© 2021 Elsevier Ltd. All rights reserved.

light, etc.) and storage conditions, and may bleach or degrade the attractive appearance and final quality of the products to which they are added (MacDougall, 2002). As a result, more study is needed to stabilize this colourant for use in stressful environments, particularly in the food industry.

Natural blue colourants are in high demand in the drinks and beverage industry, but they are extremely rare in nature, forcing producers to rely on manufactured colourants. As a result, the food sector has expressed an interest in finding, using, and stabilizing natural blue colourants. Color extraction using cyanobacteria such as *Spirulina* sp. for phycocyanin, *Haematococcus* sp. for astaxanthin pigments, and *Dunaliella* sp. for carotene pigments is becoming more popular in the commercial world (Dufossé et al., 2005). Proteins, particularly PBPs, which are light-harvesting proteins and are regarded a natural source of blue colourant, make up the majority of cyanobacteria (Sharma et al., 2020). C-phycocyanin (C-PC), allophycocyanin (A-PC), and phycoerythrin (PE) are PBPs that are blue, bluish-green, and reddish in colour respectively (Tiwareti et al., 2019b). C-PC, A-PC, and PE have optimum absorption ranges of 610–620 nm, 650–655 nm, and 540–570 nm, respectively (Kannaujiya & Sinha, 2016b). C-PC, A-PC, and PE had maximal absorption at wavelengths of 615 nm, 652 nm, and 562 nm, respectively (Bennett & Bogorad, 1973). PBPs are classed as high (PE), intermediate (C-PC), or low (A-PC) energy pigments based on their energy capacity. Phycocyanin's molecular weight varies from 44 to 260 kDa (MacColl, 1998). PBPs have a high water solubility and account for 40% (w/w) of the accessible water-soluble protein in cyanobacteria (Sharma et al., 2020; Tiwareti et al., 2020). The intensity of light, the light to days ratio (L:D), and the cyanobacteria's nutrition availability were all factors that affected the formation of PBPs (Norena-Caro & Benton, 2018; Tiwareti et al., 2019a, 2019d). Biochemical engineers will need kinetic and thermodynamic analyses of PBPs in order to design and develop a bioreactor for industrial use. Phycobiliproteins (PBPs) pigments as a colourant have an anticipated total commercial value of roughly US\$60 million, while the cost of phycocyanin (C-PC) is around 500\$-1000,00\$ per kilogramme (Borowitzka, 2013).

Cyanobacteria are also thought to be the ecosystem's primary biomass producer (Rastogi & Sinha, 2009; Sardar et al., 2018; Tiwareti et al., 2019c). PBPs are deemed Generally Recognized as Safe (GRAS) substances by the Food and Drug Administration for use as an antioxidant in functional foods (Borowitzka, 2013). PBPs, on the other hand, have certain health-promoting qualities, such as radical scavenging, anti-inflammatory, and hepatoprotective capabilities, and are frequently used in food and pharmaceuticals (Castro-García et al., 2018). As a result, food manufacturers' goals are to enhance the usage of PBPs as natural food additives. PBPs are more appealing in the food business because of their vivid bright hue (Morais, 2018). The *Oscillatoria* sp. was utilised to make butylated hydroxytoluene (BHT), which is used in food additives (Babu & Wu, 2008). Phycocyanin isolated from *Spirulina* sp. has also been reported to have chemopreventive effects (Chen & Wong, 2008). Because it possesses a tetrapyrrole chain, phycocyanin has high antioxidant qualities because it absorbs free radicals by donating hydrogen atoms (Romay et al., 2003). Despite the fact that it has positive characteristics, C-PC is extremely sensitive to both extrinsic (light and temperature) and intrinsic (pH) factors, resulting in protein denaturation in *Spirulina* extract (Kupka & Scheer, 2008). The key issue in the food industry is the stability of PBPs pigment because to its susceptibility to temperatures, pH, and light. To some extent, phycocyanin encapsulation with alginates could inhibit heat deterioration (Yan et al., 2014). The most commonly employed preservatives for C-PC for analytical purposes are dithiothreitol and sodium azide, which are not suitable for human consumption (Mishra et al., 2008).

To maintain the structure of the protein, polyols such as sorbitol, xylitol, and mannitol have been utilised (Petersen et al., 2004). It has previously been reported on the influence of polyols and mono- or disaccharides on the stability of PBPs when exposed to light, heat, and

freezing (Kannaujiya & Sinha, 2016b). Sugar also inhibited the degradation of the C-phycocyanin blue colour derived from spirulina sp. (Martelli et al., 2014). Because it is a cheap and readily available material, sugar is frequently added to proteins as a stabilizer to reduce protein heat denaturation. Monosaccharides and disaccharides are mostly utilised to stabilize proteins. Glucose, fructose, galactose, and lactose are monosaccharides, while lactose, maltose, and sucrose are disaccharides. Sugar interacts to protein primarily through an N-linked glycosidic bond, which helps to prevent protein breakdown during heat processing (Imamura et al., 2003). Sugar's stabilizing impact has been extensively studied in the food sector to reduce the degradation of anthocyanin in raspberry juice (Martelli et al., 2014). Sugar, according to Vikram et al. (2005), can reduce the breakdown of nutrients in orange juice (Vikram et al., 2005). Sadilova et al. (2009) investigated the effect of sugar addition in fruit juice on anthocyanin pigment stability (Sadilova et al., 2009). As a result, sugar can be considered the primary stabilizer in preventing PBP heat deterioration.

According to our findings, there is insufficient research on the stability of PBPs employing sugar as a stabilizing agent. The majority of the experiments were carried out in order to quantify PBPs. Therefore, the manuscript is emphasized on evaluating the influence of sugar on the stability of PBPs following thermal treatment in order to extend the use of PBPs.

2. Materials and methods

2.1. Chemicals

Chemicals from Hi-Media India Ltd were used in this study, and they are analytical grade. All of the trials in this investigation were done in triplicate. The results were presented with their mean values and standard deviation (SD) of triplicate trials.

2.2. Culturing of cyanobacteria and maintenance

The cyanobacterium *Oscillatoria* sp.(BTA-170) was collected from the Indian Agricultural Research Institute (IARI, New Delhi).The cyanobacterium employed in this work was selected from a pool of different strains based on its ability to produce high yields of phycobiliproteins in BG 11 medium (Nath et al., 2020, pp. 1–11; Tiwareti et al., 2019b). In BG 11 solid media, a pure culture was developed using a conventional procedure. BG-11 medium was used for maintenance of *Oscillatoria* sp. (BTA-170) (Tiwareti et al., 2019b).

2.3. Collection of powder from cyanobacteria

The seed cultivation of *Oscillatoria* sp. (BTA-170) was done in a conical flask (250 ml) with 100 ml BG-11 media. The seed culturing was done by transferring a loop of pure culture into BG-11 media and incubation was done at 28 °C for 5 days to the fixed light intensity at 4k Lux with a photoperiod of 12:12 (Light: Day) ratio. The manual agitation of the culture was at 24 h interval of time. The production of cyanobacterial biomass was carried out for 30 days in the second phase, in which 10% of the seed culture was incubated in a conical flask (2 L) using BG-11 (1 L) media as described for seed culture. After 30 days, the biomass was separated by centrifugation at 10,000 rpm for 10 min at 4 °C. To collect the dry biomass, the precipitate was collected and dried in a tray dryer at 40 °C for 96 h, then pulverised in a mortar and pestle to collect the powder. For further experimentation, the powder was maintained in an airtight aluminium pouch.

2.4. Sample preparation and thermal treatment

The dried powder was collected and PBPs samples were prepared for heating. The 60 mg of dried powder and sugar as (15 w/w%) was mixed into 60 ml of 0.05 M phosphate buffer (pH-7). The conical flask

containing the sample was surrounded by aluminium foil to get protected from light to avoid the PBPs degradation. The conical flask was kept in the water bath and heated for 40 min and the samples were withdrawn after 10 min interval. The thermostat was used to set the temperature at 45 °C, 55 °C, 65 °C, 75 °C, and 85 °C. Before the heat treatment, sample PBPs were measured using a UV-Vis spectrophotometer (Bennett & Bogorad, 1973) and absorbance was recorded. The colour parameters as well as the scavenging activity of the fresh and heated samples were measured on the same day. To avoid protein degradation, the samples were kept in the refrigerator at 4 °C until further analysis was finished.

2.5. PBPs measurement

The PBPs of the sample were determined using a UV-Vis spectrophotometer (LABMAN, LMSP UV1900). The 0.05 M phosphate buffer (pH-7) was used for calibration and about 3 ml of samples were poured into cuvettes. The absorbance was taken at 615, 652, and 652 nm. The C-PC, A-PC, and PE were calculated from equations (1)–(3) (Bennett & Bogorad, 1973). The PBPs were measured in milligram per liter of BTA-170 culture.

$$C-PC(\text{mg/L}) = \frac{A_{615} - 0.474(A_{652})}{5.34} \quad (1)$$

$$A-PC(\text{mg/L}) = \frac{A_{652} - 0.208(A_{615})}{5.09} \quad (2)$$

$$PE(\text{mg/L}) = \frac{A_{562} - 2.41(C-PC) - 0.849(A-PC)}{9.62} \quad (3)$$

2.6. Purity index

The purity Indexes of PBPs were measured by the spectrophotometric method (Kannaujiya & Sinha, 2016a) and calculated from eq. (4) (5) & (6). This ratio signifies the specific proteins to contaminated proteins. The purity Indexes of C-PC, A-PC, and PE were determined at wavelengths of 615, 652, and 562 nm, respectively to the total soluble protein concentration at 280 nm.

$$(C-PC) = \frac{A_{615}}{A_{280}} \quad (4)$$

$$(A-PC) = \frac{A_{652}}{A_{280}} \quad (5)$$

$$(PE) = \frac{A_{562}}{A_{280}} \quad (6)$$

When the purity Index ≥ 0.7 , PBPs represented as food-grade, and when the ratio is ≥ 4 , the PBPs are fit for the analytical grade.

2.7. Thermal kinetics of PBPs with stabilizing agent

The deactivation study of PBPs was done under various temperatures and the effect of sugar as the stabilizing agent was evaluated in the deactivation process. The deactivation of PBPs was observed, and the deactivation process was assumed to follow first-order kinetics.

$$P_A = P_D$$

P_A and P_D signify the active and inactive state of PBPs. The assumptions were made that intermediates were not formed significantly at the time of the deactivation process. The process of deactivation is presented in eq. (7)

$$\frac{dP_A}{dt} = -k_d[P_A] \quad (7)$$

Where, k_d represent the deactivation rate constant. Integration of Eq.

(7) gives

$$\alpha = \exp(-k_d \cdot t)$$

$$\text{Where, } \alpha = \frac{P_D}{P_A}$$

The calculation of k_d was done by finding the slope by plotting $\ln(\alpha)$ versus t . Half-life was determined and it is the time required to deactivate the C-PC, A-PC, and PE to half amount and calculated using Eq. (8).

$$t_{1/2} = \frac{0.693}{k_d} \quad (8)$$

Thermodynamic properties of PBPs after thermal treatment were evaluated by finding parameters like enthalpy, entropy, Gibb's free energy, and activation energy and evaluated the mechanism of the deactivation process (Naidu & Panda, 2003). The temperature dependence of the deactivation rate constant can be expressed as shown in eq. (9)

$$k_d = \frac{kT}{h} e^{\frac{\Delta S}{R}} e^{-\frac{\Delta H}{RT}} \quad (9)$$

or

$$\ln\left(\frac{k_d}{T}\right) = \ln\left(\frac{k}{h}\right) + \frac{\Delta S}{R} - \frac{\Delta H}{RT} \quad (10)$$

where ΔH is enthalpy and ΔS represents the entropy values. R denotes the gas constant and T is temperature. The h is the plank's constant and k represent the Boltzmann constant. The plot was generated to $\ln(k_d/T)$ versus $1/T$ and calculated the enthalpy and entropy values of C-PC, A-PC and PE as shown in Fig. 1a,b & 1c.

The Eq. (11) was used to calculate Gibb's free energy (ΔG)

$$\Delta G = \Delta H - T\Delta S \quad (11)$$

Similarly, the Arrhenius equation was used to determine the activation energy (E_a) as shown in Eq. (12)

$$k_d = k_0 e^{\left(\frac{-E_a}{RT}\right)} \quad (12)$$

or

$$\ln(k_d) = \ln(k_0) - \left(\frac{E_a}{R}\right) \frac{1}{T} \quad (13)$$

The graph was plotted to $\ln(k_d)$ versus $1/T$ to find the value of E_a of C-PC, A-PC, and PE as shown in Fig. 2a, b & 2c.

2.8. Colour degradation measurement

Hunter lab colorimeter (HunterLab, MSXP-4500L) was used to determine the colour of PBPs before and after heat treatment with the addition of various sugars. The sample was produced using the same procedure as for the measurement of PBPs. The calibration of the colorimeter was done with a white reference tile. The 60 μl of samples were poured into a transparent glass having a dimension of 10 cm \times 15 cm and the color parameters were evaluated. The lab coordinates values including L^* , a^* & b^* were measured and signified the lightness, red to green, and yellow to blue color of PBPs. The measurement was done by CIE scale, and change of color (ΔE^*) was evaluated with Eq. (14)

$$\Delta E^* = \sqrt{\Delta L^{*2} + \Delta a^{*2} + \Delta b^{*2}} \quad (14)$$

2.9. Antioxidant activity

The antioxidant activity of PBPs was evaluated by using the free radical DPPH (Chan et al., 2018). 1 g of PBPs was dissolved in 25 ml of methanol to make the stock solution. 80 mg of DPPH was dissolved in




Fig. 1. Plot to determine enthalpy and entropy of (a) C-PC, (b) A-PC, and (c) PE during thermal treatment.

100 mL of methanol to make the stock solution of DPPH. By diluting the sample with the required amount of methanol, different PBP concentrations were obtained. An equal volume of sample was mixed with an equal amount of DPPH stock solution to achieve various PBP concentrations. The mixed sample was incubated for 30 min at room temperature. The absorbance of mixture were determined by spectrophotometer (LABMAN, LMSP UV1900) at 517 nm (Chan et al., 2018). The inhibition percentage was calculated by equation (15)

$$\text{Inhibition}(\%) = 1 - \frac{(\text{Abs.}_{\text{sample}})}{(\text{Abs.}_{\text{control}})} \times 100\% \quad (15)$$

3. Results and discussions

3.1. Kinetics and thermodynamic properties of PBPs with sugar

In the present investigation, the C-PC, A-PC, and PE content of

Oscillatoria sp. (BTA-170) were determined to be 287.03 mg/L, 254.23 mg/L, and 82.34 mg/L, respectively, which is quite similar to our prior findings (Tiwari et al., 2019b). The purity index of C-PC, A-PC, and PE were determined to be 0.98–1.23, 0.78–0.96, and 0.85–0.99, respectively. Tables 1–3 show the results of evaluating the deactivation rate constant (k_d) for C-PC, A-PC, and PE at various temperatures and estimating the effect of sugar on the deactivation rate constant (k_d). Temperature has long been known to play a significant impact in protein deactivation (Bhunja et al., 2013). Results showed that, the k_d value for PBPs was found to be low in the temperature range of 45 °C–55 °C, but as the temperature goes up, the k_d value increased. The k_d value of C-PC was found to be 0.331 at 85 °C, with glucose lowering the value to 0.129 at the same temperature. Fructose, galactose, and lactose can all lower the k_d value for C-PC to 0.142, 0.136, and 0.159 at 85 °C, respectively. Sugars were successful in lowering the k_d values for C-PC, A-PC, and PE at temperatures higher than 55 °C. Glucose, among the sugars, reduced the k_d values to the lowest and highest k_d values held by lactose, for




Fig. 2. Arrhenius plotting during thermal treatment to determine the activation energy of (a) C-PC, (b) A-PC, and (c) PE.

Table 1

Effect of temperature and different sugar on deactivation rate constant (k_d) for C-PC.

k_d values (hr^{-1})					
Temperature ($^{\circ}C$)	Control (no sugar)	Glucose	Fructose	Galactose	Lactose
45	0.030	0.012	0.013	0.012	0.015
55	0.060	0.022	0.026	0.024	0.029
65	0.104	0.039	0.045	0.044	0.052
75	0.172	0.071	0.079	0.075	0.084
85	0.331	0.129	0.142	0.136	0.159

Table 2

Effect of temperature and different sugar on deactivation rate constant (k_d) for A-PC.

k_d values (hr^{-1})					
Temperature ($^{\circ}C$)	Control (no sugar)	Glucose	Fructose	Galactose	Lactose
45	0.022	0.008	0.009	0.009	0.010
55	0.041	0.015	0.017	0.016	0.019
65	0.073	0.024	0.028	0.027	0.030
75	0.098	0.036	0.041	0.039	0.045
85	0.141	0.051	0.060	0.057	0.065

C-PC, A-PC, and PE, as shown in Tables 1–3. At 85 $^{\circ}C$, the k_d value of A-PC was calculated to be 0.141. Glucose was shown to be the most effective sugar for A-PC, with the lowest k_d value (0.060), followed by galactose (0.057), fructose (0.060), and lactose (0.065). The k_d value of

PE was 0.124 at 85 $^{\circ}C$, but when glucose is present, it drops to 0.044 at 85 $^{\circ}C$. At 85 $^{\circ}C$, the k_d value of PE lowers to 0.051, 0.048, and 0.058 in the presence of fructose, galactose, and lactose, respectively. It was found that C-PC degraded at 6.71%, 10.83%, and 19.82% at 65, 75 &

Table 3
Effect of temperature and different sugar on deactivation rate constant (k_d) for PE.

k_d values (hr^{-1})					
Temperature ($^{\circ}\text{C}$)	Control (no sugar)	Glucose	Fructose	Galactose	Lactose
45	0.020	0.007	0.008	0.008	0.009
55	0.035	0.012	0.014	0.013	0.015
65	0.062	0.021	0.024	0.023	0.027
75	0.086	0.033	0.039	0.037	0.041
85	0.124	0.044	0.051	0.048	0.058

85 $^{\circ}\text{C}$ respectively while heating for 40 min. The glucose treatment reduced the C-PC degradation to 2.55%, 4.65%, and 8.24% at 65, 75 & 85 $^{\circ}\text{C}$ respectively. The half-life of PBPs was used to assess the effect of sugar on their degradation rate. The glucose, fructose, galactose, and lactose elevate the half-life of C-PC from 2.09 h to 5.37 h, 4.90 h, 5.10 h, and 4.36 h respectively at 85 $^{\circ}\text{C}$. Similarly, A-PC degraded at 4.45%, 6.30% and 9% at 65, 75 & 85 $^{\circ}\text{C}$ respectively while heating for 40 min. Patel et al. (2004) reported that C-PC is unstable above 55 $^{\circ}\text{C}$ (Patel et al., 2004), and according to Chronakis (2001), the denaturation temperature of PC is over 67 $^{\circ}\text{C}$ (Chronakis, 2001). According to several publications, PC solubility decreased in acidic conditions, with aggregation starting at pH 3 and denaturation happening at pH 5–7 when heated over 45 $^{\circ}\text{C}$ (Chaiklahan et al., 2012). In the present investigation, the PBPs were stable up to 55 $^{\circ}\text{C}$ at 7 pH and instability raised with increasing the temperature up to 85 $^{\circ}\text{C}$. The glucose, fructose, galactose, and lactose increase the half-life of A-PC from 4.90 h to 13.51 h, 11.60 h, 12.25 h, and 10.65 h respectively at 85 $^{\circ}\text{C}$. The PE was least degraded PBPs which degraded at 4.04%, 5.54% & 7.96% at 65, 75 & 85 $^{\circ}\text{C}$ respectively. The glucose, fructose, galactose, and lactose increase the half-life of PE from 5.57 h to 15.77, 13.51 h, 14.40 h, and 12.03 h respectively at 85 $^{\circ}\text{C}$. The PE was found to be the most stable PBP, followed by A-PC and C-PC, and a similar finding was found in a prior publication (Tiwari et al., 2019b).

In present study, glucose increased the thermal stability of PBPs at all temperatures tested. Miyawaki et al. (2016) reported that trehalose was found to be efficient in improving the heat stability of phycocyanin pigments (Miyawaki et al., 2016). The differences in thermal stability amongst sugars may be related to distinct solvent/protein interaction processes (Barbiroli et al., 2017). While formulating *Spirulina* sp. to liquid solutions, food-grade substances such as monosaccharide, organic acids, and salts have been beneficial in reducing the effect of heat on phycocyanin (Faieta et al., 2020). The mechanism for thermal stabilization of proteins by monosaccharides in aqueous phase is due to alteration in interaction between water and protein molecules (Barbiroli et al., 2017). The bonding of protein molecules controls the orientation of the secondary, tertiary, and quaternary structure of the protein, and protein deactivation happened after modifying the structure at various temperatures and pH levels. Rastogi et al. (2015) investigated the functioning and stability of pure PBPs at different temperatures and pH levels (Rastogi et al., 2015). Tables 4–6 demonstrate the variation of entropy (S) of C-PC, A-PC, and PE after heat treatment in the presence of sugar. It is evident that the values of enthalpy (H) and entropy (S) altered with temperature and were also affected by the type of sugar used. Finding H and S can be used to determine the degree of denaturation of a protein thermodynamically. Protein randomness is denoted by

entropy (S). The positive symbol of S denotes a higher amount of randomness and represents protein denaturation, whereas the negative symbol denotes a lower degree of protein denaturation (Bhunia et al., 2013).

The entropy (S) of C-PC was calculated to be -177.82 J/Mol K before the addition of sugar. Glucose elevated the entropy value to -183.25 J/Mol K . As demonstrated in Table 4, all sugars have a reduced S value, with lactose having a particularly low S value. Fructose, galactose, and lactose, on the other hand, reduce the entropy value of C-PC to -183.74 , -181.27 , and -185.60 J/Mol K , respectively. In the absence of sugar, the S value of A-PC is determined to be -178.24 J/Mol K , but when glucose is added, the value drops to -169.61 J/Mol K . As indicated in Table 5, fructose, galactose, and lactose were also prominent in lowering the S value. In the current study, the S value of PE was determined to be -176.28 J/Mol K in the absence of sugar, with glucose increasing the value to -170.97 J/Mol K . As seen in Table 6, all sugar lowers the S value to a satisfactory level for PE. It is evident that the PE had the lowest S value among the PBPs, followed by C-PC and A-PC. The drop in entropy value after adding sugar was attributed to less breakdown of PBPs as a result of the formation of linkages between protein and sugar molecules.

Enthalpy (H) signifies the amount of energy required to denature the protein. As a result, a greater enthalpy value suggests that the protein is more stable (Marangoni, 2003). Tables 4–6 show the variation of H values of C-PC, A-PC, and PE after heat treatment, as well as the effect of sugar on enthalpy values. In the absence of sugar, the H values of C-PC were determined to be 52.37 KJ/Mol . The enthalpy value increased to 53.20 KJ/Mol when glucose was added. Fructose, galactose, and lactose, on the other hand, increased the values of H to 52.70 , 53.69 , and 51.73 KJ/Mol , respectively. The H value for A-PC was calculated to be 40.63 KJ/Mol in the absence of sugar, and fructose increased the value to 41.31 KJ/Mol . Similarly, all sugars were prominent in increasing H levels in PE, with lactose being the most efficient, as indicated in Table 6. Because the free energy is reliant on the values of enthalpy and entropy as given in eq. (10), the value of Gibb's free energy is used to determine the protein's stability (Bhunia et al., 2013). The G^* value in the negative signifies the higher degree of deactivation and more denaturation of the protein. Tables 4–6 show the evaluated G values of C-PC, A-PC, and PE under sugar treatment conditions. In the absence of sugar, the G^* value of C-PC varies from 108.92 to 116.03 KJ/Mol . In the addition of glucose, the G^* value increased to 111.48 – 118.81 KJ/Mol . Similarly, when fructose, galactose, lactose were introduced, the G^* value increased to 111.12 – 118.47 KJ/Mol , 111.33 – 118.58 KJ/Mol , and 110.76 – 118.18 KJ/Mol respectively. C-PC had the highest G^* values among the PBPs, followed by A-PC and PE. To identify the minimal energy required to activate the degradation process of PBPs, the activation energy (E_a) on thermal degradation of C-PC, A-PC, and PE was investigated. The activation energy (E_a) was computed from the slope of the graph which was plotted $\ln(k_d)$ versus $1/T$. Fig. 2a, b, and 2c show Arrhenius plot during thermal treatment to calculate the activation energy for C-PC, A-PC, and PE. As shown in Table 4, the E_a value of C-PC before adding sugar was 55.17 KJ/Mol , and glucose raise activation energy to 56.00 KJ/Mol . Similarly, E_a values of A-PC and PE were computed as 43.43 KJ/Mol and 43.12 KJ/Mol respectively. Fructose raises activation energy of A-PC to 44.11 kJ/mol , whereas glucose raises activation energy of PE to 44.23 kJ/mol . At 15% concentration, sugars were dominant in increasing activation energy of PBPs, as indicated in

Table 4
Evaluated thermodynamic properties during the heating process of C-PC.

Thermodynamic parameters	Control (no sugar)	Glucose	Fructose	Galactose	Lactose
H (KJ/Mol)	52.37	53.20	52.70	53.69	51.73
S (J/Mol K)	-177.82	-183.25	-183.74	-181.27	-185.60
E_a (KJ/Mol)	55.17	56.00	55.50	56.40	54.54
G (kJ/Mol)	108.92–116.03	111.48–118.81	111.12–118.47	111.33–118.58	110.76–118.18

Table 5
Evaluated thermodynamic properties during the heating process of A-PC.

Thermodynamic parameters	Control (no sugar)	Glucose	Fructose	Galactose	Lactose
H (KJ/Mol)	40.63	40.56	41.31	40.34	40.77
S(J/Mol K)	-178.24	-169.61	-172.98	-169.76	-172.17
E _a (KJ/Mol)	43.43	43.36	44.11	43.14	43.58
G (kJ/Mol)	97.31–104.44	94.49–101.28	96.32–103.24	94.32–101.11	95.52–102.41

Table 6
Evaluated thermodynamic properties during the heating process of PE.

Thermodynamic parameters	Control (no sugar)	Glucose	Fructose	Galactose	Lactose
H (KJ/Mol)	40.32	41.43	42	40.97	41.78
S(J/Mol K)	-176.28	-170.97	-173.93	-170.45	-174.05
E _a (KJ/Mol)	43.12	44.23	44.81	43.77	44.58
G (kJ/Mol)	96.37–103.42	95.79–102.63	97.32–104.28	95.17–101.99	97.13–104.09

Tables 4–6.

3.2. Influence of heat treatment and sugar on the color parameters of PBPs

The color of the fresh PBPs was deeper blue and the CIE scale and coordinates values were, L* = 36.60, a* = 2.43, and b* = -6.8. Fig. 3a, b & 3c, show that ΔL*, Δa*, and Δb* values increased slowly up to 55 °C

and increased significantly from 65 °C as the temperature raised and the values were comparable to the literature (Chaiklahan et al., 2012). With the addition of sugar, the fructose retained the deeper blue color when compared with the other sugar samples with giving lower ΔE* values shown in Fig. 3d. As ΔE* increased, the discoloration was also clearly visible. Normally, the colour of PBPs with sugar added was darker blue when heated at 45 °C and 55 °C, but at 65 °C, the colour became lighter blue and discoloration grew dramatically until 85 °C. The ΔE* values




Fig. 3. Relation of (a) Δ L, (b) Δ a, (c) Δ b, and (d) Δ E of PBPs over heat treatment at 45°C, 55°C, 65°C, 75°C & 85°C.

were highest when the PBPs were heated in absence of sugar and the addition of sugar reduced the ΔE^* values significantly. The overall change in ΔE values of PBPs for control (no sugar), glucose, fructose, galactose, and lactose were 13.31, 7.11, 6.62, 7.47, and 7.17 respectively. Chen and Wong (2008) also found that adding fructose to phycocyanin reduced colour deterioration at 80 °C (Chen & Wong, 2008). The change in colour of phycocyanin from dark blue to light blue could be due to the creation of bonds between phycocyanin and sugar or the denaturation of PBPs. Moreira et al. (2012) investigated the stability of the purple colour of *Nostoc* sp. PBPs in yoghurt and observed that b^* values varied, indicating a loss of blue colour (Moreira et al., 2012). The difference was owing to C-instability PC's at lower pH. In our case, the experiment was carried out at pH 7 in order to maximise the stability during heat treatment. C-PC is mostly stable at 5–7 pH, according to Sadilova et al. (2009), and it starts losing colour values above and below that pH range (Sadilova et al., 2009). However, no research on the influence of sugar following heat treatment on PBP colour values has been published to far. PBPs mixed with fructose showed a deeper blue colour than those mixed with other sugars, indicating that fructose slowed the hydration reaction on phycocyanin active sites (Huang, 1956). Adding the excess sugar also degraded the color of phycocyanin due to its association with microorganisms (Garzón & Wrolstad, 2001).

3.3. Influence of heat treatment and sugar on the antioxidant activity of PBPs

PBPs were tested for their ability to scavenge DPPH radicals at concentrations of 2, 4, 6, 8, and 10 mg/ml at 45, 55, 65, 75, and 85 °C. Fig. 4a, b, 4c, 4d, and 4e show the effect of sugar treatment on inhibition percentage at various temperatures. In fresh conditions, the PBPs inhibited DPPH radicals by 65.82 percent, but this changed dramatically following heat treatment, and the change in inhibition percentage was studied by changing the sugar molecules. The variation in inhibition percentages of PBPs depends on the amount and compositions of PBPs in the solvent, therefore the variation in absorbance was seen during the experiment. There were no significant changes in inhibition percentage at temperatures below 55 °C, but it declined dramatically as the temperature was increased. At 85 °C, the inhibition percentages changed from 65.82 percent to 16.45 percent, and glucose could raise the inhibition to 46.07 percent with a sample concentration of 10 mg/ml at 85 °C.

Similarly, with 10 mg/ml of PBPs, fructose, galactose, and lactose increase by 45.94%, 19.2%, and 45.96% at 85 °C, respectively. The degradation of PBPs resulted in a decrease in the inhibition percentage as the temperature was increased. The degradation of PBPs reduced the inhibition percentage of PBPs. The addition of sugars could increase the inhibition percentage due to the stability of PBPs by the sugar molecules. As shown in 4c, 4d, and 4e, glucose, fructose, and lactose were the most effective sugars in increasing the inhibition percentage at 65 °C and higher temperatures, whereas galactose was less effective. According to Christwardana et al. (2018), adding glucose to phycocyanin increased its scavenging capacity while decreasing the IC₅₀ to 18.47% for *Spirulina* sp., and a similar result was seen in present case. (Christwardana et al., 2018). The 50% free radical scavenging activity (IC₅₀) of PBPs was determined by graphing the graph of PBP concentration vs inhibition percentage (see Table 7). The effect of thermal treatment and sugar on IC₅₀ was evaluated in the present study. PBPs had an IC₅₀ of 9.52 mg/ml, which was enhanced to 30.45 mg/ml by thermal treatment at 85 °C. Sugar was found to be beneficial in lowering the IC₅₀ at all temperatures, as indicated in Table 7. The glucose, fructose, and lactose were productive to decrease the value from 30.45 mg/ml to 17.33 ml/ml, 18.30 ml/ml, and 17.68 mg/ml respectively at 85 °C. In comparison to PC and PE, Rastogi et al. (2015) found that A-PC isolated from *Phormidium rubidium* showed increased sensitivity to free radicals (H₂O₂) (Rastogi et al., 2015). The presence of free radicals accelerates the ageing process and causes tissue damage in the body, which can lead




Fig. 4. Variation of inhibition % of PBPs at (a) 45°C, (b) 55°C, (c) 65°C, (d) 75°C, and (e) 85°C.

Table 7
Effect of temperature and different sugar on IC50 values of PBPs in BTA 170.

Temperature (°C)	Control (no-sugar) (mg/ml)	Glucose (mg/ml)	Fructose (mg/ml)	Galactose (mg/ml)	Lactose (mg/ml)
45	9.52	9.46	9.49	9.51	9.50
55	9.74	9.56	9.58	9.62	9.63
65	14.06	11.14	11.24	13.79	11.25
75	19.92	12.39	12.46	19.74	12.42
85	30.45	17.33	18.30	30.10	17.68

to the development of a variety of diseases. The present findings indicate that PBPs from *Oscillatoria* sp. could be useful food additives for scavenging free radicals.

4. Conclusions

In the present investigation, the effect of different monosaccharides such as glucose, fructose, glucose, and lactose, on the thermal stability of phycobiliproteins of *Oscillatoria* sp. (BTA-170) was examined and thermodynamic properties, degradation kinetics, color, and antioxidant properties of PBPs was evaluated. Glucose was determined to be the most important monosaccharide in comparison to other sugars that can stabilize the degradation of C-PC, A-PC, and PE at higher temperatures. When glucose was added to PBPs, the degradation rate (kd) for C-PC, A-PC, and PE was drastically reduced when compared to other sugars. The PE had the lowest S value out of all the PBPs, followed by C-PC and A-PC. When sugars were added to PBPs at a concentration of 15% (w/w), entropy (S) was reduced and enthalpy (H) was enhanced, resulting in less breakdown of PBPs. In the presence of all sugars, the G* value was found to be positive, indicating that PBPs were deactivated or denatured less during heat treatment. PBPs treated with fructose showed less discoloration than those treated with other sugar molecules. The most important stabilizers for maintaining the antioxidant activity of PBPs at 65 °C and higher temperatures were glucose, fructose, and lactose. The above investigation indicates that PBPs may be stabilized by sugars while preserving antioxidant activity, and colour characteristics and the usage of synthetic colourants in the food industry can be replaced by PBPs.

Funding

Dr. Tarun Kanti Bandyopadhyay and Dr. O N Tiwari would like to express their gratitude to the Department of Biotechnology, Government of India, for their financial support. (BT/PR25035/NER/95/973/2017).

Compliance with ethical standards

This article does not contain any studies with human participants or animals performed by any of the authors.

Declaration of competing interest

The authors declare that they have no conflict of interest.

Acknowledgments

This content is based on NIT Agartala & ICAR-IARI, New Delhi-joint sponsored research. Dr. Biswanath Bhunia and Dr. Tarun Kanti Bandyopadhyay thank the Director of the National Institute of Technology in Agartala for his encouragement and assistance. Dr. O. N Tiwari appreciates the encouragement and support he received from HoD, Division of Microbiology, ICAR-IARI, New Delhi.

References

- Babu, B., & Wu, J. T. (2008). Production of natural butylated hydroxytoluene as an antioxidant by freshwater phytoplankton. *Journal of Phycology*, 44, 1447–1454.
- Barbiroli, A., Marengo, M., Fessas, D., Ragg, E., Renzetti, S., Bonomi, F., & Iametti, S. (2017). Stabilization of beta-lactoglobulin by polyols and sugars against temperature-induced denaturation involves diverse and specific structural regions of the protein. *Food Chemistry*, 234, 155–162.
- Bennett, A., & Bogorad, L. (1973). Complementary chromatic adaptation in a filamentous blue-green alga. *Journal of Cell Biology*, 58, 419–435.
- Bhunia, B., Basak, B., Mandal, T., Bhattacharya, P., & Dey, A. (2013). Effect of pH and temperature on stability and kinetics of novel extracellular serine alkaline protease (70 kDa). *International Journal of Biological Macromolecules*, 54, 1–8.
- Borowitzka, M. A. (2013). High-value products from microalgae—their development and commercialisation. *Journal of Applied Phycology*, 25, 743–756.
- Castro-García, S. Z., Chamorro-Cevallos, G., Quevedo-Corona, L., McCarty, M. F., & Bobadilla-Lugo, R. A. (2018). Beneficial effects of phycobiliproteins from *Spirulina maxima* in a preeclampsia model. *Life Sciences*, 211, 17–24.
- Chaiklahan, R., Chirasuwan, N., & Bunnag, B. (2012). Stability of phycocyanin extracted from spirulina sp.: Influence of temperature, pH and preservatives. *Process Biochemistry*, 47, 659–664.
- Chan, C.-F., Wu, C.-T., Huang, W.-Y., Lin, W.-S., Wu, H.-W., Huang, T.-K., Chang, M.-Y., & Lin, Y.-S. (2018). Antioxidation and melanogenesis inhibition of various *Dendrobium tosaense* extracts. *Molecules*, 23, 1810.
- Chen, T., & Wong, Y.-S. (2008). In vitro antioxidant and antiproliferative activities of selenium-containing phycocyanin from selenium-enriched *Spirulina platensis*. *Journal of Agricultural and Food Chemistry*, 56, 4352–4358.
- Christwardana, M., Sutanto, H., Suzery, M., Amelia, D., & Aritonang, R. F. (2018). Kinetic study on the effects of sugar addition on the thermal degradation of phycocyanin from *Spirulina* sp. *Food bioscience*, 22, 85–90.
- Chronakis, I. S. (2001). Gelation of edible blue-green algae protein isolate (*Spirulina platensis* strain pacifica): Thermal transitions, rheological properties, and molecular forces involved. *Journal of Agricultural and Food Chemistry*, 49, 888–898.
- Downham, A., & Collins, P. (2000). Colouring our foods in the last and next millennium. *International Journal of Food Science and Technology*, 35, 5–22.
- Dufossé, L., Galaup, P., Yaron, A., Arad, S. M., Blanc, P., Murthy, K. N. C., & Ravishanker, G. A. (2005). Microorganisms and microalgae as sources of pigments for food use: A scientific oddity or an industrial reality? *Trends in Food Science & Technology*, 16, 389–406.
- Faieta, M., Neri, L., Sacchetti, G., Di Michele, A., & Pittia, P. (2020). Role of saccharides on thermal stability of phycocyanin in aqueous solutions. *Food Research International*, 132, 109093.
- Garzón, G., & Wrolstad, R. (2001). The stability of pelargonidin-based anthocyanins at varying water activity. *Food Chemistry*, 75, 185–196.
- Huang, H. (1956). The kinetics of the decolorization of anthocyanins by fungal “Anthocyanase”. *Journal of the American Chemical Society*, 78, 2390–2393.
- Imamura, K., Ogawa, T., Sakiyama, T., & Nakanishi, K. (2003). Effects of types of sugar on the stabilization of protein in the dried state. *Journal of Pharmaceutical Sciences*, 92, 266–274.
- Kannaujiya, V. K., & Sinha, R. P. (2016a). An efficient method for the separation and purification of phycobiliproteins from a rice-field cyanobacterium *Nostoc* sp. strain HKAR-11. *Chromatographia*, 79, 335–343.
- Kannaujiya, V. K., & Sinha, R. P. (2016b). Thermokinetic stability of phycocyanin and phycoerythrin in food-grade preservatives. *Journal of Applied Phycology*, 28, 1063–1070.
- Khazaei, K. M., Jafari, S., Ghorbani, M., & Kakhki, A. H. (2014). Application of maltodextrin and gum Arabic in microencapsulation of saffron petal's anthocyanins and evaluating their storage stability and color. *Carbohydrate Polymers*, 105, 57–62.
- Kupka, M., & Scheer, H. (2008). Unfolding of C-phycocyanin followed by loss of non-covalent chromophore–protein interactions: 1. Equilibrium experiments. *Biochimica et Biophysica Acta (BBA) - Bioenergetics*, 1777, 94–103.
- MacColl, R. (1998). Cyanobacterial phycobilisomes. *Journal of Structural Biology*, 124, 311–334.
- MacDougall, D. (2002). *Colour in food: Improving quality*. Woodhead Publishing.
- Marangoni, A. G. (2003). *Enzyme kinetics: A modern approach*. John Wiley & Sons.
- Martelli, G., Folli, C., Visai, L., Daglia, M., & Ferrari, D. (2014). Thermal stability improvement of blue colorant C-Phycocyanin from *Spirulina platensis* for food industry applications. *Process Biochemistry*, 49, 154–159.
- Mishra, S. K., Shrivastav, A., & Mishra, S. (2008). Effect of preservatives for food grade C-PC from *Spirulina platensis*. *Process Biochemistry*, 43, 339–345.
- Miyawaki, O., Dozen, M., & Hirota, K. (2016). Cooperative hydration effect causes thermal unfolding of proteins and water activity plays a key role in protein stability in solutions. *Journal of Bioscience and Bioengineering*, 122, 203–207.
- Morais, D. V. (2018). *Produção de ficocianina por Aphanothece microscopica Nägeli a partir de vinhaça de cana-de-açúcar*.
- Moreira, I. d. O., Passos, T. S., Chiapinni, C., Silveira, G. K., Souza, J. C., Coca-Vellarde, L. G., Deliza, R., & de Lima Araújo, K. G. (2012). Colour evaluation of a phycobiliprotein-rich extract obtained from *Nostoc PCC9205* in acidic solutions and yogurt. *Journal of the Science of Food and Agriculture*, 92, 598–605.
- Naidu, G. S. N., & Panda, T. (2003). Studies on pH and thermal deactivation of pectolytic enzymes from *Aspergillus Niger*. *Biochemical Engineering Journal*, 16, 57–67.
- Nath, P. C., Tiwari, O. N., Devi, I., Bandyopadhyay, T. K., & Bhunia, B. (2020). *Biochemical and morphological fingerprints of isolated anabaena sp.: A precious feedstock for food additives*. Biomass Conversion and Biorefinery.
- Norena-Caro, D., & Benton, M. G. (2018). Cyanobacteria as photoautotrophic biofactories of high-value chemicals. *Journal of CO2 Utilization*, 28, 335–366.

- Patel, A., Pawar, R., Mishra, S., Sonawane, S., & Ghosh, P. (2004). *Kinetic studies on thermal denaturation of C-phycoerythrin*.
- Petersen, S. B., Jonson, V., Fojan, P., Wimmer, R., & Pedersen, S. (2004). Sorbitol prevents the self-aggregation of unfolded lysozyme leading to an up to 13 C stabilisation of the folded form. *Journal of Biotechnology*, 114, 269–278.
- Rastogi, R. P., & Sinha, R. P. (2009). Biotechnological and industrial significance of cyanobacterial secondary metabolites. *Biotechnology Advances*, 27, 521–539.
- Rastogi, R. P., Sonani, R. R., & Madamwar, D. (2015). Physico-chemical factors affecting the in vitro stability of phycobiliproteins from *Phormidium rubidum* A09DM. *Bioresource Technology*, 190, 219–226.
- Romay, C., Gonzalez, R., Ledon, N., Ramirez, D., & Rimbau, V. (2003). C-phycoerythrin: A biliprotein with antioxidant, anti-inflammatory and neuroprotective effects. *Current Protein and Peptide Science*, 4, 207–216.
- Sadilova, E., Stintzing, F. C., Kammerer, D. R., & Carle, R. (2009). Matrix dependent impact of sugar and ascorbic acid addition on color and anthocyanin stability of black carrot, elderberry and strawberry single strength and from concentrate juices upon thermal treatment. *Food Research International*, 42, 1023–1033.
- Sardar, U. R., Bhargavi, E., Devi, I., Bhunia, B., & Tiwari, O. N. (2018). Advances in exopolysaccharides based bioremediation of heavy metals in soil and water: A critical review. *Carbohydrate Polymers*, 199, 353–364.
- Sharma, R., Bhunia, B., Mondal, A., Bandyopadhyay, T. K., Devi, I., Oinam, G., Prasanna, R., Abraham, G., & Tiwari, O. N. (2020). Statistical optimization of process parameters for improvement of phycobiliproteins (PBPs) yield using ultrasound-assisted extraction and its kinetic study. *Ultrasonics Sonochemistry*, 60, 104762.
- Tiwari, O. N., Bhunia, B., Bandyopadhyay, T. K., & Oinam, G. (2019a). Strategies for improved induction of lipid in *Leptolyngbya* sp. BTA 287 for biodiesel production. *Fuel*, 256, 115896.
- Tiwari, O. N., Bhunia, B., Chakraborty, S., Goswami, S., & Devi, I. (2019b). Strategies for improved production of phycobiliproteins (PBPs) by *Oscillatoria* sp. BTA170 and evaluation of its thermodynamic and kinetic stability. *Biochemical Engineering Journal*, 145, 153–161.
- Tiwari, O. N., Bhunia, B., Mondal, A., Gopikrishna, K., & Indrama, T. (2019c). System metabolic engineering of exopolysaccharide-producing cyanobacteria in soil rehabilitation by inducing the formation of biological soil crusts: A review. *Journal of Cleaner Production*, 211, 70–82.
- Tiwari, O. N., Bhunia, B., Muthuraj, M., Bandyopadhyay, T. K., Ghosh, D., & Gopikrishna, K. (2020). Optimization of process parameters on lipid biosynthesis for sustainable biodiesel production and evaluation of its fuel characteristics. *Fuel*, 269, 117471.
- Tiwari, O. N., Mondal, A., Bhunia, B., kanti Bandyopadhyay, T., Jaladi, P., Oinam, G., & Indrama, T. (2019d). Purification, characterization and biotechnological potential of new exopolysaccharide polymers produced by cyanobacterium *Anabaena* sp. CCC 745. *Polymer*, 178, 121695.
- Vikram, V., Ramesh, M., & Prapulla, S. (2005). Thermal degradation kinetics of nutrients in orange juice heated by electromagnetic and conventional methods. *Journal of Food Engineering*, 69, 31–40.
- Yan, M., Liu, B., Jiao, X., & Qin, S. (2014). Preparation of phycocyanin microcapsules and its properties. *Food and Bioproducts Processing*, 92, 89–97.

Nutritional Impact of Foods Made from Spirulina on Children of Selected Anganwadis of Siddipet District in Telangana State in India

DNVS Sandhya*², A. Ramesh¹, K. Vanitha¹, D. K. Priyanka³ and N. Rachana³

¹Vishnu Institute of Pharmaceutical Education and Research, Narsapur, Medak Dist, Telangana, India; and ²Sukrutha Organics, Punjagutta, ³Synergy India Foundation, Masab Tank, Hyderabad, India.

Received July 5, 2019; accepted August 15, 2019

ABSTRACT

In the present investigation, we sought to study the impact of introducing spirulina based nutritional supplementation to the children of Siddipet District in Telangana, India. It was observed that beneficiaries are the social community who need help, support and awareness. An integrated, spectrum and holistic study approach was made to reach the beneficiary community. Several attempts were made to find out the answers to questions raised in the concurrent development of malnourished child health status in two ICDS projects, with 30 anganwadis in Bharat Nagar and 34 anganwadis in Cherial under Siddipet District, with the guidance and help of District Collector and team of company, Sukrutha Organics. The Study encompasses both primary and

secondary source of information, covering anganwadis of ICDS, Bharat Nagar and Cherial, out of which 2119 children each were selected for the study by using information collected by anganwadi teachers scheduled as tool for data collection. Peanut Chikkis (Brittle) and Biscuits made by the addition of Spirulina were distributed among the test group and no supplement was given in the control group of children who were enrolled under Anganwadis of Bharat Nagar and Cherial ICDS of Siddipet District. Descriptive analysis was made to draw inferences. The study has come out with some major findings, in spreading the knowledge about the ill effects of malnutrition and benefits of spirulina and foods made with spirulina.


KEYWORDS: Malnutrition; Spirulina supplementation; healthy snacking.

Introduction

India's malnutrition problem results not from calorie intake but from dependence on a carbohydrate-based diet, low in protein and fat. We compromise on the intake of protein, fat and vitamins – all of which are essential for growth and inducing disease-fighting immunity at a young age. It is vital that Indian children get a balanced and nutrient-rich diet which includes all micro- and macronutrients need to bring about a healthy growth.

Poor maternal health and anemia during pregnancy is another reason for induction of stunting in children. This could have roots from adolescent anemia (Uliyar et al., 2000). This compromises resistance to diseases and nutrition value of breast milk. Poor pre-pregnancy body-mass index (BMI) and insufficient weight gain during pregnancy are common, as is blood and urine micronutrient deficiency. All of these, cause low birth weight, damaging the physiological development of a child. In many Indian households, women are taught to eat last, even when expecting.

Malnutrition or malnourishment is a condition that results from eating a diet in which nutrients are either not enough or are too much such that the diet causes health problems. It may involve calories, protein, carbohydrates, vitamins or minerals (Sandhu et al., 2010; Liu et al., 1991, Zhang and Liu, 1999). Not enough nutrients are called undernutrition or undernourishment while too much is called overnutrition. Malnutrition is often used specifically to refer to under nutrition where there is not enough a calorie, protein, or micronutrients. If under nutrition occurs during pregnancy, or before two years of age, it may result in permanent problems with physical and mental development. Extreme under nourishment, known as starvation, may have symptoms that include: a short height, thin body, very poor energy levels, and swollen legs and abdomen. People also often get infections and are frequently cold. The symptoms of deficiencies depend on the micronutrient that is lacking.



(Source: UNICEF/WHO/World Bank Group: Joint child malnutrition estimates, UNICEF global databases: Infant and young Child feeding, NCD risk Factor Collaboration, WHO Global Health Observatory).

Fig. 1. India's Progress against global nutrition targets in the year 2018.

Nutritional problems like protein energy malnutrition (PEM), anemia and vitamin A deficiency continue to plague a large proportion of Indian children. The major nutritional problems are protein energy malnutrition (PEM), vitamin A deficiency (VAD) and iron deficiency anemia (IDA). The main objective is to fight malnutrition and enhance the habit of healthy eating in all possible age groups.

In those with malnutrition, some of the signs of dehydration differ. Children; however, may still be interested in drinking, have decreased interactions with the world around them, have decreased urine output, and may be cool to touch.

TABLE 1
Signs of malnutrition.

Site	Sign
Face	Moon face (kwashiorkor), simian facies (marasmus)
Eye	Dry eyes, pale conjunctiva, Bitot's spots (vitamin A), periorbital edema
Mouth	Angular stomatitis, cheilitis, glossitis, spongy bleeding gums (vitamin C), parotid enlargement
Teeth	Enamel mottling, delayed eruption
Hair	Dull, sparse, brittle hair, hypopigmentation, flag sign (alternating bands of light and normal color), broomstick eyelashes, alopecia
Skin	Loose and wrinkled (marasmus), shiny and edematous (kwashiorkor), dry, follicular hyperkeratosis, patchy hyper- and hypopigmentation, erosions, poor wound healing
Nail	Koilonychia, thin and soft nail plates, fissures or ridges
Musculature	Muscles wasting, particularly in the buttocks and thighs
Skeletal	Deformities usually a result of calcium, vitamin D, or vitamin C deficiencies
Abdomen	Distended - hepatomegaly with fatty liver, ascites may be present

Spirulina is a natural food supplement. It is a blue-green alga (an ancient cyanobacterium) well known worldwide (Becker 1994a, 1994b; Fox 1996)

- Addresses several important micronutrient deficiencies among children;
- Approved as a food supplement & nutraceutical ingredient by the Government of India
- It is low cost, easy to produce locally, long shelf life, easy to store and transport.
- Quality standards are prescribed, and labs exist to test.

A study conducted by MCRC Madras, (volume 36 monograph, 1991) under Department of Bio Technology GoI with 5000 children with 1 gram of spirulina supplementation for 150 days has concluded that 'under prolonged under nutrition, food supplementation alone is not enough to combat malnutrition and there is requirement for micronutrients'. Today, India's national institutions like CFTRI, NIN, NDRC, are recommending Spirulina as a micronutrient supplement, a "Magic wand", enhancing the food absorption among children.

The study intended to report the social impact of intervention by the Sukrutha Organics team with the support of Anganwadi teachers to fight malnourishment among children between the age group of 1 year -5 years. In tune with the objectives mentioned above, the present study is based on detail and extensive survey of sample selected unit for collecting the data needed for the study.

Materials and Methods

Preparation Spirulina Chikki and Biscuit

Spirulina are blue-green microorganisms that was grown in fresh water and was procured from Spirulina Entrepreneurs, Kurnool. Spirulina powder was used in the preparation of the biscuits and chikkis. The chikkis were manufactured at Kriswa industries, Hyderabad, with the recipe and spirulina given as per the requirement and biscuits were manufacture at Sumo Biking foods, Hyderabad, as per the recipe given.

Peanuts, jaggery and liquid glucose were easily procured from local market. Peanut seeds have to be

roasted to golden brown colour (120–130°C), de-husked, de-germed and crushed into small bits of about 2.8 mm. Jaggery is generally crushed and made into syrup with addition of water and 10% weight of liquid glucose and warming and filtered through a nylon mesh of ~ 30 mesh to remove extraneous matter. The clear jaggery syrup is then heated until the temperature reached 145°C and immediately pre-weighed, roasted and de-husked peanuts are added and mixed thoroughly till the nuts get coated with jaggery syrup. This hot mass was then transferred on to a wooden board or clean platform, which was smeared with oil. The addition of required amount of spirulina was done. The product is then spread uniformly by rolling it with the help of a roller. Vertical and horizontal lines are marked with a cutter to make individual slabs then cooled to room temperature (27 ± 2°C) and are packed in polythene pouches.

Locally made hand biscuits are generally very popular among rural children. With a simple change in the recipe involving addition of micronutrients can take care of the wellness of the local community. There are primarily four stages of making the biscuit in a factory – mixing, forming, baking, and cooling. In the mixing stage, ragi flour, whole wheat flour, fat, sugar, water and spirulina ingredients were mixed together in the right proportion in large mixers to form the dough. The mixing time is carefully managed to achieve uniform distribution of ingredients and the right dough consistency. Convection ovens were used with belt operators maintaining a baking temperature on the belt and then cooling and packaging them to wrappers.

Analysis of the Products for their Nutritional Values

All the ingredients were approved as a food supplement & nutraceutical ingredient by the Government of India in their individual monographs. The products were tested for their nutritional values and approved in a NAAC accredited Lab (Vimta Lab, Hyderabad) as per the prescribed data.

TABLE 2
Ingredients and Nutritional value of the products used in the study.

S. No.	Products	Ingredients	Nutritional Value per 100gm
1	Spirulina Peanut Chikki	Spirulina, Peanut, Jaggery, Liquid Glucose	Calories 486, Calories from fat 213, Protein 16.62, Carbohydrates 51.71, Total fat 23.64, Saturated Fat 3.33, Trans Fat <0.1, Calcium 103.84, Iron 6.20, Dietary Fibre 11.71
2	Spirulina Ragi Biscuit	Spirulina, Ragi flour, Whole wheat, Edible Vegetable fat, Sugar, Milk Solids, Glucose, Raising Agents.	Calories 486, Calories From Fat 183, Protein 8.33, Carbohydrates 20.33, Total 20.33, Saturated Fat 11.07, Trans fat <0.1, Calcium 167.01, Iron 6.62, Dietary Fibre 7.64

Study Design

According to a study conducted by Ministry of health and welfare the malnutrition in the districts of Telangana was as follows in the year 2017. Siddipet was a new district formed after division of Medak district and

it can be observed from the table that the Stunting and wasting is relatively higher. Hence, this place was selected for the study.

TABLE 3
District wise Stunting, wasting and underweight details of children in Telangana State.

District	Children Under 5 who are stunted (%)	Children under 5 who are wasted (%)	Children under 5 who are under weight.
Adilabad	38.3	22.1	35.8
Hyderabad	15.7	14.1	16.8
Karimnagar	24.3	19.3	25.4
Khammam	26.5	13.7	22.2
Mahbubnagar	37.1	18.6	34.5
Medak	33.4	20.7	37.0
Nalgonda	28.9	23.1	34.1
Nizamabad	36.6	22.0	36.3
Ranga Reddy	26.2	14.8	25.8
Warangal	26.6	16.6	29.1
TELANGANA	28.1	18.0	28.5

Source: Press Information Bureau, Government Of India, Ministry of Health and Family Welfare, (11 August 2017 16:45 IST).

The multi-stage single blind random sampling method was implemented for the present study. Sampling has been selected from 30 Anganwadis of Bharatnagar ICDS project and 34 anganwadis of Cherial ICDS projects of Siddipet district. The list of children enrolled is as follows.

TABLE 4
Selection of Study groups.

S. No.	Selection	Name of the ICDS selected	Number of Anganwadis selected	Number of children Enrolled
1.	Control Group	Cherial (CH)	34	2119
2.	Test Group	Bharat Nagar (BN)	30	2119

TABLE 5
Study design details.

S. No	Detail	Spirulina Peanut Chikki	Spirulina Ragi Biscuit
1.	Bite Size	~25gm	~20gm
2.	Amount of spirulina	~500 mg/piece	~500mg/piece
3.	No of pieces per day	1	1
4.	Duration of the day	In addition to break-fast or evening snack alternatively	In addition to breakfast or evening snack alternatively
5.	No of days per month	25 days	25 days
6.	Data collected	Every 25 days for test and control groups	Every 25 days for test and control groups

TABLE 6
Number of children enrolled in the Anganwadis.

S. No	Name of the Anganwadi under Cherial ICDS, Siddipet, Telangana	No of children enrolled (Control Group), CH	Name of the Anganwadi under Bharath Nagar ICDS, Siddipet, Telangana	No of children enrolled (Test Group) BN
1	Cheiral - I	50	Barimam 1	71
2	Cheiral - II	83	Barimam 2	60
3	Cheiral - III	59	Bharath nagar 1	71

TABLE 6 Contd...

S. No	Name of the Anganwadi under Cherial ICDS, Siddipet, Telangana	No of children enrolled (Control Group), CH	Name of the Anganwadi under Bharath Nagar ICDS, Siddipet, Telangana	No of children enrolled (Test Group) BN
4	Cheiral - IV	56	Bharath nagar 2	76
5	Cheiral - V	49	Bharath Nagar 3	72
6	Cheiral - VI	75	Bharath Nagar 4	86
7	Gunturpally -VII	70	Charavadan 1	72
8	Cherial-VIII (Pochamma Vedhi)	62	Charavadan 2	80
9	Kadaverugu - I	76	Dogbangla	66
10	Kadaverugu - II	62	Erukawada 1	59
11	Kadaverugu - III	75	Erukawada 2	66
12	Ramsagar	61	Hanuman Nagar 1	69
13	Pothireddipally - I	50	Hanuman Nagar 2	93
14	Pothireddipally - II	61	Kanchariwada 1	60
15	Peddaraiupeta	75	Kanchariwada 2	57
16	Nagapuri - I	56	Kanchit Chowrasta	58
17	Nagapuri - II	66	Khadeerpura 1	69
18	Nagapuri - III	75	Khadeerpura 2	74
19	Nagapuri - IV	48	Khadeerpura 3	85
20	Balbajiguda	62	Moinpura 1	58
21	Gandikunta	72	Moinpura 2	57
22	Chuchannakota - I	75	Moinpura 3	72
23	Chuchannakota - II	58	Moinpura 4	64
24	Chuchannakota - III	70	Murshad Gadda 1	72
25	Mustyala - I	67	Murshad Gadda 2	75
26	Mustyala - II	41	Murshad Gadda 3	70
27	Mustyala - III	60	Nasarpura 1	77
28	Veerannapet - I	65	Nasarpura 2	80
29	Veerannapet - II	62	Nasarpura 3	68
30	Veerannapet - III	75	Ramnagar	82
31	Rampur	54	-	-
32	Kasigudiselu	62	-	-
33	Kommuravelli - I	47	-	-
34	Kommuravelli - II	40	-	-
		2119	Total	2119

Anganwadi teachers having experience from their concurrent field work were visited personally for primary data collection. All the selected anganwadis were covered in this study. The children of Bharat Nagar ICDS were supplied with the chikkis and biscuits made from spirulina in addition to their normal routine diet given by anganwadis and the other group was not provided with any supplementation but were following the normal routine diet given by anganwadis. Approximately 25gm peanut chikki and approximately 20gm ragi spirulina biscuit were given to the children. Both were given to the children alternatively during breakfast as additional supplement and during snacking in the evening. The Protein Energy Malnutrition levels were considered and the deficit of 300kcal and 10gm (Daily Nutritional requirements of Indians, NIN) of protein was calculated and the dosage was designed accordingly.

Study Base Line and End Point

The data such as social background, economical background, gender, height, weight and age of the

children were collected prior to the supplementation, during and after the supplementation at regular intervals. The anganwadi helpers were trained and were interviewed and instruction on data collection.

To monitor the growth of children in terms of height, weight, appetite (Observations on the scale of 1-10), physical activities (Observations on the scale of 1-10) and cognitive development (using VSMS tool) over a period of 32 weeks. Number of students enrolled in the each Anganwadi is given in the table below.

Results and Discussion

Data has been analyzed and given in the tabulated form and analyzed based on the obtained frequencies. The table gives clear picture that around 35.67% in Cherial and 33.84% of the respondents belongs to the Scheduled caste (SC) and 32.08% of the respondents belongs to Scheduled Tribes (ST), 49.25% of the respondents belongs to the other backward (OBC) Classes and lastly 1.83% of the respondents belongs to the other categories.

TABLE 7

Caste of the enrolled children.

S. No.	Caste	Frequency CH	%	Frequency BN	%
1	SC	758	35.67	717	33.84
2	ST	609	28.77	527	24.86
3	OBC	713	33.69	823	38.90
4	Others	39	1.87	52	2.45
	Total	2119	100%	2119	100%

The caste-based enrollment was similar in the two ICDS projects selected.

The table below tells that 56.2% of the respondents were male and 43.8% of the respondents were female in Bharat Nagar ICDS, whereas 54.55% were male and 45.44% female children in Cherial ICDS.

TABLE 8

Gender of the enrolled children.

S. No.	Gender	Frequency CH	%	Frequency BN	%
1	Male	1156	54.55	1191	56.2
2	Female	963	45.44	928	43.8
	Total	2119	100%	2119	100%

The table 9 tells that children enrolled under the control group were not given the supplements at all but in the test group, about 96.33% of the respondents have consumed the spirulina chikkis and biscuits regularly, 3.25% of the respondents have not consumed the spirulina chikkis and biscuits regularly and only 0.42% of the respondents have not taken spirulina biscuits and chikkis. It is because they were hesitant towards the smell of spirulina after consuming. So, they could not continue the dosage. 3.25% of the respondents have not taken spirulina regularly because they have been out of the station, migration, change of their houses from one place to another place. So, they could not take the dosage regularly.

TABLE 9
Consumption of spirulina biscuits and chikkis regularly.

S. No.	Consumption of Spirulina biscuits and chikkis regularly	Frequency CH	%	Frequency BN	%
1	Regular	0	0	2041	96.33
2	Irregular	0	0	69	3.25
3	No	2119	100%	9	0.42
	Total	2119	100%	2119	100%

The table 10 expresses the observation of anganwadi teachers of the children after taking spirulina-based biscuits and chikkis and the ones without the supplementation. Only 54.9% of children from the control group and 79.42% of the respondent from the Test group have replied that the child’s appetite has increased. With respect to the physical activity, teachers observed that 62.74% children have shown improvement in their physical activities in the control group whereas, 81.92% of the respondents from test group have shown improvement in their physical activities. Regarding cognitive development of the children, teachers told that as less as 45.27% children have shown an improvement in the control group whereas 79.75% of the respondents have shown positive response towards cognitive development in the test group.

The below graph represents the improvement of the increase in appetite, physical activities and cognitive development over the period of the study. This shows that there was a considerable increase in the children with supplementation when compared to the children without supplementation.

The difference in the increase in weights and heights of the students were calculated and have been recorded for every 25 days. After 32 weeks, it was found observed that over 82.64% of the children had an increase of their weight of more than 900gm in the test group when compared to only 68.39% children of control group. Also, the increase in height was calculated and analyzed. About 85.04% of the children gained height more than 5cm in the group with the supplementation whereas, only 71.79% of the children gained height above 5cm.

The increase in heights and weights was summarized every month and the growth in the control group was much lesser than that of the test group. Apart from the daily activities the children have shown good development in their BMI.

The graphical representation of the above work is represented in figure 3 here under.

TABLE 10
Anganwadi teacher’s observation after intervention.

Sl. No	Teachers Observation after intervention	Yes (CH)		No (CH)		Yes (BN)		No (BN)	
		Frequency	%	Frequency	%	Frequency	%	Frequency	%
1	Increase in Appetite	1163	54.90	956	45.1	1690	79.75	429	20.24
2	Physical activities	1329	62.74	790	37.26	1736	81.92	383	18.07
3	Cognitive Development (Response)	959	45.27	1160	54.73	1683	79.42	436	20.58




Fig. 2. Graphical representation of the recorded data in control and test groups.

TABLE 11

Calculation of differences in heights and weights after the intervention.

S. No	Data summarized after 32 weeks of intervention	Yes (CH)		No (CH)		Yes (BN)		No (BN)	
		Frequency	%	Frequency	%	Frequency	%	Frequency	%
1	Increase in Weight (>900gm)	1449	68.39	670	31.61	1751	82.64	386	17.36
2	Increase in Height (>5cm)	1522	71.79	597	28.21	1802	85.04	317	14.96




Fig. 3. Graphical representation on increase in heights and weights of the children with and without the spirulina supplementation.




Fig. 4. The monthly increase in the weights of the children.

Also, the taste of the spirulina biscuits and chikkis was much appreciated by the children and the parents of the respondents. The anganwadi teachers referred to an increase in the regularity of the children after the intervention was started. It was also reported by Anganwadi teachers that there were no adverse effects recorded.

TABLE 12

Number of respondents wish to continue at Bharath Nagar ICDS.

Sl. No.	Wish to continue to feed Spirulina chikkis and biscuits	Frequency	Percentage
1	Yes	2080	98.16
2	No	39	1.84
	Total	2119	100%

Conclusions

From the above study, it was found that majority of the parents of the children enrolled under the program at ICDS Bharatnagar and Cherial were ignorant about their child's nutritional requirements. The data collected have given major findings on how micronutrients like spirulina can be given to children by masking its taste and odour. This way the intake was regular and consistent. The study also suggested that the children had benefitted in their height, weight, appetite, physical activities and their psychomotor skills. The average deficit of energy and protein, including the essential micronutrients like iron, calcium, dietary fiber etc., were provided with this healthy snacking. Considering the successful implementation at Siddipet, it can be expanded to other area where severe malnourished children are present. To enhance the scalability of the process and decentralized production of Spirulina, chikkis and biscuits, it would be better to involve rural women and build a capacity to encourage them to initiate small and micro enterprises so that the women and the entire community can produce and made available in the villages at a very reasonable cost to sustainability.

Acknowledgements

We acknowledge Shri. Venkata Rami Reddy, Honorable District collector, who helped in providing the necessary permissions and funding for the project.

References

Becker EW (1994a). In: Chapter 13: Nutrition. Microalgae. Cambridge University Press, Cambridge, 196-249.

Becker EW (1994b). In: Chapter 11: Yield. Microalgae. Cambridge University Press, Cambridge, 172-176.

Li DM (1995). In: Spirulina Chapter 4: Spirulina as a health food. Chinese Agrotechnology Publisher, Beijing. 21-28.

Liu LC, Guo B and Ruan JS (1991). Antitumour activity of polysaccharides extracted from Spirulina. *Oceanography* **5**: 33-37.

Long CS, Guo BJ and Ruan JS (1988). Spirulina polysaccharides enhanced the activity of nuclease and DNA repair. *J. Genetics* **15**: 374-381.

Ruan JS, Guo BJ and Shu LH (1990). Effect of Spirulina polysaccharides on changes in white blood corpuscles induced by

radiation in mice. *J. Radiation Res. Technol.* **8**: 210-213. (In Chinese)

Ruan JS, Long CS, and Guo BJ (1988). Spirulina prevented damage induced by radiation. *J. Genetics* **10**: 27-30.

Al-Batshan HA, Al-Mufarrej SI, Al-Homaidan AA and Qureshi MA (2001). Enhancement of chicken macrophage phagocytic function and nitrite production by dietary Spirulina platensis. *Immunopharm Immunotox* **2(23)**: 281-289.

Beaton LJ, Allan DA, Tarnopolsky MA, Tiidus PM and Phillips SM (2002). Contraction-induced muscle damage is unaffected by vitamin E supplementation. *Med Sci Sports Exerc* **34(5)**: 798-805.

Belay A, Kato T and Ota Y (1996). Spirulina (Arthrospira): potential application as an animal feed supplement. *J Appl Phycol* **4-5(8)**: 303-311.

Chien YH, Pan CH and Hunter B (2003). The resistance to physical stress by Penaeus monodon juveniles fed diets supplemented with astaxanthin. *Aquaculture* **216(1-4)**: 177-192.

Fox RD (1996). Spirulina, production and potential. *Aix-en-Provence, Edisud*, pp 9-232

Goldfarb AH (1995). Nutritional anti-oxidants as therapeutic and preventive modalities in exercise-induced muscle damage. *Can J Appl Physiol* **24(3)**: 249-266

Gireesh T, Nair PP and Sudhakaran PR (2004). Studies on the bioavailability of the provitamin A carotenoid, beta-carotene, using human exfoliated colonic epithelial cells. *Br J Nutr* **92(2)**: 241-245

Hayashi K, Hayashi T and Kojima I (1996). A natural sulfated polysaccharide, calcium spirulan, isolated from Spirulina platensis: *in vitro* and *ex vivo* evaluation of anti-herpes simplex virus and anti-human immunodeficiency virus activities. *AIDS Res Human Retrovir* **15(12)**: 1463-1471

Hayashi O, Hirahashi T, Katoh T, Miyajima H, Hirano T and Okuwaki Y (1998). Class specific influence of dietary Spirulina platensis on antibody production in mice. *J Nutr Sci Vitaminol* **6(44)**: 841-851

Huang LX, Lu XC, Yang B and Lin JS (2000). Effects of Spirulina platensis on exercise-induced muscle damage in rats. *Sport Sci* **20(2)**: 58-59

Mani UV, Desai S and Iyer U (2000). Studies on the long-term effect of spirulina supplementation on serum lipid profile and glyated proteins in NIDDM patients. *J Nutra Func Med Foods* **3(2)**: 25-32

Mathew B, Rengaswamy S, Nair PP, Varghese C, Thara S, Amma BP, Amma NS and Nair MK (1995). Evaluation of chemoprevention of oral cancer with Spirulina fusiformis. *Nutr Cancer* **2(24)**: 197-202

Matuschek E and Svanberg U (2002). Oxidation of polyphenols and the effect of *in vitro* iron accessibility in a model food system. *J Food Sci* **67(1)**: 420-424

Micheletti A, Rossi R and Rufini S (2001). Zinc status in athletes: relation to diet and exercise. *Sports Med* **31(8)**: 577-582

Paredes-Carbajal MC, Torres-Duran PV, Diaz-Zagoya JC, Mascher D and Juarez-Oropeza MA (2001). Effects of the ethanolic extract of Spirulina maxima on endothelium dependent vasomotor responses of rat aortic rings. *J Ethnopharm* **1(75)**: 37-44

Uliyar M, Alefia S, Uma I and Panam P (2000). The effect of Spirulina supplementation on blood hemoglobin levels of anaemic adult girls. *J Food Sci Technol (Mysore)* **6(37)**: 642-644

Vonshak A (1997). Spirulina platensis (Arthrospira): physiology, cell-biology, and biotechnology, Taylor and Francis, London, pp 1-233

Zhang YF and Liu XC (1999). Study on the anti-fatigue effect of polysaccharide and polysaccharide-protein from Spirulina platensis. *Mar Sci Bull/Haiyang Tongbao Tianjin* **18(3)**: 89-91

Johnson M, Hassinger L, David J., Devor ST and DiSilvestro RA (2016). A randomized, double blind, placebo controlled study of spirulina supplementation on indices of mental and physical fatigue in men. *Int J Food Sci Nutr* **67(2)**: 203-206.

- Lu HK, Hsieh CC, Hsu JJ, Yang YK and Chou HN (2006). Preventive effects of *Spirulina platensis* on skeletal muscle damage under exercise-induced oxidative stress. *Eur J Appl Physiol* **98**(2): 220-226.
- Miczke et al (2016). Effects of spirulina consumption on body weight, blood pressure, and endothelial function in overweight hypertensive Caucasians: a double-blind placebo controlled randomized trial. *Eur. Rev Med Pharmacol Sci* **20**(1): 150-156.
- Sandhu et al. (2010). Efficacy of Spirulina Supplementation on Isometric Strength and Isometric Endurance of Quadriceps in Trained and Untrained Individuals – a comparative study. *Ibnosina Journal of Medicine and Biomedical Sciences* **2**(2): 79-86.








Address correspondence to: Dr. K. Vanitha, *Vishnu Institute of Pharmaceutical education and research, Vishnupur, Narsapur, Medak Dist, Telangana, India.*
E-mail: vanitha.k@viper.ac.in, sanjumnvs@gmail.com








Development of nitric oxide releasing quinoline derivatives as inhibitors of doxorubicin resistance in cancer cells

Protein ligand interactions of the chlorine containing acridones with calmodulin dependent *c*AMP – Phosphodiesterase (PDE1c) enzyme were studied by employing an efficient docking protocol, GLIDE XP. Initially, a theoretically built digitalized structure of the protein PDE1C was retrieved from the protein databank with PDB ID: 1LXS. Structure of the protein was corrected by adding hydrogens to satisfy the valence and optimized by using OPLS-2005 force field (optimized potentials for liquid simulations). Binding pockets were identified by using the SITEMAP tool. Receptor grid generation was accomplished using Glide docking protocol and ligands were docked by employing XP mode of Glide. Best pose of each ligand was ranked according to the E-model energy. The docking score from Glide (Glide Score) is entirely based on Chem Score. It also includes a steric-clash term, adds polar terms featured by Schrodinger to correct electrostatic mismatches.

$$\text{GScore} = 0.065 \times \text{Van der Waals energy} + 0.130 \times \text{Coulomb energy} + \text{Lipophilic term (Hydrophobic interactions)} + \text{H bonding} + \text{Metal binding} + \text{BuryP (Penalty for buried polar groups)} + \text{RotB (Penalty for freezing rotatable bonds)} + \text{Site (Polar interactions in the active site)}$$

Table 1: Structures and Docking result

Compound	Structure	Dock Score
31		-6.95975
27		-6.50991
22		-5.43411
15		-5.26858
13		-5.1381
7		-5.12026
34		-5.1168

2		-5.07641
5		-4.94562
30		-4.85447
17		-4.8065
1		-4.59469
25		-4.50395
29		-4.39855








23		-4.35577
26		-3.88481
21		-3.80914
6		-3.78187
18		-3.63449
35		-3.56668
9		-1.06874

Table 2: Molecular Properties

Molecule	MW	Dipole	SASA	FOSA	FISA	PISA	WPSA	Volume
31	458.86	11.039	658.349	70.563	157.026	359.325	71.436	1230.942
27	424.415	8.66	629.351	77.161	151.305	400.884	0	1183.541
22	415.835	6.198	656.94	79.116	122.556	383.686	71.582	1176.015
15	520.931	6.794	747.129	0	152.374	536.597	58.158	1423.571
13	492.92	9.201	707.719	0	123.415	512.658	71.646	1337.1
7	500.512	7.376	767.625	88.161	150.923	528.54	0	1450.461
34	415.835	6.487	650.65	47.848	111.776	430.403	60.623	1168.089
2	443.461	7.605	728.319	0	97.518	630.801	0	1310.486
5	472.502	7.522	732.85	82.362	123.984	526.504	0	1361.525
30	415.835	6.966	663.243	76.295	110.553	407.046	69.348	1180.372
17	448.437	7.167	721.472	0	129.216	592.256	0	1295.234
1	458.475	6.013	723.914	0	108.808	615.106	0	1335.377
25	396.404	6.763	671.211	73.812	153.163	444.236	0	1214.115
29	430.849	6.856	675.721	73.187	155.319	408.472	38.741	1227.895
23	458.86	7.6	651.175	77.096	164.548	350.14	59.391	1222.537
26	381.39	6.457	644.47	76.561	109.386	458.523	0	1139.713
21	430.849	4.657	669.92	57.369	131.282	409.689	71.58	1207.827
6	457.487	6.821	732.655	88.049	121.623	522.983	0	1349.379
18	433.422	5.903	681.657	0	113.21	568.447	0	1246.227
35	458.86	8.331	680.817	45.996	161.111	411.045	62.665	1230.239
9	506.947	9.143	689.689	56.737	124.562	436.846	71.543	1338.67

Recommended range: MW – molecular weight (130-725), dipole (1-12.5), SASA- solvent accessible surface area (300-1000), FOSA – hydrophobic component of SASA (0-750), FISA – hydrophilic component of SASA (7-330), PISA - π (carbon and attached hydrogen) component of the SASA (0.0 – 450.0), WPSA - Weakly polar component of the SASA (halogens, P, and S) (0.0 – 175.0), volume (500-2000).

Table 3: Predicted Pharmacokinetic (ADME) profiles of compounds

Molecule	CNS	QPlog Po/w	QPlog S	QPlog HERG	QPP Caco	QPlog BB	QPP MDCK	QPlog Kp	QPlog Khsa	% Human Oral Absorption
31	-1	3.628	-5.438	-4.4	240.341	0.792	356.954	3.052	0.356	90.802
27	-1	3.135	-4.549	-4.338	268.094	0.861	165.928	-2.8	0.218	88.761
22	0	4.163	-5.936	-6.271	681.864	0.536	806.72	2.331	0.518	100
15	-1	5.074	-6.918	-5.643	268.846	0.928	336.946	2.245	0.873	74.222
13	0	4.887	-6.294	-6.738	669.197	0.638	791.177	-1.7	0.727	100
7	-2	5.028	-7.071	-5.797	280.164	1.101	167.433	2.247	0.951	74.274
34	0	4.199	-5.769	-6.426	862.827	0.445	906.119	1.967	0.495	100
2	0	5.23	-6.813	-7.854	1177.97 7	0.585	590.528	0.903	0.866	100
5	-1	4.778	-6.442	-7.107	660.931	0.875	316.199	1.662	0.791	100
30	0	4.293	-6.045	-6.476	886.179	0.438	1041.15 1	2.027	0.531	100
17	-1	4.162	-6.169	-7.65	589.582	0.915	279.47	1.623	0.526	100
1	-1	4.819	-6.278	-7.538	920.605	0.723	452.395	-1.07	0.718	100
25	-2	3.537	-5.479	-6.563	349.506	1.076	158.81	2.585	0.424	93.178
29	-1	3.716	-5.73	-6.382	333.431	0.999	246.037	2.751	0.463	93.863
23	-1	3.465	-5.251	-4.269	204.091	0.873	256.757	3.223	0.332	88.573
26	0	3.832	-5.387	-6.651	909.058	0.585	446.264	1.824	0.413	100
21	0	3.88	-5.767	-6.419	563.58	0.687	656.569	2.304	0.406	100
6	-1	5.191	-6.896	-7.165	695.904	0.805	334.322	1.727	0.979	95.256
18	0	4.386	-5.83	-7.13	836.237	-	407.753	-	0.588	100

						0.615		1.507		
						-		-		
35	-1	3.622	-5.96	-5.102	236.863	0.958	290.196	2.945	0.354	90.655
						-		-		
9	0	4.806	-5.965	-6.015	652.642	0.587	769.041	1.988	0.737	92.504

Recommended range: CNS Predicted central nervous system activity on a -2 (inactive) to +2 (active) scale; QPlogPo/w: Predicted octanol/water partition coefficient (-2.0 - 6.5); QPlogS: Predicted aqueous solubility (-6.5 – 0.5); QPlogHERG: Predicted IC50 value for blockage of HERG K+ channels (below -5); QPPCaco: Predicted apparent Caco-2 cell permeability in nm/sec. Caco- 2 cells are a model for the gut-blood barrier (<25: poor, >500: great); QPlogBB: Predicted brain/blood partition coefficient (-3 – 1.2); QPPMDCK: Predicted apparent MDCK cell permeability in nm/sec. MDCK cells are considered to be a good mimic for the blood-brain barrier (<25: poor, >500: great); QPlogKp: Predicted skin permeability, log Kp (-8.0 – -1.0); QPlogKhsa: Prediction of binding to human serum albumin (-1.5 – 1.5); %Human- Oral Absorption (>80% is high, <25% is poor).

Table 4: Binding energy predictions using MMGBSA calculations

Compound	Prime MMGBSA Ligand Energy	Prime MMGBSA Receptor Energy	Prime MMGBSA Complex Energy	Prime MMGBSA DG bind
31	10.614942	-12400.48218	-12461.73689	-71.869657
27	31.020423	-12400.48218	-12436.37635	-66.914599
22	26.875696	-12400.48218	-12417.01052	-43.404036
15	24.361114	-12400.48218	-12438.3363	-62.215234
13	12.897055	-12400.48218	-12457.31489	-69.729772
7	35.067764	-12400.48218	-12418.86285	-53.44844
34	29.497186	-12400.48218	-12429.6953	-58.710309
2	44.695166	-12400.48218	-12422.17456	-66.387554
5	19.412305	-12400.48218	-12437.80588	-56.736014
30	17.752203	-12400.48218	-12450.17266	-67.442686
17	21.947572	-12400.48218	-12431.30236	-52.767752
1	22.618603	-12400.48218	-12441.6908	-63.827227
25	12.295664	-12400.48218	-12436.40754	-48.221029
29	-7.729278	-12400.48218	-12461.50121	-53.289759
23	18.010575	-12400.48218	-12445.86514	-63.39354
26	38.163555	-12400.48218	-12417.89096	-55.572336
21	-4.800136	-12400.48218	-12470.05472	-64.772412
6	36.72764	-12400.48218	-12389.21948	-25.464948
18	40.025004	-12400.48218	-12398.78225	-38.325076
35	25.292569	-12400.48218	-12403.00388	-27.814275
9	10.790788	-12400.48218	-12437.26277	-47.57138

The Prime MM-GBSA approach is used to predict the free energy of binding for a receptor and a set of ligands. MM-GBSA is an acronym for a method that combines OPLS molecular mechanics energies (EMM), an SGB solvation model for polar solvation (GSGB), and a nonpolar solvation term (GNP) composed of the nonpolar solvent accessible surface area and van der Waals interactions. The total free energy of binding is then expressed as:

$$\Delta G_{\text{bind}} = G_{\text{complex}} - (G_{\text{protein}} + G_{\text{ligand}})$$

where

$$G = E_{\text{MM}} + G_{\text{SGB}} + G_{\text{NP}}$$

The ligand in the unbound state is minimized in SGB solvent but is not otherwise sampled. In the calculation of the complex, the ligand is minimized in the context of the receptor. The protein is currently held fixed in all calculations. The following descriptors generated by the Prime MM-GBSA approach:

MM-GBSA_DG_bind: Ligand binding energy, ΔG_{bind}

MM-GBSA_E_complex: Energy of the complex, G_{complex}

MM-GBSA_E_protein: Energy of the receptor without the ligand, G_{protein}

MM-GBSA_E_ligand: Energy of the unbound ligand, G_{ligand}

Table 5: Embrace calculations for ligand binding energy

Compound	MBAE Complex Total Energy- OPLS-2005	MBAE Rec Total Energy- OPLS-2005	MBAE Lig Total Energy- OPLS-2005	MBAE Del Total Energy- OPLS-2005
31	-4464.179668	-4365.702312	93.740479	-192.217834
27	-4363.533169	-4365.702312	176.034424	-173.86528
22	-4453.182247	-4365.702312	149.049454	-236.529388
15	-4465.980438	-4365.702312	155.900314	-256.17844
13	-4486.879223	-4365.702312	70.90551	-192.08242
7	-4442.784595	-4365.702312	193.26413	-270.346413
34	-4412.546429	-4365.702312	166.637756	-213.481873
2	-4328.60968	-4365.702312	218.52951	-181.436878
5	-4477.749912	-4365.702312	97.529282	-209.576881
30	-4387.141613	-4365.702312	109.180939	-130.620239
17	-4420.547894	-4365.702312	110.716797	-165.562378
1	-4470.624641	-4365.702312	98.782898	-203.705227
25	-4580.207062	-4365.702312	50.148129	-264.652878
29	-4675.097286	-4365.702312	-26.948503	-282.44647
23	-4449.573925	-4365.702312	130.186203	-214.057816
26	-4316.43198	-4365.702312	193.465561	-144.195229
21	-4694.094612	-4365.702312	-12.645243	-315.747057
6	-4308.456825	-4365.702312	209.598465	-152.352978
18	-4363.897919	-4365.702312	178.150131	-176.345737
35	-4335.764233	-4365.702312	162.9133	-132.97522
9	-4540.806538	-4365.702312	58.089577	-233.193802

Embrace calculates ligand-receptor binding energies by molecular mechanics energy minimization of the complex and the separated receptor and ligand, with or without continuum solvation. The Embrace calculation is run in energy difference mode. The following descriptors are generated from the calculation:

Embrace_Total_Energy_without_constraints: Ligand binding energy

Embrace_Valence_Energy: Valence energy difference


Embrace_vdW_Energy: van der Waals energy difference

Embrace_Electrostatic_Energy: Coulomb energy difference

Embrace_Solvation_Energy: Solvation energy difference


Embrace_Constraint_Energy: Constraint energy difference

Figure 1: site map calculations for the protein 1LXS.




- Site map calculation identifies the possible receptor pockets along with their area and volumes.
- Site map is useful for binding site characterization and also in SBDD.
- Red colour: hydrogen bond acceptor region (high conc of oxygen)
- Blue color: hydrogen bond donor region (high conc of nitrogen)
- Yellow colour: hydrophobic region.

Figure 2: 1LXS Grid position for docking




- Magenta colour cube represents the grid established for docking.
- Ligands with maximum of 20Å can fit into the grid.

Figure 3: protein ligand interactions of the docked PDE1c enzyme and ligand 31 complex.



- 1 hydrogen bond with Histidine 66 with a bond length of 2.132 Å
- Hydrogen bond is represented in yellow dotted lines.
- Magnified image shows the ligand conformational fitting into the receptor pocket.

Figure 4: Docking conformations of compound 27 and 22.



- Compound 27, and 22 interact with Histidine 66 residue of protein at hydrogen bond distance of 2.269Å and 2.107 Å respectively.

Date: 03-10-2020.

CERTIFICATE

This is to certify that Miss. **AFREEN KHANAM (HT.NO.18DH1S1201)** pursuing her M. Pharmacy in **VISHNU INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH** has carried out her project work in our Organization entitled **“SIMULTANEOUS ESTIMATION OF NEW ANALYTICAL METHOD DEVELOPMENT AND VALIDATION OF DOLUTEGRAVIR AND LAMIVUDINE BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY”** in the department of Pharmaceutical Analysis from **2-MAY-2019 TO 03-OCTOBER- 2020.**

During her tenure she was sincere, hardworking and Punctual in her Project work.

We wish her to success in her future career.

Authorized Signatory

Mrs. Rajita Sura
Managing Director





CMCR
Centre for Molecular Cancer Research
Vishnu Institute of Pharmaceutical
Education & Research - VIPER
Narsapur, Medak, Telangana,
India-502313.
cmcr@viper.ac.in
www.viper.ac.in

Study No: GNC2018-002

Sample Type (Matrix): Serum

Assay Kit: 25(OH) Vitamin D Kit: Krishgen Biosystems Cat# KBH501

Animal No.	Sample ID	25(OH) Vit-D Concn. (ng/ml) in Serum [Final Day (Day 84)]
1	S1	31.72
2	S2	46.23
3	S3	23.27
4	S4	24.38
5	S5	26.42
6	S6	21.49
7	S7	24.50
8	S8	25.95
9	S9	24.44
10	S10	23.10
11	S11	20.79
12	S12	24.69
14	S13	20.26
16	S14	26.42
17	S15	24.26
18	S16	23.91
19	S17	23.85
20	S18	21.75
21	S19	16.43

Prepared by:

(Mr. Y. Vishwanadham)

Authorized by:

(Dr. V.V.S. Rajendra Prasad)
Principal Investigator,
Centre for Molecular Cancer Research
(CMCR)



Dr. V.V.S. Rajendra Prasad, Ph.D
Professor & Principal Investigator
Department of Pharmaceutical Chemistry
VISHNU INSTITUTE OF PHARMACEUTICAL
EDUCATION & RESEARCH

Narsapur, Medak, Telangana District-502 313, T.S., India

Approved by: AICTE, PCI New Delhi, Affiliated to JNTU-Hyderabad Accredited by NAAC & NBA,

Recognised by DSIR under SIRC



VIPER

Vishnu Institute of Pharmaceutical
Education & Research

Vishnupur, Narsapur
Medak Dist. - 502 313, TS, India.
t : 08458 222 087 / 88, f : 08458 222 002
e : viper@viper.ac.in
www.viper.ac.in
www.srivishnu.edu.in


INVOICE

Date: 13.02.2020

S.No	Particulars	No. of Samples	Amount in Rs.
1	Charges for Elisa Tests conducted in our Laboratory	36	50,000-00
	TOTAL		50,000-00

(Rupees Fifty Thousand Only)

For Vishnu Institute of Pharmaceutical Education & Research


Authorized Signatory





VIPER

Vishnu Institute of Pharmaceutical
Education & Research

Vishnupur, Narsapur
Medak Dist. - 502 313, TS, India.
t : 08458 222 087 / 88, f : 08458 222 002
e : viper@viper.ac.in
www.viper.ac.in
www.srivishnu.edu.in

Date: 13.02.2020

To,

Head'
Cell & Molecular Biology,
R&D Centre,
Lila Nutraceuticals
Vijayawada
Andhra Pradesh

Dear Sir,

Sub: Request for payment of Charges for Research work done at our Laboratory - Reg.

We are happy to support Elisa testing for biological samples at our Research Laboratory i.e. Centre for Molecular Cancer Research (CMCR). The testing charges for the same is amounting Rs.50,000/- We request for the payment of Rs. 50,000/- (Fifty thousand Rupees only).

With regards,

PRINCIPAL

Encl: Invoice



Date: 03-10-2020.

CERTIFICATE

This is to certify that **Miss. CHAPALA UMARANI (HT.NO.18DH1S1203)** pursuing her M. Pharmacy in **VISHNU INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH** has carried out her project work in our Organization entitled "**SIMULTANEOUS DETERMINATION OF DARUNAVIR AND COBICISTAT IN BULK FORM AND COMBINED MARKETED FORMULATION BY USING REVERSE PHASE-HPLC METHOD**" in the department of Pharmaceutical Analysis from **2-MAY-2019 TO 03-OCTOBER-2020.**

During her tenure she was sincere, hardworking and Punctual in her Project work.

We wish her to success in her future career.

Authorized Signatory


Mrs. Rajni Sura

Managing Director



Date: 03-10-2020.

CERTIFICATE

This is to certify that Miss. ANUSHA AWOODODI (HT.NO.18DH1S1202) pursuing her M. Pharmacy in VISHNU INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH has carried out her project work in our Organization entitled "DEVELOPMENT OF A NEW ANALYTICAL METHOD AND VALIDATION OF LORNOXICAM AND THIOCOLCHICOSIDE IN PURE FORM AND PHARMACEUTICAL FORMULATION BY USING RP-HPLC" in the department of Pharmaceutical Analysis from 2-MAY-2019 TO 03-OCTOBER-2020.

During her tenure she was sincere, hardworking and Punctual in her Project work.

We wish her to success in her future career.

Authorized Signature


Mrs. Rajini Sura

Managing Director



Date: 03-10-2020.

CERTIFICATE

This is to certify that Miss. FARHEEN SULTHANA (HT.NO.18DHIS1205) pursuing her M. Pharmacy in VISHNU INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH has carried out her project work in our Organization entitled "METHOD DEVELOPMENT AND VALIDATION OF A RP-HPLC FOR THE SIMULTANEOUS ESTIMATION OF ALOGLIPTIN AND PIOGLITAZONE IN BULK AND MARKETED PHARMACEUTICAL DOSAGE FORM" in the department of Pharmaceutical Analysis from 2-MAY-2019 TO 03-OCTOBER-2020.

During her tenure she was sincere, hardworking and Punctual in her Project work.

We wish her to success in her future career.

Authorized Signature


Mrs. Rajni Sura
Managing Director



Date: 03-10-2020

CERTIFICATE

This is to certify that **Miss. METHARI MAMATHA (HT,NO.1800151200)** pursuing her M. Pharmacy in **VISHNU INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH** has carried out her project work in our Organization entitled **"SIMULTANEOUS ESTIMATION OF ESCITALOPHAM AND CLONAZEPAM IN NATURAL SHAPE AND ADVERTISED PHARMACEUTICAL DOSAGE FORM THROUGH THE USAGE OF REVERSE PHASE-HPLC APPROACH"** in the department of Pharmaceutical Analysis from **2 MAY-2019 TO 03-OCTOBER-2020.**

During her tenure she was sincere, hardworking and Punctual in her Project work.

We wish her to succeed in her future career.

Authorized Signatory

Mrs. Rajashree

Managing Director



Date: 03-10-2020.

CERTIFICATE

This is to certify that **Miss. R.MANASA (HT.NO.18DH1S1213)** pursuing her M. Pharmacy in **VISHNU INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH** has carried out her project work in our Organization entitled **"A NEW ANALYTICAL METHOD DEVELOPMENT AND VALIDATION FOR THE QUANTITATIVE DETERMINATION OF SITAGLIPTIN AND SIMVASTATIN IN BULK FORM AND COMBINED MARKETED PHARMACEUTICAL DOSAGE FORM BY USING REVERSE PHASE-HPLC"** in the department of Pharmaceutical Analysis from **2-MAY-2019 TO 03-OCTOBER-2020**.

During her tenure she was sincere, hardworking and Punctual in her Project work.

We wish her to success in her future career.

Authorized Signature


Mrs. Rajini Sura

Managing Director



Date: 03-10-2020.

CERTIFICATE

This is to certify that Miss. NAZMA BEGUM (HT.NO.18DHIS1210) pursuing her M. Pharmacy in VISHNU INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH has carried out her project work in our Organization entitled "A NEW RP-HPLC METHOD AND IT'S VALIDATION FOR THE ANALYSIS OF ARTESUNATE AND MEFLOQUINE IN BULK AND PHARMACEUTICAL DOSAGE FORM AS PER ICH GUIDELINES" in the department of Pharmaceutical Analysis from 2-MAY-2019 TO 03-OCTOBER- 2020.

During her tenure she was sincere, hardworking and Punctual in her Project work.

We wish her to success in her future career.

Authorized Signature


Mrs. Rajini Sura

Managing Director



Date: 03-10-2020.

CERTIFICATE

This is to certify that **Miss. P.BHAVANA (HT.NO.18DHIS1212)** pursuing her M. Pharmacy in **VISHNU INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH** has carried out her project work in our Organization entitled **“DEVELOPMENT AND VALIDATION OF A SIMPLE AND NOVEL RP-HPLC METHOD FOR THE SIMULTANEOUS DETERMINATION OF LEVODOPA AND CARBIDOPA IN BULK FORM AND PHARMACEUTICAL DOSAGE FORM ACCORDING TO ICH GUIDELINES”** in the department of Pharmaceutical Analysis from **2-MAY-2019 TO 03- OCTOBER- 2020.**

During her tenure she was sincere, hardworking and Punctual in her Project work.

We wish her to success in her future career.

Authorized Signature


Mrs. Rajini Sura

Managing Director



20th November 2020.

TO WHOM SO EVER IT MAY CONCERN

This is to certify that Ms.CH. Shailaja, (Regd. No: 18DH1S1204, of (Vishnu Institute of pharmaceutical education and research), has undergone industrial training in “**Analytical Research and Development Department**” in “**Analytical Method Development and Method Validation of Stability Indicating Related Substances by RP-HPLC for Levomilnacipran Pellets**” at Pellets Pharma Limited from 01st October 2019 to 31st July 2020.

During this period, we found that her conduct is satisfactory. We wish her all the best for her future endeavors.

For Pellets Pharma Limited,



Authorized Signatory,

Human Resource-Department

30th November 2020.

TO WHOM SO EVER IT MAY CONCERN

This is to certify that Ms. Yarlagadda. Navya, (Regd. No: 18DH1S0310, of (Vishnu Institute of pharmaceutical education and research), has undergone industrial training in “**Formulation Research and Development Department**” in “**Formulation Development and Invitro Evaluation of Esomeprazole Magnesium Trihydrate Capsule**” at Pellets Pharma Limited from 01st October 2019 to 02nd June 2020.

During this period, we found that her conduct is satisfactory. We wish her all the best for her future endeavors.

For Pellets Pharma Limited,



Authorized Signatory,

Human Resource-Department

Admn. Office : 784, Vivekanandanagar Colony, Kukatpally, Hyderabad, Telangana, INDIA - 500 072.

Phone : + 91-40-23160194-95, www.pelletspharma.com

Factory : Plot No. 8 & 9, TSIC-EPIP, Pashamylaram, Patancheru (Mandal), Sangareddy (Dist.)
Telangana (T.S), INDIA - 502 307.



HETERO LABS LIMITED

(FORMULATIONS R&D)

"Hetero Corporate", 7-2-A2, Industrial Estates, Sanath Nagar, Hyderabad - 500 018, Telangana, INDIA.

Tel : 91-40-23704923/24/25, Fax : 91-40-23704926, 23714250

E-mail : contact@heterodrugs.com URL : <http://www.heterodrugs.com>

CIN: U24110TG1989PLC009723

Date: 21-05-2020

TO WHOMEVER IT MAY CONCERN

This is to certify that Ms.Y.Girisha Reddy bearing roll no: 18DH1S1215 Student of M.Pharmacy from Vishnu Institute of Pharmaceutical Education & Research, Narsapur affiliated to JNTU-H University has been allotted a project on "**Method Development & Validation for the Estimation of Solifenacin Succinate in Bulk & tablet dosage form by RP - HPLC**" in Analytical Research & Development Department of our unit, as part of her curriculum.

She has successfully completed her project from 10th October, 2019 to 20th March, 2020.

We found her sincere and hardworking during the project period.

We wish her all the best in future career.

Authorized Signatory,



21-05-2020

HR Department.



VISHNU INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH
VISHNUPUR, NARSAPUR, MEDAK 502313.

GRANULES INDIA LIMITED



GIL BSC 3 & 4 BATCH 1st YEAR I SEMESTER TIMETABLE

S.NO	DATE	9.00-11.00	11.00-1.00	1.00-3.00	3.00-5.00	5.00-7.00
1	16-10-2019	CHEMISTRY I,MSRIKANTA	MATRS, MNTYADAV	CHEMISTRY, I,MSRIKANTA	MATRS, MNTYADAV	MATRS, MNTYADAV
2	23-10-2019	MATRS, MNTYADAV	MATRS, MNTYADAV	MATRS, MNTYADAV	MATRS, MNTYADAV	PHYSICS, N. SUSHMA
3	30-10-2019	MATRS, MNTYADAV	PHYSICS, N. SUSHMA	MATRS, MNTYADAV	PHYSICS, N. SUSHMA	PHYSICS, N. SUSHMA
4	06-11-2019	CHEMISTRY, FLA WERENCE	PHYSICS, N. SUSHMA	CHEMISTRY, FLA WERENCE	PHYSICS, N. SUSHMA	PHYSICS, N. SUSHMA
5	12-11-2019	CHEMISTRY, FLA WERENCE	PHYSICS, N. SUSHMA	CHEMISTRY, FLA WERENCE	PHYSICS, N. SUSHMA	PHYSICS, N. SUSHMA
6	19-11-2019	CHEMISTRY, FLA WERENCE	MATRS, MNTYADAV	CHEMISTRY, FLA WERENCE	MATRS, MNTYADAV	CHEMISTRY, FLA WERENCE
7	26-11-2019	CHEMISTRY, PURUSHOTTAM	PHYSICS, N. SUSHMA	CHEMISTRY, PURUSHOTTAM	PHYSICS, N. SUSHMA	PHYSICS, N. SUSHMA
8	03-12-2019	CHEMISTRY, PURUSHOTTAM	MATRS, MNTYADAV	CHEMISTRY, PURUSHOTTAM	MATRS, MNTYADAV	MATRS, MNTYADAV
9	10-12-2019	CHEMISTRY, PURUSHOTTAM	MATRS, MNTYADAV	CHEMISTRY, PURUSHOTTAM	MATRS, MNTYADAV	MATRS, MNTYADAV
10	17-12-2019	CHEMISTRY, PURUSHOTTAM	MATRS, MNTYADAV	CHEMISTRY, PURUSHOTTAM	MATRS, MNTYADAV	MATRS, MNTYADAV
11	24-12-2019	CHEMISTRY, PURUSHOTTAM	CHEMISTRY, PURUSHOTTAM	CHEMISTRY, PURUSHOTTAM	CHEMISTRY, PURUSHOTTAM	CHEMISTRY, PURUSHOTTAM
12	31-12-2019	CHEMISTRY, PURUSHOTTAM	CHEMISTRY, PURUSHOTTAM	CHEMISTRY, PURUSHOTTAM	CHEMISTRY, PURUSHOTTAM	CHEMISTRY, PURUSHOTTAM
13	07-01-2020	CHEMISTRY, PURUSHOTTAM	PHYSICS, N. SUSHMA	CHEMISTRY, PURUSHOTTAM	PHYSICS, N. SUSHMA	PHYSICS, N. SUSHMA
14	14-01-2020		Holiday		Holiday	
15	21-01-2020		PRACTICALS		PRACTICALS	
16	28-01-2020	PHYSICS, N. SUSHMA	CHEMISTRY, PURUSHOTTAM	PHYSICS, N. SUSHMA	CHEMISTRY, PURUSHOTTAM	CHEMISTRY, PURUSHOTTAM
17	04-02-2020	MATRS, MNTYADAV	CHEMISTRY, PURUSHOTTAM	MATRS, MNTYADAV	CHEMISTRY, PURUSHOTTAM	CHEMISTRY, PURUSHOTTAM
18	11-02-2020	CHEMISTRY, PURUSHOTTAM	CHEMISTRY, PURUSHOTTAM	CHEMISTRY, PURUSHOTTAM	CHEMISTRY, PURUSHOTTAM	CHEMISTRY, PURUSHOTTAM
19	18-02-2020	CHEMISTRY, PURUSHOTTAM	CHEMISTRY, PURUSHOTTAM	CHEMISTRY, PURUSHOTTAM	CHEMISTRY, PURUSHOTTAM	CHEMISTRY, PURUSHOTTAM
20	25-02-2020	MATRS, MNTYADAV	CHEMISTRY, PURUSHOTTAM	MATRS, MNTYADAV	CHEMISTRY, PURUSHOTTAM	CHEMISTRY, PURUSHOTTAM
21	05-03-2020	CHEMISTRY, PURUSHOTTAM	CHEMISTRY, PURUSHOTTAM	CHEMISTRY, PURUSHOTTAM	CHEMISTRY, PURUSHOTTAM	CHEMISTRY, PURUSHOTTAM
22	12-03-2020	MATRS, MNTYADAV	MATRS, MNTYADAV	MATRS, MNTYADAV	MATRS, MNTYADAV	MATRS, MNTYADAV
23	17-03-2020	PHYSICS, N. SUSHMA	PHYSICS, N. SUSHMA	PHYSICS, N. SUSHMA	PHYSICS, N. SUSHMA	PHYSICS, N. SUSHMA
24	24-03-2020	CHEMISTRY, PURUSHOTTAM	CHEMISTRY, PURUSHOTTAM	CHEMISTRY, PURUSHOTTAM	CHEMISTRY, PURUSHOTTAM	CHEMISTRY, PURUSHOTTAM
25	31-03-2020	MATRS, MNTYADAV	MATRS, MNTYADAV	MATRS, MNTYADAV	MATRS, MNTYADAV	MATRS, MNTYADAV

BREAK

COORDINATOR

Principal
 Vishnu Institute of Pharmaceutical
 Education & Research
 Narsapur, Medak dist-502313

VISHNU INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH
VISHNUPUR, NARSAPUR, MEDAK Dt-502313

Sl.No	Batch No	Invoice Amount	TDS %	Amount Received	Amount Due	Expenditure paid	Expenditure to be paid	Balance retained in Ptl. & AO A/c, VIPER
1	GIL BSC -1(FIRST BATCH)	282000	7.5%	260850	0	90600	0	170250
2	GIL BSC -2(FIRST BATCH)	282000	7.5%	260850	0	68200	0	192650
3	GIL BSC -3(FIRST BATCH)	282000	7.5%	260850	0	76800	0	184050
4	GIL BSC -1(SECOND BATCH)	282000	7.5%	260850	0	98400	0	162450
5	GIL BSC -2(SECOND BATCH)	282000	10%	253800	0	92800	0	161000
6	GIL BSC -3(SECOND BATCH)	282000	10%	253800	0	28000	0	225800
7	GIL BSC -4(FIRST BATCH)	282000	10%	253800	0	64000	0	189800
8	GIL BSC -5(FIRST BATCH)	282000	10%	253800	0	61600	0	192200
9	GIL BSC -6(FIRST BATCH)	282000	10%	0	253800	19200	0	-19200
10	GIL BSC -4(SECOND BATCH)	282000	10%	0	253800	0	54200	0
TOTAL		2820000		2058600	507600	599600	54200	1459000

Principal
Vishnu Institute of Pharmaceutical
Education & Research
Narsapur, Medak dist -502313

“Phytochemical screening and evaluation of acute oral toxicity on Sandhivaataari gutika”

Sandhivaataari gutika is a poly herbal formulation which posses many therapeutic effects on human body.

Preparation of Sandhivaataari Gutika

The purified hingulam, guggulu (commiphora mukul) and bola(Commiphora molmol) are made into powder. This powder is pounded in Godugdha(cow's milk)for one day followed by drying and powdering . Powder is made into pills in the dose of 125mg.

METHODOLOGY


Table no.1 Materials

Material	Supplier
Sandhivaataari gutika	Davasaz (herbal shops) Begum bazaar ,Hyderabad.
solvent	water
Animals	Mahaveer enterprises

Preparation of plant extract

MATERIALS AND METHODS:

S.no	Equipment	Manufacturer
1	Borosil Soxhlet extractor	Borosil Manufacture
2	Solvent evaporator	Chemi Tech
3	Analgesiometer	INCO


 Principal
 Vishnu Institute of Pharmaceutical
 Education & Research
 Narsapur, Medak Dist - 502 313

4	Eddy's hot plate	INCO
5	Digital balance	ELB 300- SHIMADZU
6	Syringes and needles	Local Market

PROCESS:

BOROSIL SOXHLET EXTRACTOR:

Soxhlet extractor is not limited to the extraction of lipids. Typically, a Soxhlet extraction is only required where the desired compound has a *limited* solubility in a solvent, and the impurity is insoluble in that solvent. If the desired compound has a significant solubility in a solvent then a simple filtration can be used to separate the compound from the insoluble substance. Fruit extraction in progress. The sample is placed in the thimble.

Normally a solid material containing some of the desired compound is placed inside a thimble made from thick filter paper, which is loaded into the main chamber of the Soxhlet extractor. The Soxhlet extractor is placed onto a flask containing the extraction solvent. The Soxhlet is then equipped with a condenser.

The solvent is heated to reflux. The solvent vapour travels up a distillation arm, and floods into the chamber housing the thimble of solid. The condenser ensures that any solvent vapour cools, and drips back down into the chamber housing the solid material.

The chamber containing the solid material slowly fills with warm solvent. Some of the desired compound will then dissolve in the warm solvent. When the Soxhlet

chamber is almost full, the chamber is automatically emptied by a siphon side arm, with the solvent running back down to the distillation flask. This cycle may be allowed to repeat many times, over hours or days.

During each cycle, a portion of the non-volatile compound dissolves in the solvent. After many cycles the desired compound is concentrated in the distillation flask. The advantage of this system is that instead of many portions of warm solvent being passed through the sample, just one batch of solvent is recycled.

After extraction the solvent is removed, typically by means of a rotary evaporator, yielding the extracted compound. The non-soluble portion of the extracted solid remains in the thimble, and is usually discarded[13]

Preparation of extracts:

First the powdered drug was subjected to extraction. The extracts were prepared by using hot air percolation technique using Soxhlet apparatus, a process of extraction of a drug with a solvent with several daily shakings. This method was based on the extraction of active constituents by simple hot air percolation using water as solvent.

50g of the powdered material was placed inside a thimble supported by cotton pads which is loaded into the main chamber of the Soxhlet extractor. The Soxhlet extractor is placed onto a flask containing the extraction solvent. The Soxhlet is then equipped with a condenser.

The solvent is heated to reflux. The solvent vapour travels up a distillation arm, and floods into the chamber housing the thimble of solid. The condenser ensures that any solvent vapour cools, and drips back down into the chamber housing the solid material.


- The chamber containing the solid material slowly fills with warm solvent. Some of the desired compound will then dissolve in the warm solvent. When the Soxhlet chamber is almost full, the chamber is automatically emptied by a siphon side arm, with the solvent running back down to the distillation flask. This cycle may be allowed to repeat many times, over hours or days.

During each cycle, a portion of the non-volatile compound dissolves in the solvent. After many cycles the desired compound is concentrated in the distillation flask.

After 24 hrs, the water extract was filtered and the marc was repeated two more times with the same solvent for effective extraction. Extract was concentrated by open air drying. And the acquired extract was stored in a dessicator[14].

A Schematic Representation of Extraction

50g of powder was percolated with 500ml water as solvent for several times



4.2 Phytochemical screening of drug

PROCEDURE:

Test solution: Depending upon the type of natural drug under examination, the test solution may be a aqueous extract or alcoholic extract.

1. Alkaloids:

- (a) **Dragendroff's reagent:** Alkaloids give reddish brown precipitate with Dragendroff's reagent (potassium bismuth iodide solution)
- (b) **Mayer's reagent:** Alkaloids give cream colour precipitate with Mayer's reagent (potassium mercuric iodide solution)
- (c) **Wagner's reagent:** Alkaloids give reddish brown precipitate with Wagner's reagent (Iodine potassium iodide solution)
- (d) **Hager's reagent:** Alkaloids give yellow precipitate with Hager's reagent (saturated solution of picric acid)[15].

2. Carbohydrates (with aqueous test solution)

(a) **Molisch's test:** To the test solution few drops of alcoholic 1-naphthol was added. Then few drops of conc.H₂SO₄ was added through sides of test tube; purple to violet colour ring appears at the junction.

(b) **Barfoed's test:** 1ml of the test solution is heated with 1ml of barfoed's reagent on water bath, appearance of red color, indicates the presence of monosaccharide. Disaccharides on prolonged heating (about 10min) may also cause reduction, owing to partial hydrolysis to monosaccharide.

(C) **Seliwanoff's test** : To the test solution, crystals of resorcinol and equal amount of conc.HCl were added and heated on a water bath, appearance of pink color indicates the presence of carbohydrates

(d) **Test for pentose**: To the test solution, equal volume of hydrochloric acid containing small amount of phloroglucinol were added and heated, red color indicates the presence of carbohydrates[16].

3 . Proteins:

(a) **Warming test**: The test solution was heated in a boiling water bath, proteins gets coagulated.

(b) **Test with trichloroacetic acid**: To the test solution, trichloro acetic acid was added, precipitate formation indicates the presence of proteins.

(c) **Biuret test**: To the test solution (2ml) violet colour indicates presence of proteins.

(d) **Hydrolysis test**: Hydrolyze the test solution with HCl or H₂SO₄.Then carry out for ninhydrin test for amino acids.

(e) **Xanthoproteic test**: To the (5ml) of test solution, 1ml of conc.HNO₃ was added and boiled, yellow precipitate is formed. After cooling it, 40% NaOH solution was added, orange colour is formed[17]

4. Flavanoids:

(a) **Shinoda test**: To the test solution, few magnesium turnings were added and conc.HCl was added drop wise, pink scarlet, crimson red or occasionally green to blue colour appears after few minutes.

(b) **Alkaline reagent test:** To the test solution, few drops of sodium hydroxide solution were added, intense yellow is formed which turns to colourless on addition of few drops of dilute acid indicates presence of flavanoids.

(c) **Zinc hydrochloride test:** To the test solution, a mixture of zinc dust and conc.Hcl was added. It gives red colour after few minutes[18].

5. Cardiac glycosides:

(a) **Kedde's test:** The drug was extracted with chloroform and evaporated to dryness. One drop of 90% alcohol and 2 drops of 2% 3, 5-dinitrobenzoic acid in 90% alcohol were added. The solution was made alkaline with 20% NaOH solution, purple colour is produced. The colour reaction with 3,5 dinitro benzoic acid depends on the presence of a, b-unsaturated lactones in the aglycone.

(b) **Keller-killiani test (test for deoxy sugars):**

The drug was extracted with chloroform and evaporated to dryness. 0.4ml of glacial acetic acid containing trace amounts of $FeCl_3$ was added. The solution was transferred to a small test tube and 0.5ml of conc. H_2SO_4 was added by the sides of the test tube. Acetic acid layer shows blue colour.

(c) **Raymond's test:** The test solution was treated with hot methanolic alkali, violet colour is produced.

(d) **Baljet's test:** The test solution was treated with picric acid or sodium picrate, orange colour is formed[19].

6. Anthra quinone glycosides:

- a) **Borntrager's test:** The test material was boiled with 1ml of sulphuric acid in a test tube for five min. The solution was filtered while hot, the filtrate was cooled and shaken with equal volume of dichloromethane or chloroform followed by shaking it with half of its volume of dilute ammonia. A rose pink to red colour is produced in the ammonical layer
- b) **Modified borntrager's test:** 200mg of the test material was boiled with 2ml of dil.H₂SO₄.The solution was treated with 2ml of 5% aqueous FeCl₃ solution (freshly prepared) for 5min, shaken with equal volume of chloroform and continued as the test above. As some plants contain anthracene aglycone in a reduced form, if ferric chloride is used during the extraction, oxidation to anthraquinones takes place, which shows response to Borntrager's test.
- c) **TEST FOR HYDROXY-ANTHRAQUINONES:** The sample was treated with KOH solution, red colour is produced[20].

7. SAPONIN GLYCOSIDES:

(a) **FROTH FORMATION TEST:** 2ml solution of drug in water is shaken in a test tube, stable froth (foam) is formed.

(b)**Haemolysis test:** 0.2ml of solution of Saponin was added(prepared in 15 normal saline) to 0.2ml blood in normal saline and mixed well. Centrifuge and note the red supernatant.

Compare with control tube containing 0.2ml of 10% blood in normal saline diluted with 0.2ml of normal saline[21].

8. TANNINS (PHENOLIC COMPOUNDS)

- (a) **Goldbeater's skin test:** 2% HCl was added to a small piece of gold beater's skin, rinsed with distilled water and placed in the test solution for five minutes. Then wash was given with distilled water and transferred to 1% ferrous sulphate solution. A brown or black colour on the skin indicates of tannins.
- (b) **Ferric chloride test:** The extract was treated with ferric chloride solution, blue colour appears if hydrolysable tannins are present and green colour appears if condensed tannins are present.
- (c) **Phenazone test:** 0.5gm of sodium acid phosphate was added to 5ml of aqueous extract. The solution was subjected to warming and filtered. To the filtrate 2% phenazone solution was added, bulky precipitate is formed which is often coloured.
- (d) **Gelatin test:** To the test solution, 1% gelatin solution containing 10% sodium chloride was added. Precipitate is formed.
- (e) **Test for catechin:** A matchstick was dipped in the test solution, dried and lastly moistened with concentrated HCl. Stick was placed near flame. The colour of the wood changes to pink due to phloroglucinol (phloroglucinol is formed when catechins are treated with acids)
- (f) **Test for chlorogenic acid:** The test solution was treated with aqueous ammonia and exposed to air gradually, green colour is developed[22].

9 . STEROIDS AND TERPENOIDS:

- (a) **Libermann – burchard test:** The extract was treated with few drops of acetic anhydride, boiled and cooled. Then conc.H₂SO₄ was added from the sides of the test tube, brown ring is formed at the junction two layers and upper layer turns

green which shows presence of steroids and formation of deep red colour indicates presence of tri terpenoids.

(b) **Salkowski test:** The extract was treated with few drops of conc.H₂SO₄, red colour at lower layer indicates presence of steroids and formation of yellow coloured lower layer indicates presence of tri terpenoids.

(c) **Sulphur powder test:** Small amounts of sulphur powder was added to the test solution ,it sinks at the bottom[23].

Experimental animals:

Male Wistar rats (150-200g) were purchased from Mahaveer enterprises, hyderabad. The animals had free access to standard rodent pellet diet with water *ad libitum*. Animals were habituated to laboratory conditions prior to experimental protocol (22 ± 3°C temperature, 50-60% humidity). All the protocols and experiments were conducted in strict compliance according to guidelines provided by Committee for the Purpose of Control and Supervision of Experiments on Animals(CPCSEA/). The approval (Proposal No. IAEC/NCP/07/09) of the Institutional Animal Ethical Committee (IAEC) Vishnu institute of pharmaceutical education and research was taken prior to the experiments[24].

Grouping and dosing

Animals were divided into two groups of seven animals each. One group was administered with 2000mg/kg body weight and other group was administered with 5000mg/kg body weight.

Administration of doses.

Animals were fasted prior to dosing (food but not water should be withheld over-night). Following the period of fasting, the animals were weighed and the test substance was administered. The test substance was administered in a single dose by gavage using a stomach tube or a suitable intubation canula. After the substance has been administered, food was withheld for a further 3-4 hours in rats[25].

Table no.2 Administration of doses to first group

S.no	Weight of animal(g)	Weight of drug (mg/kg)	Volume of dose for each animal (ml)
1	175	0.35	0.71
2	180	0.36	0.73
3	170	0.34	0.69
4	168	0.33	0.67
5	180	0.36	0.73
6	170	0.34	0.69

n=6

Dose = 2000mg/kg body weight

Table no.3 Administration of doses to second group

S.no	Weight of animal(g)	Weight of drug (mg/kg)	Volume of dose for each animal (ml)
1	190	0.95	1.84
2	190	0.95	1.84
3	180	0.9	1.74
4	190	0.95	1.84
5	220	1.1	2.13

n=6

Dose = 5000mg/kg body weight

RESULTS

Table no.4 Phytochemical constituents of sadhaavataari gutika

CHEMICAL CONSTITUENT	OBSERVATION
ALKALOID	NEGATIVE
CARBOHYDRATES:	POSITIVE
PROTIENS	POSITIVE
FLAVANOIDS	NEGATIVE
CARDIAC GLYCOSIDES:	NEGATIVE
ANTHRA QUINONE GLYCOSIDES	NEGATIVE
SAPONIN GLYCOSIDES:	NEGATIVE
TANNINS &PHENOLS:	POSITIVE
STEROIDS	NEGATIVE

ACUTE TOXICITY STUDIES:

Administration of sadhavaataari gutika (2000mg/kg) showed no change in body weight of animals. Convulsions and tremors were not found. Food and water intake were also found to be normal.

Administration of sadhavaataari gutika (5000mg/kg) showed no significant change in body weight of animals. Convulsions and tremors were absent . Food and water intake were also found to be normal.

DISCUSSION

Phytochemicals are non-nutritive plant chemicals that have protective or disease preventive properties. Phytochemical screening is a process of tracing plant constituents. Sadhavaataari gutika was found to have carbohydrates, proteins and tannins as its phytochemical constituents.

It is clear that the strategy for toxicity testing has changed significantly over the years in order that early toxicology information can help support decisions on the best compounds to progress as potential human medicines. Lower dose (2000mg/kg body weight) has not shown changes in body weights of rats. It has not shown any convulsions or tremors. Food and water intake of animals was also found to be normal. Higher dose (5000mg/kg) has shown slight decrease in body weight of animals which was not significant. It has not shown any convulsions and tremors. Food and water intake of animals was also found to be normal.

CONCLUSION

Sadhavaataari gutika was found to have carbohydrates (aqueous extract), proteins (aqueous extract), tannins and phenols (aqueous extract) as their phytoconstituents. Lower dose of sadhavaataari gutika (2000mg/kg body weight) and higher dose (5000mg/kg body weight) did not produce any clinical signs of toxicity and death of animals.

BIBLIOGRAPHY

1. Resin from the mukul myrrh tree, guggul, can it be used for ncbi
www.ncbi.nlm.nih.gov/pubmed/1911422
2. Myrrh(commiphora myrrha)www.global herbal
supplies.com/herb_information/myrrh.htm
3. Cinnabar - wikipedia, the free encyclopedia en.wikipedia.org/wiki/cinnabar
4. Toxicology - wikipedia, the free encyclopedia en.wikipedia.org/wiki/toxicology
5. Toxicity - wikipedia, the free encyclopedia en.wikipedia.org/wiki/toxicity
6. Toxicology studies www.kids4research.org/kids/toxicology_studies
7. Oecd test guideline 401- acute oral toxicity (1987-rescinded ...
iccvam.niehs.nih.gov/docs/acutetox_docs/udpproc_app1.pdf
8. Oecd test guideline 423:acute oral toxicity acute toxic classic
cvam.niehs.nih.gov/suppdocs/feddocs/oecd/oecd_gl423.pdf
Soxhlet extraction www.chem-ilp.net/lab_techniques/soxhlet_extraction.htm
9. The extraction procedure {www.behr-labor.com/pdf/app_extraktion_gb.pdf}
10. Some microchemical tests for alkaloids {brary.sciencemadness.org/some_micro-chemicals}
11. Some micro-chemical tests for alkaloids library.sciencemadness.org/some_micro-chemicals
12. Tests of proteins, biuret millon's nihydrin test, iit jee ...www.askiitians.com/iit_jeecarbohydrates_tests-of-proteins
13. Chemical tests for flavonoids wiki.answers.com/wiki/answers_categories_science_biology
14. Glycosides-classification, testing and uses www.bukisa.com_education_college_and_university
15. Anthraquinone glycoside pharmaceutical ...the_pharmacistpharma.blogspot.com/anthraquinone-glycosides.htm
Saponin glycosides www.phar.kufauniv.com/staff/saponin%20%20glycosides.doc
16. Tannins pharmaxchange.info/notes/cognosy/tannins.pdf

17. The chemical specificity of the schultz test for ...
jhc.sagepub.com/content/9/1/2.full.pdf
18. Test no. 423: acute oral toxicity - acute toxic class ... - oecd ilibrarywww.oecd-ilibrary.org/.../test-no-423-acute-oral-toxicity-acute-toxic-
19. Oecd guideline for the testing of
chemicalswww.oecd.org/dataoecd/54/11/41761436.pdf
Oecd (2000) guidance document on acute oral toxicity. environmental health and safety monograph series on testing and assessment no 24.
20. Oecd (2000) guidance document on the recognition, assessment and use of clinical signs as humane endpoints for experimental animals used in safety evaluation environmental health and safety monograph series on testing and assessment no 19.
21. Oecd (1998) harmonized integrated hazard classification system for human health and environmental effects of chemical substances as endorsed by the 28th joint meeting of the
22. Oecd (rome, 1995). report of the consultation meeting on sub-chronic and chronic toxicity/carcinogenicity testing.combes rd, gaunt, i, balls m (2004). a scientific and animal welfare assessment
23. Oecd health effects test guidelines for the safety testing of chemicals under the european union reach system. atla 32, 163-208.
24. Oecd guidelines for the testing of chemicals. no. 39. draft guidance document on acute inhalation toxicity testing. version 9, march 2008.
25. Oecd guidelines for the testing of chemicals. tg 412, subacute inhalation toxicity: 28-day study.
26. OECD Guidelines for the Testing of Chemicals. TG 412, Subacute Inhalation Toxicity: 28-Day Study.
27. OECD Guidelines for the Testing of Chemicals. TG 413, Subchronic Inhalation Toxicity: 90-Day Study.
28. OECD Guidelines for the Testing of Chemicals. No. 19. Guidance Document on the recognition, assessment, and use of clinical signs as humane endpoints for experimental animals used in safety evaluation (2000).

Vishnu Institute of Pharmaceutical Education & Research
Warananik, Dist. - 507 002



Date: 24-05-2019

CERTIFICATE

This is to certify that Miss. G. SANDHYA (HT. No. 17DH1S0302) pursuing her M.Pharmacy In VISHNU INSTITUTE OF PHARMACEUTICAL EDUCATION & RESEARCH (VIPER) she carried out her project work in our Organization entitled "FORMULATION AND EVALUATION OF PALIPERIDONE SUSTAINED RELEASE TABLETS" in the department of pharmaceutics from 19-NOV-2018 to 24-JUNE-2019.

During her tenure she was sincere, hardworking and Punctual in her Project work.

We wish her to success in her future career.

Authorized Signature

Mrs. Rajini Sura

Managing Director





Date: 24-05-2019

CERTIFICATE

This is to certify that **Miss. K.A.RAJESHWARI (HT. No. 17DH1S0303)** pursuing her M.Pharmacy In **VISHNU INSTITUTE OF PHARMACEUTICAL EDUCATION & RESEARCH (VIPER)** she carried out her project work in our Organization entitled **“FORMULATION AND INVITRO EVALUATION OF MIRABEGRON EXTENDED RELEASE TABLETS”** in the department of pharmaceutics from **19-NOV-2018 to 24-JUNE-2019**.

During her tenure she was sincere, hardworking and Punctual in her Project work.

We wish her to success in her future career.

Authorized Signature

Mrs. Rajini Sura

Managing Director





Date: 24-05-2019

CERTIFICATE

This is to certify that Miss. M. HARIKA (HT. No. 17DH1S0305) pursuing her M.Pharmacy In VISHNU INSTITUTE OF PHARMACEUTICAL EDUCATION & RESEARCH (VIPER) she carried out her project work in our Organization entitled "FORMULATION, CHARACTERISATION AND EVALUATION OF CONTROLLED RELEASE MATRIX TABLETS OF FELODIPINE" in the department of pharmaceutics from 19-NOV-2018 to 24-JUNE-2019.

During her tenure she was sincere, hardworking and Punctual in her Project work.

We wish her to success in her future career.

Authorized Signature

Mrs. Rajini Sura

Managing Director





Date: 24-05-2019

CERTIFICATE

This is to certify that Miss. M.VENNELA (HT. No. 17DH1S0307) pursuing her M.Pharmacy In VISHNU INSTITUTE OF PHARMACEUTICAL EDUCATION & RESEARCH (VIPER) she carried out her project work in our Organization entitled "FORMULATION DEVELOPMENT AND INVITRO EVALUATION OF PERAMPANEL IMMEDIATE RELEASE TABLET'S" in the department of pharmaceutics from 19-NOV-2018 to 24-JUNE-2019.

During her tenure she was sincere, hardworking and Punctual in her Project work.

We wish her to success in her future career.

Authorized Signature _____



Mrs. Rajini Sura

Managing Director



Date: 30-07-2019.

CERTIFICATE

This is to certify that Mr. P.SRAVAN KUMAR (HT.NO. 17DH1S0308) pursuing his M.Pharmacy in VISHNU INSTITUTE OF PHARMACEUTICAL EDUCATION & RESEARCH (VIPER) he carried out his project work in our Organization entitled "FORMULATION DEVELOPMENT & INVITRO CHARACTERIZATION OF SUSTAINED RELEASE MATRIX TABLETS OF GRANISETRON" in the department of Pharmaceutics from 12- NOV-2018 TO 30-JULY-2019.

During his tenure he was sincere, hardworking and Punctual in his Project work.

We wish him to success in his future career.

Authorized Signature _____

Mrs.Rajini Sura

Managing Director





Date: 24-05-2019

CERTIFICATE

This is to certify that Miss. SARA BEGUM (HT. No. 17DH1S0311) pursuing her M.Pharmacy in VISHNU INSTITUTE OF PHARMACEUTICAL EDUCATION & RESEARCH (VIPER) she carried out her project work in our Organization entitled "FORMULATION AND EVALUATION OF SUSTAINED RELEASE MATRIX TABLETS OF PIOGLITAZONE HYDROCHLORIDE" in the department of pharmaceutics from 19-NOV-2018 to 24-JUNE-2019.

During her tenure she was sincere, hardworking and Punctual in her Project work.

We wish her to success in her future career.

Authorized Signature _____

Mrs. Rajini Sura
Managing Director



11 /08/2019

Certificate

Sub: Certification of Project Completion

This is to certify that Ms. **THAMMI VEENA M.** Pharmacy final year student of **VISHNU INSTITUTE OF PHARMACEUTICAL EDUCATION & RESEARCH**, bearing Registration No: **17DH1S0312**, has done project on "**FORMULATION DESIGN AND IN-VITRO EVALUATION OF CANDESARTAN CILEXETIL BUCCAL PATCHES BY SOLVENT CASTING METHOD**" under the guidance of **MD.IMRAN, M. Pharm** towards the fulfillment of award of Master of Pharmaceutical Sciences during the period **FEB 10th 2019 to AUG 10th 2019.**

She has successfully completed her project work in our FR&D as part of M. Pharmacy course.

We wish her the very best in all her future endeavors.

Best Regards,

CHANDRA LABS



Authorized Signatory



404, 4th Floor, Raja Enclave,
KPHB Colony, Opp. R.S. Brothers,
Hyderabad - 500 072, INDIA.
Tel : 040 - 40 189 585 Mob : +91 89789 11190
Website : www.activepharmalabs.com
E-mail : info@activepharmalabs.com

Ref:APL/Project/Syed Shahabaz/0210/2017

07th August, 2017

TO WHOM SO EVER IT MAY CONCERN

This is to certify that Mr.Syed Shahabaz, H.T.No: 15DH1S0318 is a bonafide student of Vishnu Institute of Pharmaceutical Education and Research, Vishnupur,Narsapur,Medak Telangana. Has undergone project work in our organization from 21-01-2017 to 07-08-2017, as a part of *partial fulfillment* of his M-Pharmacy course.

The title of the project is "Formulation and Evaluation of Oral Disintegrating Tablets of Nimodipine".

During the aforesaid period, we found his hard working, sincere and learning attitude.

With Best Wishes.

For ACTIVE PHARMA LABS



Authorized Signatory

April 27 , 2017

TO WHOMSOEVER IT MAY CONCERN

This is to certify that **Ms.G Sneha**, student of Vishnu Institute of Pharmaceutical, Education & Research, Narsapur, Medak district has undergone training in our organization from **16.09.2016** to **15.03.2017**. She has completed her project work on **Harmonization of Excipients using different pharmacopoeias** with the **Global Quality Assurance department, FTO-HO** at Dr. Reddy's Laboratories Limited.

Her conduct during the training period was satisfactory and we wish her all success in future endeavors.

With best regards,
For Dr.Reddy's Laboratories Ltd.,



Authorized Signatory

DRL ALL 28 BATCHES - SMT

S.NO	BATCH NO	INVOICE AMOUNT	INVOICE DATE	REC DATE	REC AMOUNT	TDS
22	DRL-22	322357	25-12-2016	12-04-17,	260677.5	25399
23	DRL-23	262018.5	28-01-2017	15-04-2017	235817	26202
24	DRL-24	306761	14-09-2017	13-07-18,03-11-18	276084	30677
25	DRL-25	306762	14-09-2017	11-04-2018	276085	30677
26	DRL-26	301943	14-12-2017	03-08-18,12-09-18	286201	26525
27	DRL-27	276569	23-03-2018	19-04-2018	248912	27657
28	DRL-28	276569	23-03-2018	19-04-2018	248912	27657
29	DRL-29	132555	30-11-2011	04-03-2022	119299	13255

**Principal**

Vishnu Institute of Pharmaceutical
Education & Research
Narsapur, Medak dist -502313

VISHNU INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH
VISHNUPUR, NARSAPUR, MEDAK Dt-502313

DRL ALL 4 BATCHES - BSC PROGRAM

S.NO	BATCH NO	INVOICE AMOUNT	INVOICE DATE	REC DATE	REC AMOUNT	TDS	
1	DRL-1, 2 YEAR	293250	11-12-2016	15-04-2017	263925	29325	
		293250	25.06.2016	12.11.2016	263925	29325	
2	DRL-1, 3 YEAR	109250 , 247250	03-20-2018 , 05.05.2017	11-04-2018 , 14.07.2017	98325 , 222525	10925 24725	
		188887	28.07.2016	29.07.2016	188887	0	
		209875		04.11.2015	188887	20988	
3	DRL-2, 2 YEAR	209875 , 184000	11-12-2016 , 05.05.2017	04-05-2017 , 15.07.2017	188887 , 165600	20988 , 18400	
		DRL-2, 3 YEAR	171250 & 7000	03-20-2018 & 25-09-2018	11-04-2018 & 06-03-2019	154125 & 6300	17125 & 700
			192625	11-12-2016	19-04-2017	173362	19263
			192625	30.05.2016	12.11.2016	173362	19263
3	DRL-3, 1 YEAR	120750	03-20-2018	12-04-2018	108675	12075	
		192625	05.05.2017	21.06.2017	173362	19263	
	DRL-3, 3 YEAR	120500 & 120750	03-20-2018 & 25-09-2018	30-07-2018 & 06-03-2019	108450 & 108675	12050 & 12075	

Principal
Vishnu Institute of Pharmaceutical
Education & Research
Narsapur, Medak dist -502313

**VISHNU INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH
VISHNUPUR, NARSAPUR, MEDAK 502313.**

Dr. Reddy's Laboratories



**INCOZEN THERAPEUTICS PRIVATE LIMITED
&
Vishnu Institute of Pharmaceutical Education & Research**


6. Methodology:

i. *In-Silico* drug design:

Initially a data set ligand library consisting acridone/phenoxazine as major scaffold was designed and prepared for all the computational studies. These data set ligands also include few ligands that were already synthesized in our lab and screened for MDR reversal activity. These ligands were used for the identification of possible potential pharmacophore responsible for MDR reversal activity using PHASE module of Schrodinger Suite 2012. Thus obtained model was validated using 3D-QSAR studies. All the ligands were evaluated for inhibition of Calmodulin dependent cAMP phosphodiesterase (PDE1c).

Digital protein structure of PDE1c was retrieved from protein data bank (<http://www.rcsb.org/pdb/home>) with a PDB ID 1LXS. All the ligands were geometrically optimized by minimizing the energy using LIGPREP module of Schrodinger Suite 2012. Metal binding and ionization states were generated where ever necessary. In the same way retrieved protein was also geometrically optimized by satisfying valencies and filling the missing amino acid groups and a grid was generated for docking studies. All the ligands were docked into the developed grid using GLIDE module of Schrodinger Suite 2012. Compounds with better fitness were synthesized and characterized. Synthetic scheme was shown in **Annexure: I**.

ii. Synthesis of designed molecules:



A series of phenoxazines were synthesized by tagging quinazolinones (**Scheme I & II**) using standard synthetic procedure with optimized techniques. Quinazolinone derivatives were synthesized by following previously described method shown in **Scheme I**. Briefly 2-substituted-1,2-dihydro-4*H*-3,1-benzoxazin-4-one was prepared by the condensation of anthranilic acid with different acid chlorides followed by cyclization in the presence of acetic anhydride gave compounds (III a-c). Quinazoline derivatives (IV a-l) were synthesized by the treatment of compounds (III a-c) with hydrazine at high temperature. Total of nine Phenoxazine derivatives were synthesized by reacting p-amino phenol and diiodobenzinitrile followed by

N-alkylation. NO donating group was fused as N-alkyl substitution. Cyano group attached to phenyl ring is oxidized to an acid group for which previously listed quinazolinones were tagged (**Scheme II**).

All the acridones were synthesized (**Scheme III**) by Ullman condensation reaction of animation of aryl halides (by using 2-chloro benzoic acid and anthranilic acid) in the presence of Cu as catalyst. Followed by the cyclization of intermediate in the presence of freshly prepared poly phosphoric acid at room temperature for three hours to get corresponding acridone carboxylic acid derivatives. Condensation of acridone carboxylic acid with different secondary amines was done in the presence of thionyl chloride in dry toluene and pyridine. The reaction mixture was stirred at room temperature for 3 hrs and then combined with excess of p-toluidine and triethylamine and stirred for another 3 hrs. The reaction was monitored by TLC. Then solvent was removed under vacuum and water was added to the solid residue. The precipitate was filtered, washed with water and dried.

Further *N*-alkylation of acridone carboxylic amide derivatives with alkyl halides (1-chloro 3-bromo propane & 1-chloro 4-bromo butane) were done by using phase transfer catalyst (PTC) tetra butyl ammonium bromide in the presence of KOH in tetra hydro furan for 24 hours. Completion the reaction is evidence by TLC the product was recovered and extracted with chloroform and purified by using column chromatography. In addition introduction of nitric oxide donating group into *N*-alkylated acridone was done by using silver nitrate in acetonitrile to get target lead molecules. Physical and chemical characterization of the molecules were done and shown in the **Table 1**.

iii. *In-vitro* cytotoxic activity evaluations by SRB assay:

Cytotoxic activity of the selected sixteen acridones was done by using following methodology and results were displayed in **Table 2**. The acridone derivatives were evaluated for cytotoxicity against cancer cell lines by using the sulforhodamine B (SRB) assay. The cells were cultured in RPMI 1640 (Gibco) supplemented with 10% fetal calf serum (Gibco), and cultures were passed once or twice a week using trypsin-EDTA to detach the cells from their culture flasks. The rapidly growing cells were harvested, counted, and plated at appropriate concentrations in 96-well microplates. After incubation for 24 h, the compounds, dissolved in the culture medium, were added to the culture wells in triplicate and incubated for 72 h at 37° C under a 5% CO₂ atmosphere. The cultures were fixed with cold TCA and stained with 0.4% SRB dissolved in 1% acetic acid. After dissolving the bound stain with 150 μ l of 10 mM unbuffered Tris base (Tris(hydroxymethyl) aminomethane) solution using gyratory shaker, absorbance at 540 nm was measured using a microplate reader. The cytotoxic activity cytotoxicity was evaluated by measuring the concentration needed to inhibit protein synthesis by 50% (i.e., IC₅₀) as comparison. Each value represents the mean of triplicate experiments.

iv. Determination of rate nitric oxide release (Detection of nitrite):

The levels of nitrate/nitrite formed from individual compounds in the cells were determined by the colorimetric assay using the nitrate/nitrite colorimetric assay kit. Then nitrite production was measured by mixing 100 μ l of cell lysates with 100 μ l of Griess reagent in a 96-well plate, and after a (30-300) minute incubation at 37^o C in the dark, absorbance was measured at 540 nm with a Tecan microplate reader, then 50 μ l of cell suspension used for measurement of cellular proteins. A blank was prepared for each experimental condition in the absence of cells, and its absorbance was subtracted from that obtained in the presence of cells. Nitrite concentration was expressed as nano moles of nitrite per 24 h/mg cellular protein. The results are displayed in the **Table 3**.

7. Salient Research Achievements:

- We have designed novel nitric oxide donating acridones & phenoxazines and performed virtual screening (*In silico*) against calmodulin dependent cAMP Phosphodiesterase (PDE1c).
- Efficient pharmacophore hypotheses have identified for the MDR reversal activity from acridones among the dataset ligands.
- We have synthesized and characterized desired molecules with good yields by using novel synthetic strategies.
- The studies to detect the percentage of nitrile indicate that these molecules have shown considerable NO releasing pattern when compared with a standard NO donating molecule.
- Molecules screened for the anti-cancer and MDR reversal studies shown significant results and proved to be efficient and further studies are to performed to correlate NO donating pattern and MDR reversal activity.

7.1 Summary of Progress:

Various computational and *In silico* studies like pharmacophore modeling, 3D QSAR and molecular docking were performed for designing and identification of molecules with potential anticancer and MDR reversal activity from which most efficient molecules from the library were synthesized by using novel synthetic strategies with good yields. Desired molecules were tested and proved for the considerable release patterns of nitric oxide. These molecules were

screened for anticancer and MDR reversal activity against various drug sensitive and resistant cell lines and found to be significant. Further studies have to be performed to identify the correlation between NO release and anticancer and MDR reversal activity and also further mechanistic studies have to be performed for the above stated biological activities.

7.2 New Observations:

- Efficient pharmacophore has been identified for MDR reversal.
- Synthetic strategies have been developed like N-alkylation under phase transfer catalyst with good yields.
- Synthesized molecules have shown better release patterns of NO when compared with the standards.
- Physico chemical properties of the molecules were found to be favorable and molecules shown significant cytotoxic properties.

7.3 Innovations:

- In general, pharmacophore modeling and 3D QSAR studies will be performed with respect to ligand and its receptor but, in the present investigation same principle has been implemented for ligand and cell lines (sensitive and drug resistant).
- Optimized synthetic methodologies were developed for development of nitric oxide releasing phenoxazines and acridones.
- Synthesized molecules were shown to have good nitric oxide donating property.

7.4 Application Potential:

7.4.1 Long Term

- Since targeting MDR is an emerging strategy in cancer chemotherapy, the present investigation focused on regulation of indirect iNOS pathway by designing NO donating molecules. These molecules will be a promising hit to reverse multidrug resistance in cancer chemotherapy.

7.4.2 Immediate:

- These investigations lead to design more efficient other NO donating scaffolds.
- The results of this investigation strongly support the role of iNOS pathway and exogenous nitric oxide release in the cellular apoptosis.


7.5 Any other: None

8. Research work which remains to be done under the project (for on-going projects)

- Remaining designed molecules of the library have to be synthesized by using efficient synthetic strategy.
- Plan to elucidate anticancer mechanism of novel molecules by targeting other possible cancer drug targets.
- Evaluation of *in vitro* cytotoxic activity against various sensitive and resistant cancer cell lines.
- Intracellular doxorubicin accumulation studies.
- Mechanistic studies and 3D QSAR studies.


<p>Ph.Ds Produced no:</p> <p>One scholar currently working</p>	<p>Technical Personnel trained:</p> <p>NO</p>	<p>Research Publications arising out of the present project:</p> <p>One publication in cited journal (Elsevier publications) with impact factor 2.33</p> <p>One paper accepted for publication in Journal Archive der Pharmazie with Impact factor of 1.54.</p> <p>One papers are under review in reputed journals.</p>
---	--	--

Scheme I: Synthesis of quinazoline derivatives



R: $-\text{CH}_3$, $-\text{C}_6\text{H}_5$, $-\text{C}_6\text{H}_4\text{CH}_3$

Scheme 2: NO donating Quinazolinone linked Phenoxazines



Scheme 3: Synthesis of NO donating acridone carboxamide derivatives





Table 1: Physical characterization data of acridone carboxamide derivatives.



Molecule	R1	R	MW	Volume	LogP
II a	-(CH ₂) ₃ -ONO ₂	-OH	342	1181.482	1.481
III b	H		383	1224.549	2.453
III c	H		306	1261.474	1.214
III e	H		334	1297.145	1.985
III i	H		425	1168.487	1.687
IV b	-(CH ₂) ₃ -Cl		459	1304.678	1.049
IV k	-(CH ₂) ₄ -Cl		473	1138.013	1.650
1	-(CH ₂) ₃ -ONO ₂		411	1163.379	1.217
2	-(CH ₂) ₃ -ONO ₂		486	1405.695	3.463
3	-(CH ₂) ₃ -ONO ₂		409	1151.482	1.814
4	-(CH ₂) ₃ -ONO ₂		457	1244.549	1.685
5	-(CH ₂) ₃ -ONO ₂		437	1231.474	1.087














6	$-(\text{CH}_2)_3\text{-ONO}_2$		427	1233.797	2.347
7	$-(\text{CH}_2)_3\text{-ONO}_2$		424	1264.463	1.082
8	$-(\text{CH}_2)_3\text{-ONO}_2$		438	1318.14	1.465
9	$-(\text{CH}_2)_3\text{-ONO}_2$		528	1528.458	2.842
10	$-(\text{CH}_2)_4\text{-ONO}_2$		425	1247.593	1.642
11	$-(\text{CH}_2)_4\text{-ONO}_2$		500	1491.145	3.749
12	$-(\text{CH}_2)_4\text{-ONO}_2$		423	1268.487	2.304
13	$-(\text{CH}_2)_4\text{-ONO}_2$		471	1304.678	2.076
14	$-(\text{CH}_2)_4\text{-ONO}_2$		451	1313.067	1.604
15	$-(\text{CH}_2)_4\text{-ONO}_2$		441	1280.458	2.636
16	$-(\text{CH}_2)_4\text{-ONO}_2$		438	1338.013	1.530
17	$-(\text{CH}_2)_4\text{-ONO}_2$		452	1362.198	1.888
18	$-(\text{CH}_2)_4\text{-ONO}_2$		542	1611.872	3.163

Table 2: Cytotoxic activity of acridone carboxamide derivatives against various drug sensitive and resistant cancer cell lines.

Compound	Cell lines/IC ₅₀ (µM) ± SEM ^a					
	MCF7/Wt ¹	MCF7/Mr ²	MCF7/Dx ³	SW1398 ⁴	WIDR ⁵	LS174T ⁶
II a	3.1 ± 0.7	3.4 ± 0.9	3.9 ± 1.1	7.9 ± 1.3	4.7 ± 1.0	3.75 ± 0.9
III b	4.5 ± 0.8	5.1 ± 1.1	6.5 ± 1.2	-	-	-
III c	22.0	32.0	30.	-	-	-
III e	30	55	60	-	-	-
III i	8.5 ± 1.5	10.2 ± 0.9	9.5 ± 0.5	-	-	-
IV b	10.5 ± 0.8	20.3 ± 1.9	18.5 ± 1.6	-	-	-
IV k	17.5 ± 1.6	30.1 ± 2.1	26.7 ± 2.0	-	-	-
1	1.2 ± 0.4	0.9 ± 0.1	2.9 ± 0.4	2.9 ± 0.1	4.5 ± 0.8	3.8 ± 1.0
2	2.0 ± 0.3	1.4 ± 0.2	6.2 ± 0.5	8.0 ± 0.7	13.0 ± 0.8	12 ± 2.4
3	3.1 ± 0.2	2.3 ± 0.4	7.8 ± 0.3	-	-	-
7	1.6 ± 0.2	1.1 ± 0.2	3.2 ± 0.4	-	-	-
10	0.8 ± 0.1	0.7 ± 0.1	1.9 ± 0.1	1.7 ± 0.2	2.8 ± 0.7	3.1 ± 0.3
11	0.7 ± 0.2	0.8 ± 0.1	2.0 ± 0.1	2.8 ± 0.1	4.0 ± 0.5	3.7 ± 0.4
12	2.8 ± 0.3	3.8 ± 0.6	5.8 ± 0.3	7.2 ± 0.4	14.5 ± 1.1	11.5 ± 2.7
16	1.4 ± 0.6	0.7 ± 0.1	4.2 ± 0.2	11.0 ± 0.7	19.1 ± 1.5	18.2 ± 3.1
Mitoxantrone (Mr)	0.090	3.0	-	-	-	-
Doxorubicin (Dx)	0.098	-	3.7	-	-	-

^a SEM - standard error of the mean

¹ MCF7 – WT: Human breast cancer cell line

² MCF7-MR: BCRP expressed Mitoxantrone resistant breast cancer cell line

³ MCF7-DX: P-gp expressed doxorubicin resistant breast cancer cell line

⁴ SW 1398: Human colorectal cancer cell line

⁵ WiDr: Colon adenocarcinoma cell line

⁶ LS 174T: Human Caucasian colon adenocarcinoma cell line

Table 3: Nitrite release of NO-acriones in MCF7 cancer cell lines

Compound	Nitrite $\mu\text{M}/\text{mg}$ protein	
	MCF7/Wt	MCF7/Dx
2	5.21	4.31
7	4.65	3.49
10	7.02	6.64
11	6.11	6.24
12	5.51	4.94

BogaR Laboratories
&
Vishnu Institute of Pharmaceutical Education & Research (VIPER)


4-Anilino Quinazolines As potent EGFR Inhibitors.

The clinical success of a number of kinase-directed drugs indicates that kinase represent therapeutically relevant targets. The epidermal growth factor receptor (EGFR) belongs to the ErbB family of receptor tyrosine kinases (RTKs), which plays an important role in the regulation of cell growth, differentiation, and survival. Because of their multidimensional role in the progression of cancer, EGFR and its family members have emerged as attractive targets for anticancer therapy. Accordingly, targeting EGFR has been intensely pursued, with the approval of gefitinib, erlotinib, and lapatinib for use in the clinic. As is common with many therapies, challenges with respect to treatment resistance emerge over time. This situation is certainly true of EGFR inhibitor therapy.


Clinical studies have demonstrated the occurrence of resistance to gefitinib with the T790M mutation accounting for 50% of the clinically observed resistant mutations. In order to overcome the T790M mutation related drug resistance, a variety of irreversible inhibitors were developed. These compounds contain a Michael acceptor moiety designed to form a covalent bond with the conserved cysteine residue (Cys797) at the lip of the EGFR ATP binding site. So far, caner tinib, neratinib, dacomitinib, and afatinib have been developed as second generation irreversible inhibitors with imited clinical efficacy. These drugs demonstrate the utility of quinazoline derivatives as an attractive scaffold for the development of EGFR inhibitors. To date, many studies have been targeted at finding new structures based on quinazolines that are potent EGFR inhibitors. All of these inhibitors share a common feature: upon the binding to EGFR, a

hydrogen bond forms between the N1 atom of the compound and the backbone NH of Met769 in the hinge region. To investigate the potential use of a novel scaffold as an EGFR ATP binding site inhibitor, a series of conformationally constrained quinazoline derivatives were synthesized (consisting of 34 structurally characterized compounds with purity >98%). (For general synthetic procedures refer to Schemes 1 and 2 and Supporting Information.) From this set of new compounds, a specific analogue was identified that inhibits the growth of both gefitinib-resistant (H1975) [T790M/L858R] and gefitinib-sensitive (A431WT, overexpression) cell lines but is not effective against EGFR-negative (A549, K562, and SW620) cells.

Scheme 1. Synthesis of Compounds 7a–e and 8a–b




Scheme 2. Synthesis of Compounds 9a–9p




The screening result (Table S1, Supporting Information) of the synthesized analogues 7a–7o and

hydrogen bond forms between the N1 atom of the compound and the backbone NH of Met769 in the hinge region. To investigate the potential use of a novel scaffold as an EGFR ATP binding site inhibitor, a series of conformationally constrained quinazoline derivatives were synthesized (consisting of 34 structurally characterized compounds with purity >98%). (For general synthetic procedures refer to Schemes 1 and 2 and Supporting Information.) From this set of new compounds, a specific analogue was identified that inhibits the growth of both gefitinib-resistant (H1975) [T790M/L858R] and gefitinib-sensitive (A431WT, overexpression) cell lines but is not effective against EGFR-negative (A549, K562, and SW620) cells.

Scheme 1. Synthesis of Compounds 7a–e and 8a–b



Scheme 2. Synthesis of Compounds 9a–9p



The screening result (Table S1, Supporting Information) of the synthesized analogues 7a–7o and

8a –8b did not show obvious inhibition on the proliferation of A431 human epithelial carcinoma cells with overexpressed EGFR WT , but surprisingly, some of the synthesized analogues suppressed the enzymatic activity of EGFR WT , which might be due to the complex genomic background and the strong binding of EGFR WT with ATP. For instance, 7b inhibited the enzymatic activities of EGFR WT with an IC₅₀ value of 1.29 nM, but its activity on A431 cancer cells was approximately 20 000 times less potent (IC₅₀ value was more than 30 μM). The results indicated that a further modification of the scaffold might prove to be an effective strategy for identifying more potent inhibitors. The impact of the R3 group was first studied by replacement with other acrylamide groups. Interestingly, the inhibitory potency against A431 WT, overexpression and wild-type EGFR was significantly increased by over 20-fold (Table S2, Supporting Information). For instance, when the hydrogen on the R3 substitution was replaced with acrylamide, the resulting compounds 9a – 9e are almost 5 times more potent than 7a – 7e . However, when the substituted acrylamide was replaced with a slightly hydrophobic moiety (9f– 9h), the potencies against A431 WT, overexpression and wild-type EGFR kinase were almost completely abolished.

Further investigation also revealed that the potency loss of 9f – 9h was partially restored by introducing a N-morpholino moiety (9i–9l) at the position of the original phenyl moiety. The result suggests that the substituted acrylamide at the R3 position can be replaced with a more hydrophilic group in order to improve the potency against the A431 and wild-type EGFR kinases. This hypothesis was verified by the in vitro screening result of 9m –9p

. The inhibitory activities against A431 WT, overexpression and EGFR WT were improved, with IC₅₀ values almost equal to the reference irreversible inhibitor, canertinib. We further profiled the synthesized analogues 9a–9p against NSCLC cell line H1975. The H1975 cell line bears the drug

resistant mutation in EGFR [L858R/T790M] and is a typical EGFR-driven cell lines. Several compounds (8c–8d and 9n–9p) also displayed strong antiproliferative effects on gefitinib-resistant H1975 cells, with the IC₅₀ value equal to or more potent than that of canertinib (Table S2, Supporting Information). Three closely related analogues, 9n–9p, were identified from the screen. The screening result (Table S1, Supporting Information) of the synthesized analogues 7a–7o and 8a–8b did not show obvious inhibition on the proliferation of A431 human epithelial carcinoma cells with overexpressed EGFR WT, but surprisingly, some of the synthesized analogues suppressed the enzymatic activity of EGFR WT, which might be due to the complex genomic background and the strong binding of EGFR WT with ATP. For instance, 7b inhibited the enzymatic activities of EGFR WT with an IC₅₀ value of 1.29 nM, but its activity on A431 cancer cells was approximately 20 000 times less potent (IC₅₀ value was more than 30 μM). The results indicated that a further modification of the scaffold might prove to be an effective strategy for identifying more potent inhibitors. The impact of the R 3 group was first studied by replacement with other acrylamide groups. Interestingly, the inhibitory potency against A431 WT, overexpression and wild-type EGFR was significantly increased by over 20-fold (Table S2, Supporting Information).

For instance, when the hydrogen on the R 3 substitution was replaced with acrylamide, the resulting compounds 9a – 9e are almost 5 times more potent than 7a–7e. However, when the substituted acrylamide was replaced with a slightly hydrophobic moiety (9f–9h), the potencies against A431 WT, overexpression and wild-type EGFR kinase were almost completely abolished. Further investigation also revealed that the potency loss of 9f – 9h was partially restored by introducing a N - morpholino moiety (9i – 9l) at the position of the original phenyl moiety. The result suggests that the substituted acrylamide at the R 3 position can be

replaced with a more hydrophilic group in order to improve the potency against the A431 and wild-type EGFR kinases. This hypothesis was verified by the in vitro screening result of 9m –9p. The inhibitory activities against A431 WT, overexpression and EGFR WT were improved, with IC₅₀ values almost equal to the reference irreversible inhibitor, canertinib. We further profiled the synthesized analogues 9a – 9p against NSCLC cell line H1975. The H1975 cell line bears the drug resistant mutation in EGFR [L858R/T790M] and is a typical EGFR- driven cell lines. Several compounds (8c–8d and 9n–9p) also displayed strong antiproliferative effects on gefitinib-resistant H1975 cells, with the IC₅₀ value equal to or more potent than that of canertinib (Table S2, Supporting Information). Three closely related analogues, 9n–9p, were identified from the screen that possessed approximately equal IC₅₀ values against A431 WT, expression and 1975 [L858R/T790M] as the reference inhibitors (Figure 1 and Tables S2 and S3, Supporting Information).




Figure 1. Compounds 9n–9p are novel EGFR inhibitors, suppress the growth of EGFR^{WT}/EGFR^{L858R/T790M} containing cancer cell lines, and inhibit the enzymatic activities of EGFR^{WT}/EGFR^{T790M} kinase. (a) Chemical structures of 9n–9p. IC₅₀ values for A431 (top left), H1976 (top, right), EGFR^{WT} (bottom, left), and EGFR^{T790M} (bottom, right). Growth inhibitory was assessed using the MTT.

To better understand how our conformationally constrained compounds interact with the ATP-binding cleft of EGFR and how this relates to their potency for EGFR T790M, we determined a putative binding mode of one representative compound 9n within the active binding pocket of the EGFR T790M (Figure 2). The morpholine fused scaffold is located in the ATP-binding pocket. Two highly conserved hydrogen bonds are formed between the quinazoline core and the hinge region. The molecule is oriented such that 6-substituted acrylamide branch extends

toward the solvent, and the 4-aniline moiety is directed into the backpocket of EGFR kinase. The docking result is shown to form a covalent bond with Cys797 as expected, with a measured distance of 2.54 Å. The prediction is consistent with observed result from Western blot studies (Figure 3). In addition, a salt bridge was formed between the carboxyl group of Asp800 and the nitrogen atom of the dimethylamino group. Furthermore, the protonated dimethylamino group might facilitate the nucleophilic attack of the sulfhydryl group of Cys797. The prediction is also consistent with our observations that a hydrophobic substituent (e.g., phenyl) led to a decrease in the potency in comparison with the dimethylamino group.

Compound 9n and canertinib inhibit the autophosphorylation of EGFR in no wash (left) and wash out (right), while gefitinib has no effects in the wash out group. The result is the evidence of irreversible binding mode, suggesting 9n is acting the same as irreversible inhibitor canertinib. The *in vitro* data shown in Figure 1 demonstrates that the new synthesized analogues 9n – 9p strongly inhibit the EGFR WT kinase. Because many tissues use wild-type EGFR for normal cellular processes, the potential for toxicity from irreversible EGFR inhibitors is a concern. Therefore, the growth inhibitory of the compounds against various cancer cell lines was evaluated to control the potential toxicity. As shown in Table 1, the potent EGFR inhibitor 9n did not display obvious inhibition on the growth of A549, SW620, and K562 cancer cells, all of which have low levels of EGFR expression. The results indicate that the cytotoxic effects of 9n are minimal. Meanwhile, in the human ether-a-go-go-related gene (hERG) potassium channel patch clamp assay, 9n has an $IC_{50} > 10 \mu M$, which indicates it has a low potential for cardiac toxicity (Table S4, Supporting Information). Furthermore, 9n and 9p have a good pharmacokinetic *in vitro* ADME profiles: the inhibition of cytochrome P450 was assessed in recombinant human cytochrome P450 isoforms (1A2, 2C9, 2D6, and 3A4), and the IC_{50} values were higher than $10 \mu M$, suggesting a low

potential for 9n and 9p to be involved in any drug –drug interactions. The intrinsic clearance found in liver microsomes predicts good to excellent in vivo clearance (Table S5, Supporting Information). A pharmacokinetic study of 9n and 9p was performed in BALB/c mice. As shown in Table 2, 9n demonstrated desirable results with a half-life (9.1 h) and oral bioavailability (26.1%), while 9p displayed an unsatisfactory pharmacokinetic profile (F= 6.42%) (Table S6, Supporting Information).

We further determined the effectiveness of 9n in vivo by using a nude mouse xenograft model harboring EGFR WT, expression. We chose 9n for the in vivo studies because, in vitro, it is effective against EGFR expressing cancer cell lines and has a good ADME profile. Gefitinib (200 mg/kg) was used as a reference drug to validate the models. In the A431 tumor model, the mice were treated via oral gavage once daily with either 9n or gefitinib once the tumor had grown to a volume of 50 –150 mm². Oral administration of 9n and gefitinib at 200 mg/kg/day inhibited tumor growth at 66.8% and 35.9%, respectively. No mortality or significant weight loss was observed during the treatment (Figure 4). In summary, a series of conformationally constrained quinazoline derivatives have been designed and synthesized and shown utility as EGFR inhibitors. The most potent compounds 9n and 9p strongly inhibited the enzymatic activities of wild-type EGFR kinase as well as clinical resistant EGFR T790M mutant kinase.

The kinase inhibitory efficiency of the compounds were further validated by Western Blot analysis for the activation of EGFR. Further in vitro assay demonstrated that 9n and 9p are effective against H1975 non-small cell lung cancer cells bearing EGFR [L858R/T790M], with potencies better than Gefitinib. Compounds 9n and 9p showed minimal cytotoxicity to K562 and SW620. A hERG assay demonstrated their unlikely cardiac toxicity, indicating that these analogues might possess a high safety index. An in vivo antitumor assay demonstrates that an oral once daily

dose of 9n at 200 mg/kg produces considerable tumor inhibition in the A431 xenograft model, as compared to gefitinib. The pharmacokinetic studies indicate that 9n possesses good pharmacokinetic properties. In conclusion, our studies identified a new lead compound containing a novel scaffold ideally suited for the development of therapeutically relevant EGFR inhibitor effective against EGFR T790M mutations. Further detailed studies of the mechanisms of action for 9n are currently underway.




Figure 2. Putative binding mode of 9n within the active pocket of the EGFR^{T790M} (PDB code: 4I24).




Figure 3. Inhibition of EGFR autophosphorylation in A431 by Western blot assay. G, gefitinib; C, caerterinib.

Table 1. In Vitro Growth Inhibitory Activities against Various Cancer Cell Lines

cancer type	cell line	characteristic	9n (μM)	9p (μM)	gefitinib (μM)
epidermal	A431	EGFR ^{WT} overexpression	2.2	0.9	4.0
NSCLC	H1975	EGFR ^{L858R/T790M}	4.9	3.61	10.48
NSCLC	A549	EGFR ^{WT} no Ras mutation	>10	>10	>10
colon	SW620	EGFR negative	25.4	6.2	28.20
malignant myeloid	K562	EGFR negative	>10	>10	>10

Table 2. Pharmacokinetic Parameters for 9n^a

route	AUC(0-24 h) ($\mu\text{M}\cdot\text{min}$)	$t_{1/2}$ (min)	t_{max} (min)	C_{max} (μM)	10%
i.v.	25.4	762	2	0.29	
p.o.	133	548	45	0.36	26.1

^aThe pharmacokinetic parameters are obtained after a single i.v. (3 mg/kg) or oral (10 mg/kg) administration. The data are obtained from 12 mice in each treatment group.

STABILITY STUDIES OF SULPHAMETHAZOLE AND CIPROFLAXACIN TABLETS

Introduction:

Sulfamethoxazole is N1-(5-methylisoxazole-3-yl) sulfanilamide. Its closed formula is $C_{10}H_{11}N_3O_3S$ and molecular weight 253.3 g/mol. White and yellowish white colored, crystallized powder. It does not dissolve in chloroform and ether. Its solubility in water is very low, it dissolves in ethanol 1 : 50 and in acetone 1 : 30. On the other hand, it dissolves in alkaline hydroxide solutions. It is a drug which is used in both systemic and urinary infections.

Ciprofloxacin hydrochloride is basically 1-cyclopropyl-6-fluoro-1, 4-dihydro-4-oxo-7-(piperazin-1-yl)-quinoline-3-carboxylic acid hydrochloride. Its empirical formula is $C_{17}H_{18}FN_3O_3$, HCl. The molecular weight of which is 367.8. Ciprofloxacin hydrochloride is a fluoroquinolone antibacterial agent with a wide spectrum of activity.

Several analytical methods including spectrophotometry 5- 9, HPLC 10 -12 and capillary zone electrophoresis 13 were reported for the analysis of the samples consisting of sulfamethoxazole and ciprofloxacin.

In this study, a simple spectrophotometric classical least square calibration was proposed and successfully applied to simultaneous analysis and stability test of the commercial veterinary formulation containing sulfamethoxazole and ciprofloxacin.

Experimental section

Instruments

A Shimadzu UV-160 double beam UV-Vis spectrophotometer possessing a fixed slit width (2 nm) connected to a computer loaded with Shimadzu UVPC software and a LEXMARK E-320 printer were used to record the absorption spectra. Data analysis was performed by using the Microsoft EXCEL software.

Formulation:

A formulation was assayed. Its declared content was as follows: 400 mg sulfamethoxazole, 80 Ciprofloxacin per mL were obtained.

Standard Solutions:

Stock solution of 25 mg/50 ml sulfamethoxazole and ciprofloxacin were prepared in methanol-water (50:50, v/v). A standard series in the concentration range of 2-11 $\mu\text{g/mL}$ sulfamethoxazole and 3-18 $\mu\text{g/mL}$ ciprofloxacin in the same solvent were obtained from the above stock solutions.

Sample solutions preparation

Sulfamethoxazole and ciproflaxacin was transferred into 250 mL calibrated flask and the volume was completed with methanol-water (50:50, v/v). The content of the flask was mechanically shaken for 10 min and then, clear solution was obtained. In the following step, by adding 5 mL of the buffer solution (ammonium chloride/ammonium hydroxide, pH=10) to 25 mL flask and 312.5 μ L of the above sample solution was dissolved in 25 mL flask in methanol-water (50:50, v/v). In the preparation of the sample for the stability tests, at the beginning of study, the formulations with the same batch numbers were opened up (twice from each formulation) and their analysis were done, the control data were obtained. Following that the other formulations in their original containers were stored in different conditions (room temperature, refrigerator) for next experimental periods. Their analysis was done every 3 months during 12 months. The temperature and humidity of storage conditions were 20-29 $^{\circ}$ C and 30-33 % for room temperature.

Results and Discussion:

Application of the Spectrophotometric Classical Least Square Method In this method, the standard series of each compound in the concentration range 2-11 μ g/mL for sulfamethoxazole and 3-18 μ g/mL for ciproflaxacin in methanol-water (50:50, v/v) were prepared. Their absorption spectra were recorded between 200-350 nm. Similar procedure was applied to the sample solutions. The absorption spectra of standard series were measured at three-wavelength set (237, 257 and 288 nm). At the above wavelength set, the absorptivity value for each compound was calculated by using the following equation:

$$\epsilon = A / C \text{ (pathlength, } l=1 \text{ cm)} \quad (1)$$

where ϵ is the absorptivity, A represents the absorbance and C is the concentration of the compound in solution in, expressed in μ g/mL. The mean absorptivity values calculated at three-wavelength set were presented

Formulations were analysed each 3 months during 12 months. These formulations kept up in their original containers until analyzing procedure and stored in different conditions (room temperature, refrigerator, etuve). Standard and sample solutions preparations were done as explained above. Their absorption spectra were recorded between 200-350 nm. Similar procedure was applied to the sample solutions. The absorption various of standard series were measured at the 3-wavelength set (237, 257 and 288 nm). At the above wavelength set the absorptivity various for each compound were calculated by using the formula $\epsilon = A$ (absorbance) / C (concentration, μ g/mL).

Conclusion:

According to USP, the claimed label quantities of sulfamethoxazole and ciproflaxacin in a formulation should not be less than 90 % and should not exceed 110 %. At the end of study, the degradation in the active compounds of formulation during 12 months was compatible with USP formulation.



Date: 04-08-2018.

CERTIFICATE

This is to certify that **Ms. D.CHANDI PRIYA GOUD (HT.NO. 16DHISO303)** pursuing her M. Pharmacy in **VISHNU INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH** has carried out her project work in our Organization entitled **“FORMULATION AND EVALUATION OF SUSTAINED RELEASE TABLETS OF GLIBENCLAMIDE USING NATURAL POLYMERS”** in the department of pharmaceutics from **11TH DECEMBER, 2017 TO 04TH AUGUST, 2018.**

During her tenure she was sincere, hardworking and Punctual in her Project work.

We wish her to success in her future career.

Authorized Signature

Mrs. Rajini Sura

Managing Director





Date: 31-08-2018

CERTIFICATE

This is to certify that Ms. G. FLAWRENCE (HT. No.16DH1S0409) pursuing her M.Pharmacy In VISHNU INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH has carried out her project work in our Organization entitled "DEVELOPMENT AND VALIDATION OF A REVERSE PHASE HPLC METHOD FOR SIMULTANEOUS DETERMINATION OF CILNIDIPINE AND CHLORTHALIDONE IN PURE AND PHARMACEUTICAL DOSAGE FORM" in the department of Pharmaceutics Analysis from 05 -FEB-2018 to 31-AUG 2018.

During her tenure she was sincere, hardworking and Punctual in her Project work.

We wish her to success in her future career.

Authorized Signature

Mrs.Rajini Sura

Managing Director





Date: 31-08-2018

CERTIFICATE

This is to certify that Ms. D. JHANSI (HT. No.16DH1S0405) pursuing her M.Pharmacy In VISHNU INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH has carried out her project work in our Organization entitled "RP-HPLC METHOD DEVELOPMENT AND VALIDATION FOR SIMULTANEOUS ESTIMATION OF CEFUROXIME AND CALVULANIC AND IN PURE AND PHARMACEUTICAL DOSAGE FORM" in the department of Pharmaceutics Analysis from 05 -FEB-2018 to 31-AUG 2018.

During her tenure she was sincere, hardworking and Punctual in her Project work.

We wish her to success in her future career.

Authorized Signature

Mrs.Rajini Sura

Managing Director



Date: 04-08-2018.

CERTIFICATE

This is to certify that **Ms. G.LAXMI PRASANNA (HT.NO.16DH1S0408)** pursuing her M. Pharmacy in **VISHNU INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH** has carried out her project work in our Organization entitled "**DEVELOPMENT AND VALIDATION OF A RP-HPLC-PDA METHOD FOR SIMULTANEOUS DETERMINATION OF TRITHIOPARAMETHOXYPHENYLPROPENE AND CHLORPHENIRAMINE MALEATE IN PURE AND PHARMACEUTICAL DOSAGE FORM.**" in the department of Pharmaceutical Analysis & Quality Assurance from **05TH FEBRUARY, 2018 TO 04TH AUGUST, 2018.**

During her tenure she was sincere, hardworking and Punctual in her Project work.

We wish her to success in her future career.

Authorized Signature



Mrs. Rajini Sura

Managing Director

Ref: APL/Project/K.Deekshitha/0323/2018

18th August, 2018

TO WHOM SO EVER IT MAY CONCERN

This is to certify that **Ms. K.Deekshitha, H.T.No: 16DH1SO306** is a bonafide student of **Vishnu Institute of Pharmaceutical Education and Research, Vishnupur, Narsapur, Medak dist, Telangana.** Has undergone project work in our organization from **15-02-2018** to **18-08-2018**, as a part of *partial fulfillment* of her M-Pharmacy course.

The title of the project is **"Formulation and Evaluation of Chlorthalidone and Nifedipine as Bilayer Tablets"**.

During the aforesaid period, we found her hard working, sincere and learning attitude.

With Best Wishes.

For **ACTIVE PHARMA LABS**

K. Ram Lakshmi

Authorized Signatory





404, 4th Floor, Raja Enclave,
KPHB Colony, Opp. R.S. Brothers,
Hyderabad - 500 072, INDIA.
Tel : 040 - 40 189 585 Mob : +91 89789 11190
Website : www.activepharmalabs.com
E-mail : info@activepharmalabs.com

Ref:APL/Project/L.Tejaswini/0322/2018

04th August, 2018

TO WHOM SO EVER IT MAY CONCERN

This is to certify that **Ms. L.Tejaswini**, H.T.No: 16DH1SO308 is a bonafide student of **Vishnu Institute of Pharmaceutical Education and Research**, Vishnupur, Narsapur, Medak dist, Telangana. Has undergone project work in our organization from 05-02-2018 to 04-08-2018, as a part of *partial fulfillment* of her M-Pharmacy course.

The title of the project is "**Formulation and Evaluation of Amlodipine and Enalapril Bilayered Tablets**".

During the aforesaid period, we found her hard working, sincere and learning attitude.

With Best Wishes.

For **ACTIVE PHARMA LABS**

Authorized Signatory



Ref: APL/Project/ M.Durga Bhavani/0328/2018

04th August, 2018

TO WHOM SO EVER IT MAY CONCERN

This is to certify that **Ms. M.Durga Bhavani**, H.T.No: 16DH1SO310 is a bonafide student of **Vishnu Institute of Pharmaceutical Education and Research**, Vishnupur, Narsapur, Medak dist, Telangana. Has undergone project work in our organization from 05-02-2018 to 04-08-2018, as a part of *partial fulfillment* of her M-Pharmacy course.

The title of the project is **"To Formulate, Optimize and Evaluate Atazanavir Nanospheres Drug Delivery System for Enhancing its Oral Bioavailability and Efficacy"**.

During the aforesaid period, we found her hard working, sincere and learning attitude.

With Best Wishes.

For **ACTIVE PHARMA LABS**



Authorized Signatory



Jun 20th , 2018

TO WHOMSOEVER IT MAY CONCERN

This is to certify that **Ms. B.Prashanthi (Reg. No: 16DH1S0404)** of **Vishnu Institute of Pharmaceutical Education and Research(VIPER),Narsapur Medak.** Has undergone project Training at OTC- FARD Department–Formulation Division titled **“DEVELOPMENT AND VALIDATION OF STABILITY INDICATION HPLC METHOD FOR THE SIMULTANEIUS ESTIMATION OF ACETAMINOPHEN, DEXTROMETHORPHAN HBr AND DOXYLAMINE SUCCINATE IN PHARMACEUTICL DOSAGE FORM”** at our APL Research Centre - II, from 20th Dec 2017 to 20th Jun 2018.

During this period, we found her to be hard working and committed.

We wish her all the best in her future endeavors.

With Best Wishes.

for APL Research Centre - II



Pallavi G

Manager – Human Resources

APL RESEARCH CENTRE - II

(A Division of Aurobindo Pharma Ltd.)

VISHNU INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH

Vishnupur, Medak District, TS.

&

SURAKSHA PHARMA, HYDERABAD

Title

Formulation of Potassium Chloride 600 mg and 1500 mg extended release tablets

DISSOLUTION PROFILE OF KCL- EXTENDED RELEASE TABLET

Kcl Release pattern based on USP monograph

2nd Hour 5- 65%

4th Hour 50-85%

6th Hour NLT 65%

12th Hour NLT 85%

<u>Time in Hours</u>	<u>IInd</u>	<u>IVth</u>	<u>VIth</u>	<u>XIIth</u>
First formula	37.4%	57.6%	69.04%	87.2%
Second formula	37.4%	60.0%	76.25%	82.8%

S.Dinesh Mohan, D.Appaji,

IIIIC-VIPER

Monthly expenses statement

Month-August2011

Under head	Amount in Rs
1. To Salary to Coordinator	25,000=00
2. To conveyance expenses	4,500=00
3.Towards Purchase of chemicals and other utilities required for projects	4,200=00

Month-September2011

Under head	Amount in Rs
1. To Salary to Coordinator	25,000=00
2. To conveyance expenses	5,400=00
3.Towards Purchase of chemicals and other utilities required for projects	5400=00

POTASSIUM CHLORIDE EXTENDED RELEASE TABLETS

Potassium chloride Release pattern

Time	Release
2 hr	5 - 65 % (NLT 35%)
4hrs	50- 85%
6hrs	NLT 65%
12hrs	NLT 85%

SCALE UP BATCH PROCESSING INSTRUCTIONS

First formula

Batch size: 10,000 tablets

Formula	Each trablet	10,000tablets
Potassium chloride:	600mg	6.0kg
Ethyl cellulose: E10	6mg	60 gms
Ethyl cellulose: E10	12mg	120gms
Ethyl cellulose: E10	18mg	180gms
Ethyl cellulose: E10	24mg	240gms
Cross povidone:	6mg	60gms
Mcc:	60mg	600gms
Talc:	6mg	60gms
Magnesium stearate:	6mg	60gms

HPMCK100:	60mg	600gms
HPMC E15 (for coating of tablets)	6mg	60 gms
	Total Wt	8.04kg

Average weight of core tablet: 798mg

PROCEDURE

Preparation of 4 Ethyl cellulose polymer solutions separately

- Take Ethyl cellulose E10 grade material 60 gms and dissolve it in about 1.0 liter of IPA by stirring
- Take Ethyl cellulose E10grade material 120 gms and dissolve it in about 2.0 liters of IPA by stirring
- Take Ethyl cellulose E10grade material 180 gms and dissolve it in about 3.0 liters of IPA by stirring
- Take Ethyl cellulose E10grade material 240 gms and dissolve it in about 4.0 liters of IPA by stirring.

Coating of KCl

Divide KCl into 4 portions of 1.5kg each

- Take first portion of 1.5 kg of KCl in coating pan spray (a) Ethyl cellulose solution on to the KCl slowly while rotating the pan at 12 rpm, continuously dry the coated KCl by switching on hot air blower. Complete solution of 1 liter should be sprayed on to KCl .After completion of solution ensure complete drying of coated material by continuing drying for another 10minutes.Take out the granules in polythene bag and label as lot 1
- Take second portion of 1.5 kg of KCl in coating pan spray (b) Ethyl cellulose solution on to the KCl slowly while rotating the pan at 12 rpm, continuously dry the coated KCl by switching on hot air blower. Complete solution of 2 liters should be sprayed on to KCl .After completion of solution ensure complete drying of coated material by continuing drying for another 10minutes. Take out the granules in polythene bag and label as lot 2
- Take third portion of 1.5 kg of KCl in coating pan spray (c) Ethyl cellulose solution on to the KCl slowly while rotating the pan at 12 rpm, continuously dry the coated KCl by switching on hot

air blower. Complete solution of 3 liters should be sprayed on to Kcl .After completion of solution ensure complete drying of coated material by continuing drying for another 10minutes. Take out the granules in polythene bag and label as lot 3

4. Take fourth portion of 1.5 kg of Kcl in coating pan spray (d) Ethyl cellulose solution on to the Kcl slowly while rotating the pan at 12 rpm, continuously dry the coated Kcl by switching on hot air blower. Complete solution of 3 liters should be sprayed on to Kcl .After completion of solution ensure complete drying of coated material by continuing drying for another 10minutes. Take out the granules in polythene bag and label as lot 4

Coating of Granules with HPMC

Preparation of HPMC K₄ 100 Mucilage

Take about 3.0 lts of DM water in a vessel and slowly add HPMC K₄ 100 -600gms with vigorous stirring, care must be taken to avoid formation of lumps.

Coating

Take the 4 lots (ethyl cellulose coated into the coating pan again and mix for 10mts.

Coat the granules with above HPMC K100 solution by spraying the 3.0 liters of solution slowly on the granules .After completion of solution dry the granules completely by rotating the pan and blowing hot air for another 10mts.

Blending

Take the above HPMC coated granules into blender and add

Cross povidone ,MCC ,Talc and magnesium stearate and blend for 15 mts.

Compression

Compress the blended granules into tablets using 11mm round punches

Film Coating of tablets

Dissolve 60 gms of HPMC E15 in 1.0 liter of DM water

Carryout film coating of tablets with above HPMC solution in the coating pan in a routine manner

Dissolution Profile got for lab trials(3 trials)

Time in Hrs	% of Drug release		
	F1	F2	F3
30Min	7.4	6.8	5.1
1	16	14.3	13.2
2hrs	36%	34.8%	31.7%
3	52	47	42
4hrs	62%	59.6%	56.4%
5	68	65	62
6hrs	75.4%	73.7%	70.6%
7	78	76	73.8
8	79.4	77.1	75.2
9	82	79.7	78.2
10	85.4	82.1	81.6
11	89.2	86	84.3
12hrs	92.7%	90%	88.23%

Fig : Release profile of KCL

Dear Sir,

In fact we only wanted give the feed back to you. Please excuse us for that.

As you are aware that in view of the agitation college is not working properly and students stopped coming to college .In spite of that we the faculty is exclusively engaged on your work and carrying out the work in the college

1. KCl tablets

We have been taking n number of trials with different formulas using different polymers as release .retarding agents.

We have achieved up to 6 hourly release pattern .But unfortunately our testing equipment (Flame photometer) used for release pattern studies, in between has broken down. Hence the delay .We have set the instrument right and started the trials again.

We have so many trials of tablets kept ready for dissolution study and since it is 12 hourly studies it is taking long time. We hope within another 4 or 5 days we will be able to break through and achieve the release pattern and freeze the formula.

Trust you will understand the issue in a positive way and give us a few days more time for us to complete the trials and arrive at conclusion which we are very much hopeful to achieve

We shall give the feed back within next two days again

2. Cefpodoxime tablets

We have received your materials and simultaneously started the work

We have changed the formula completely and taken trials .The tablets have come out very well .We shall produce some quantity of tablets and send to you shortly .We need to pack the tablets and keep the packs for study. Please arrange for packing of tablets and send some blisters to us for our study

Thanking you

With best regards

Yours truly

P.Prabhakar

We have achieved up to 8 hourly dissolution pattern of Kcl tablets and in the final stage of achieving 12th hourly release which we are hopeful of achieving within a day or two.

As you are aware Kcl is a highly water soluble molecule and achieving such long extended release pattern is very difficult.

After achieving the release pattern we shall have to consolidate and optimize the formulation by taking slightly bigger batches and checking the dissolution pattern .Once we do that we can be confident of achieving the same when we scale up the operations. We are hopeful all these final stages shall take another four or five days

Kindly bear with us

As far as Cefpodoxime is concerned we shall send the tablets to you within next two days, which you have to arrange for packing and keeping the packs for observation.

After completion of the projects we shall come and meet you personally to explain in detail

Thanks and regards

P.Prabhakar

Oct 22.2011

Dear Sir

We have visited Suraksha Pharma again yesterday to discuss about the progress of the projects personally and about further projects he can give to us .He has appreciated the progress taken place in the projects

He has assured us few more projects for us after completion of current projects.Likely projects 1.Sustained action formulation development for Aceclofenac tablets 2. Stability studies for certain antibiotic dry syrup and tablets formulations etc

After completion of the projects we shall come and meet you personally to explain in detail

Thanks and regards

P.Prabhakar

Oct 22.2011

Dear Sir

We have visited Suraksha Pharma again yesterday to discuss about the progress of the projects personally and about further projects he can give to us .He has appreciated the progress taken place in the projects

He has assured us few more projects for us after completion of current projects.Likely projects 1.Sustained action formulation development for Aceclofenac tablets 2. Stability studies for certain antibiotic dry syrup and tablets formulations etc

Regards

P.Prabhakar

Oct 9, 2011

Dear Sir

Further to our earlier mail regarding the status of the projects, we are glad to inform you that we have come to final stages of both the projects.

We have achieved up to 8 hourly dissolution pattern of Kcl tablets and in the final stage of achieving 12th hourly release which we are hopeful of achieving within a day or two.

As you are aware Kcl is a highly water soluble molecule and achieving such long extended release pattern is very difficult.

After achieving the release pattern we shall have to consolidate and optimize the formulation by taking slightly bigger batches and checking the dissolution pattern. Once we do that we can be confident of achieving the same when we scale up the operations. We are hopeful all these final stages shall take another four or five days

Kindly bear with us

As far as Cefpodoxime is concerned we shall send the tablets to you within next two days, which you have to arrange for packing and keeping the packs for observation.

Mail Gmail Calendar Documents Photos Web More

Search Mail Search the Web Show search options Create a filter

Mail
Contacts
Tasks

BlackBerry® PlayBook™ - in.blackberry.com/playbook-tablet/ - Now available. Introducing the First pr

Archive Spam Delete Move to inbox Labels More

Compose mail

status of projects X Inbox X

Inbox (2)

Buzz

Starred

Important

Sent Mail

rafts (13)

Personal

Travel

6 more v

from Prabhakar Pisipati hide details Oct 9 (2 days ago) Reply
prabhakar1808@gmail.com
to md@surakshapharma.com
cc rameshcology
<rameshcology@gmail.com>
date Sun, Oct 9, 2011 at 5:56 PM
subject status of projects
mailed-by gmail.com

Dear Sir

Further to our earlier mail regarding the status of the projects, we are glad to inform you that we have come to final stages of both the projects.

We have achieved up to 8 hourly dissolution pattern of Kcl tablets and in the final stage of achieving 12th hourly release which we are hopeful of achieving within a day or two.

As you are aware Kcl is a highly water soluble molecule and achieving such long extended release pattern is very difficult.

After achieving the release pattern we shall have to consolidate and optimize the formulation by taking slightly bigger batches and checking the dissolution pattern .Once we do that we can be confident of achieving the same when we scale up the operations. We are hopeful all these final stages shall take another four or five days

Kindly bear with us

As far as Cefpodoxime is concerned we shall send the tablets to you within next two days, which you have to arrange for packing and keeping the packs for observation.

After completion of the projects we shall come and meet you personally to explain in detail

Thanks and regards
P.Prabhakar

Reply Reply to all Forward

MD Sunil to me, rameshcology show details Oct 9 (2 days ago) Reply

Thanks for the update and good to know about positive results.hoping to meet asap
Rgds

- Show quoted text -

Reply Reply to all Forward

Chat

Search, add, or invite

Prabhakar Pisipati

add photos here

vishnu pharmacy

Anjit Bhattacharya

anjit.bhattacharya

bhattacharya.anjit

Dr. A Ramesh

md

rameshcology

u.varunvarma

Varun

varun_apcl

Invite a friend

Give Gmail to:

Send invite 50 left

Preview invite

STATUS/PROGRESS OF THE PROJECTS – A REPORT FROM SITA COLLEGE

I. Kcl 600mg Tablets

1. The 12th hourly dissolution release pattern in small scale level batches for 600mg dose tablets .The following is the release pattern

DISSOLUTION PROFILE OF KCL- EXTENDED RELEASE TABLET

Kcl Release pattern based on USP monograph

2nd Hour 5- 65%

4th Hour 50-85%

6th Hour NLT 65%

12th Hour NLT 85%

<u>Time in Hours</u>	<u>2hrs</u>	<u>4hrs</u>	<u>6hrs</u>	<u>12hrs</u>
First formula	37.4%	57.6%	69.04%	87.2%
Second formula	37.4%	60.0%	76.25%	82.8%

Thickness of the tablets: 6.5mm to 7.0mm,

2. We are repeating the trials to check the repeatability

3. We are planning to take slightly bigger batches and also scale up batch for consolidation and confirmation of the results, which we are doing within next two to three days.

II. KCl 1500mg tablets

As discussed over phone we are doubtful about accommodation of more weight within 7.5mm thickness of the tablets with punch set sent by you as per our earlier trial

Any way we are taking trials for this dose again and check the same and let you know tomorrow as to how much thickness to be kept for achieving for accommodating the weight and to achieve release pattern

Please inform whether same release pattern to be achieved for the higher dose tablets also

We shall take full-fledged trials of 1500 mg tablets after closing the 600mg tablets within next 2 or 3 days

III. Cefpodoxime proxetil film coated tablets

Regarding Cefpodoxime proxetil tablets we have changed the formula again and we are producing slightly large no of tablets and request you to go for the packing (alu-alu) and keep the blisters for some days for observation.

We shall bring the tablets to you on day after tomorrow (on 20/10/11) and hand it over to you

IV.Cefpodoxime proxetil dispersible tablets

We have started the trials for this dosage form also. After producing tablets we shall send the tablets for packing to you

**Highly practical and cost-efficient synthesis of Bis-benzimidazole
(2-n-Propyl-4-methyl-6-(1-methylbenzimidazole-2-yl)
benzimidazole), Key Intermediate of Telmisartan.**

BY

**Mr.APPAJI DOKALA, M.Pharm
Assist. Professor,
Dept.of Pharmaceutical chemistry,
Sitha Institute of Pharmaceutical Sciences,
Bachupally, Hyderabad-072.**

Highly practical and cost-efficient synthesis of Bisbenzimidazole (2-n-Propyl-4-methyl-6-(1-methylbenzimidazole-2-yl) benzimidazole), Key Intermediate of Telmisartan.

ABSTRACT:

Telmisartan is an angiotensin II receptor antagonist (angiotensin receptor blocker, ARB) used in the management of hypertension. A novel and cost-efficient strategy for synthesis of bis-benzimidazole, chemically 2-n-Propyl-4-methyl-6-(1-methylbenzimidazole-2-yl) benzimidazole) an intermediate of an antihypertensive drug telmisartan is described. Here, we developed the key strategy for the construction of bis-benzimidazole by reductive cyclization of o-nitroanilines with butylaldehyde and cyclo-condensation of aromatic aldehydes with o-phenylenediamine. The simple operation and workup procedure, along with the low production costs, make it suitable for industrial production and will benefits those with cardiovascular disease.

I. INTRODUCTION:

Telmisartan is an angiotensin II receptor antagonist (angiotensin receptor blocker, ARB) used in the management of hypertension. Telmisartan shows high affinity for the angiotensin II receptor type 1 (AT₁), with a binding affinity 3000 times greater for AT₁ than AT₂. It has the longest half-life of any ARB (24 hours) and the largest volume of distribution.


In addition to blocking the RAs, telmisartan acts as a selective modulator of peroxisome proliferator-activated receptor gamma (PPAR- γ), a central regulator of insulin and glucose

metabolism. It is believed that telmisartan's dual mode of action may provide protective benefits against the vascular and renal damage caused by diabetes and cardiovascular disease (CVD).

MARKETED BRANDS IN INDIA:

It is marketed under the trade names CRESAR tabs by CIPLA and STAMLO-T tab by Dr. Reddys, TARGIT tab by Pfizer TELEACT-R tab by Ranbaxy, TELISTA by Lupin Pharma.

WORLDWIDE ECONOMY & SALES:



INDIAN MARKET:

Approximately Indian market takes 5th position in telmisartan production world wide. Annual sales of Indian market for this molecule increasing year by year. Approximate Indian market sales are listed below.

Telmisartan Sales in last three Consecutive years:

S.No	Year	Indian market in Cr.
1.	2009-2010	210
2.	2010-2011	274
3.	2011-2012	320


COST BENEFIT OF NEW SYNTHETIC TECHNOLOGY:

S.No	<u>Production Cost per 1 ton</u>		<u>Cost benefit per</u>
	Older Synthetic technology	Newly designed synthetic technology	<u>one ton</u>
1.	30 lacs	21 lacs	9 lacs

II. BASIC WORK-UP:

I developed the key strategy for the construction of bis-benzimidazole by reductive cyclization of o-nitroanilines with butylaldehyde and cyclo-condensation of aromatic aldehydes with o-phenylenediamine. The simple operation and workup procedure, along with the low production costs, make it suitable for industrial production and will benefit those with cardiovascular disease.

Synthetic route:



Reagents and Conditions:


- (a) CHCl_3 , 10% aqueous NaOH solution, 60°C .
- (b) Fuming HNO_3 , -15°C .
- (c) Me_2SO_4 , 2.7 mol/l aqueous NaOH Solution, 0°C - 70°C .
- (d) O-phenylenediamine, H_2O_2 , CH_3OH , rt.
- (e) K_2CO_3 , Me_2SO_4 , DMF, 0°C to rt.
- (f) Concentrated Ammonia solution, EtOH, 90°C .
- (g) n-prCHO, $\text{Na}_2\text{S}_2\text{O}_4$, MeOH/ H_2O (1:1) reflux.

Instruments and Techniques Used:

1. Heating mantels, Sunshine Instruments, Coimbatore.
2. Rotamantles, Remi Elektrotechnik Limited, Mumbai.
3. Magnetic stirrer with hot plate, Remi Elektrotechnik Limited, Mumbai.
4. Magnetic stirrers, Scientific International, New Delhi, Delhi
5. Laboratory Static mixtures, Fluidyne Instruments Pvt.Ltd.
6. Digital Melting Point Apparatus, Labindia Analytical Instruments Private Limited, Thane.
7. PG Instruments T60 UV/VIS Spectrophotometer.
8. Waters 486 HPLC UV-Visible Detector.
9. Column chromatography (Preparative)
10. Thin layer Chromatography (Analytical)
11. Recrystallization (Bi-solvent and single solvent techniques)
12. Other glass wares of High grade borosilicate quality. Etc.


Highly practical and cost-efficient synthesis of Bisbenzimidazole (2-n-Propyl-4-methyl-6-(1-methylbenzimidazole-2-yl) benzimidazole), Key Intermediate of Telmisartan.

Synthetic route :



STEP WISE SYNTHESIS:

Step: 1 Synthesis of 4-Hydroxy-3-methylbenzaldehyde (2)



Procedure:

To 300 ml of an aqueous 20% sodium hydroxide solution are added 27.0 g of the catalyst (fixed β -cyclodextrin) and 3.0 g of o-cresol. The resulting mixture is heated to 60° C. while agitating by means of a magnetic stirrer. Then, while drop wise adding 18 ml of

chloroform to the mixture and the reaction is allowed to proceed for 12 hours. After completion of the reaction, the catalyst is removed by decantation. The recovery of the catalyst is 86 - 94%. The obtained reaction mixture is acidified with hydrochloric acid, and subjected to extractions each with 300 ml of diethyl ether 3 times. The ether layer is washed with water, and then dried, there by to obtain 3.9 g of a product. The analysis of the product by means of UV spectra shows that the product is a mixture of 0.61 g of 4-hydroxy-3-methylbenzaldehyde and 0.24 g of o-cresol. Namely, the yield of 4-hydroxy-3-methyl-benzaldehyde is 87% on molar basis, and the selectivity is 100%.


Preparation of Fixed beta cyclodextrin:

Hydroxyl groups of β -cyclodextrin are crosslinked with 2-hydroxy-n-propylene group to prepare a solid, fixed β -cyclodextrin in the manner as described below.

In 80 ml of an aqueous 50% sodium hydroxide solution is dissolved 50 g of β -cyclodextrin. To the resulting solution is added 50 mg of sodium borohydride, and 34 ml of epichlorohydrin is drop wise added to the mixture with agitating by means of a magnetic stirrer. The resulting mixture is allowed to react at 50° C for 40 minutes. The resulting solid is washed with acetone 3 times and with water thoroughly, and then dried in vacuum at 60° C. for 12 hours. Thus, there is obtained 50 g of a fixed β -cyclodextrin which is white particulate matter. As a result of elementary analysis of the fixed β -cyclodextrin, the carbon and hydrogen contents are found to be 47.0% and 6.6%, respectively. Therefore, the fixed β -cyclodextrin contains 87% by weight of β -cyclodextrin.

S.No	Compound Information	Report	
		Practical	Reference
1.	CAS No:	<u>15174-69-3</u>	-
2.	Physical Appearance:	Tan to brown colour crystalline powder in Nature	Tan to brown colour crystalline powder in Nature
3.	Melting point:	108 to 115 °C	115-117 °C
4.	Yeild on molar Basis:	72 to 78 %	87%
5.	Purity (on the basis of UV spectra)	81 to 83 %	-

Step: 2 Synthesis of 4-Hydroxy-3-methyl-5-nitrobenzaldehyde (3)




Procedure:

To a stirring fuming nitric acid (21 ml) was added slowly aldehyde 2 (3.0 g, 0.022 mol) portion-wise over the course of 40 min at -15 °C and stirred for 1 hr at this temperature. Then the reaction mixture was poured slowly into a mixture of ice-water (63 ml) with stirring. The resultant suspension was filtered and the collected solid washed with water and dried under vacuum to give compound 3. (3.32 g, 83%) as brown solid; mp: 150 - 152 °C;

S.No	Compound Information	Report	
		Practical	Reference
1.	CAS No:	<u>Not Available</u>	-
2.	Physical Appearance:	Brown colour solid in Nature	Tan to brown colour crystalline powder in Nature
3.	Melting point:	148 to 156 °C	150 - 152 °C
4.	Yeild on molar Basis:	81 to 86 %	83%
5.	Purity (on the basis of UV spectra)	78 to 81%	-

Step: 3 Synthesis of 4-Methoxy-3-methyl-5-nitrobenzaldehyde (4)




Procedure:

After a solution of compound 3 (2.71 g, .015 mol) in 2.7 mol/l aqueous sodium hydroxide solution (6.74 ml) was stirred for 0.5 h, dimethyl sulfate (1.65 ml, 0.017 mol) was added drop wise at 0 °C over 15 min. Then the reaction mixture was heated to 70 °C and stirred for 6 h. The resultant mixture was filtered, after cooling, and collected solid washed with water and dried under vacuum to give anisole 4 (2.62 g, 90%) as yellow solid; mp: 75 - 77 °C;

S.No	Compound Information	Report	
		Practical	Reference
1.	CAS No:	Not Available	-
2.	Physical Appearance:	Yellow colour solid in Nature	Yellow colour solid in Nature
3.	Melting point:	72 to 78 °C	75 - 77 °C
4.	Yeild on molar Basis:	89 to 91 %	90 %
5.	Purity (on the basis of UV spectra)	77 to 79 %	-

Step: 4 Synthesis of 2-(4-Methoxy-3-methyl-5-nitrophenyl)-1-methyl-1H-benz-imidazole (5)




Procedure:

To a solution of o-phenylenediamine (3.35 g, 0.031 mol) in methanol (25 ml) was added anisole 4 (2.5 g, 0.013 mol). The mixture was cooled to 5 °C and 30% hydrogen peroxide (3.85 ml, 0.037 mol) was added drop wise, at such rate that the temperature was maintained at 5 - 10 °C, for 4 h after completion of the addition of the hydrogen peroxide. Then the reaction mixture was poured slowly into a mixture of ice-water (75 ml) with stirring. The resultant suspension was filtered and the collected solid washed with water and dried under vacuum. The resultant solid was then dissolved in N, N-dimethylformamide (15 ml), potassium carbonate (3.54 g, 0.025 mol) was added, and the mixture was stirred for 0.5 h. After cooling to 5 °C, dimethyl sulfate (1.19 ml, 0.012 mol) was added drop wise at 5 °C over 30 min, then warmed to room temperature and stirred for 3 h. The reaction mixture was poured slowly into a mixture of ice-water (75 ml) with stirring. The resultant suspension was filtered and the collected solid washed with water and dried under vacuum to give crude compound 5, which was recrystallized from ethyl acetate to afford compound 5 (2.86 g, 75%) as light yellow solid; mp: 125 - 127 °C;

S.No	Compound Information	Report	
		Practical	Reference
1.	CAS No:	Not Available	-
2.	Physical Appearance:	Light yellow colour solid in Nature	Light yellow colour solid in Nature
3.	Melting point:	120 to 125 °C	125 - 127 °C
4.	Yield on molar Basis:	71 to 73 %	75 %
5.	Purity (on the basis of UV spectra)	84 to 85 %	-

Step: 5 Synthesis of 2-Methyl-4-(1-methyl-1H-benzimidazol-2-yl)-6-nitrobenzen-amine (6)




Procedure:

The compound 5 (2.97 g, 0.01 mol) was dissolved in a mixture of ethanol (10 ml) and concentrated ammonia solution (10 ml) in autoclave (Autoclave ammonolysis), then the stirred mixture was heated at 90 °C for 6 h. After cooling, the reaction mixture was poured slowly into water (30 ml) with stirring. The resultant suspension was filtered and the collected solid washed with water and dried under vacuum to give compound 6 (2.68 g, 95%) as brown solid; mp: 164 -165 °C;

S.No	Compound Information	Report	
		Practical	Reference
1.	CAS No:	Not Available	-
2.	Physical Appearance:	Brown colour crystalline powder in Nature	Brown colour crystalline powder in Nature
3.	Melting point:	161 to 165 °C	164 – 165 °C
4.	Yield on molar Basis:	89 to 94 %	95 %
5.	Purity (on the basis of UV spectra)	91 – 94 %	-

Step: 6 Synthesis of 1, 7' -Dimethyl-2'-propyl-2, 5'-bi (1H-benzimidazole) (7)



Procedure:

The compound 6 (2 g, 0.007 mol) and sodium dithionite (7.4 g, 0.04 mol) was suspended in a mixture (50:50) of methanol (16 ml) and water (16 ml), butyl aldehyde (12.5 ml, 0.014 mol) was added, then the stirred mixture was heated at reflux (70°C) for 12 h. After cooling, the reaction mixture was poured slowly into water (120 ml) with stirring. The resultant suspension was filtered and the collected solid washed with water, and crystallized from toluene to give bis-benzimidazole 7 (1.85 g, 85%) as light yellow solid; mp: 138 - 139 °C;

S.No	Compound Information	Report	
		Practical	Reference
1.	CAS No:	Not Available	-
2.	Physical Appearance:	Colorless to Light yellow solid in Nature.	Colorless to Light yellow solid in Nature.
3.	Melting point:	136 to 141°C	138 - 139 °C
4.	Yield on molar Basis:	81 to 86 %	85 %
5.	Purity (on the basis of UV spectra)	87 – 89 %	-



Vishnu Institute of Pharmaceutical Education & Research

(Approved by AICTE & Affiliated to JNTU)

Vishnupur, Narsapur, Medak District - 502 313. Ph. : 08458 287589, Fax : 287588 E-mail : Viper.nsp@gmail.com

RESEARCH PROJECT

Phytochemical screening and Invitro Anti microbial, Anthelmintic, Analgesic and Anti-inflammatory activities of different extracts of Polyherbal formulation.

(Rasona pinda)

RASONA PINDA (List of Ingredients)

Sl. no.	Name of the Drug	Latin Name	Parts Used
1	Peta	Banincasa hispida (THUMB) Cong	Fruit/Seed
2	Rason	Allium Sativum Linn	Bulbs
3	Til Tail	Sesamum Indicum Linn	Seeds
4	Hingu	Ferula Asfoetida Linn	Resinous exudate of the Root
5	Dalchini	Cinnamomum Verum Presl	Bark, Oil
6	Jeera	Cuminum Cyminum Linn	Roots
7	Rai		-
8	Lavang	Syzygium Aromaticum (Linn) Rhizome	Dried flower bud
9	Shunti	Zingiber Officinalis Roxb	Rhizome
10	Kali Mirchi	Piper Nigrum Linn	Fruits
11	Pippali	Piper Longum Linn	Roots, dried spikes
12	Akara Karra	Anacyclus Pyrethrum DC	Roots
13	Tejpatra		-
14	Kala Jeera	Nigella sativa Linn	seeds
15	Azwain	Trachyspermum Robxburghianum (DC) Craib	Fruits
16	Pippali mool	Piper Longum Linn	Root
17	Dhaniya	Coriandrum Sativum Linn	Leaves Fruits
18	Saindava Lavan		-
19	Vayuvindang	Embelia Ribes Burm.F.	Roots, Leaves, fruits
20	Eranda mool	Carica Papaya.L	Roots
21	Guggulu	Commiphora Mukul (Hook.ex stocks) engl	Resinous gum



Preparation of Rasona pinda (Prepared Formulation)

Take one riped Peta (Gummadikaya) of 5 kg and remove the stalk and kept a side. Remove all the seeds having within the Peta and fill it with Garlic (remove the husk and ankur radical and plumule) from the garlic of about 400 grams (40 tola) 1 tola = 10 grams, 40 tola = 400 grams) then reinstall the stalk on its position as usual and seal it with the cloth and multhani mitti). This is subjected to putapaka in cow dung cakes till multhani mitti gets become red. Now remove the peta and allow it to cool. The scrach the multhani mitti and cloth from the peta and clean it with hands. Then grind the peta & lason to make the kalka. Take 1 big frying pan made up of brass and coated with "Kalai" and put 200 grams of Til tail in the frying pan and heat it. Seasoning it with Hing - 1 tola, Dalchini, Jeera, Rayi, Lavang 2 ½, tola each add the kalk of peta and cook it for some time. After it gets cool, add prakshep dravya and fine powder of shunti, Kalimirchi, Pippali, Akarakarra, Dalchini, Tejpatra, Kalajeera, Azwain, Pippalimool, Dhaniya, and jeera of 1 tola each and saindava lavan 5 tolas. Mix it thoroughly and keep it in a glass container.

MATERIALS AND METHODS

Materials:

Borosil soxhlet extractor, solvent evaporator, Analgesiometer or Eddy's hot plate [Purchased from INCO] Digital balance [ELB 300, Manufactured from SHIMADZU], Tramadol Hcl inj (Tramazac^R, Manufactured from Zydus Alidac Batch No. AFH 1063), Gentamicin which is used as a standard in this experiment was purchased from local market (manufactured by Concord Drugs Limited, batch number 91215), Mebendazole also purchased from local market Syringes and needles were purchased from local market. All reagents and chemicals used were AR grade.

Plant Material

Polyherbal powder sample was collected from Ayurvedic Research Centre, Erragadda, Hyderabad.

Preparation of Extracts

2 Kg of Polyherbal powder sample was collected from Dr. B.R Ambedkar Ayurvedic Medical Sciences and Research Hyderabad. Crushed to coarse powder and passed through sieve # 44. The sieved powder was stored in air tight, high density polyethylene containers before extraction. Extraction was performed by using soxhlet apparatus (12 hours), carried out first

with petroleum ether (60-80 °C) to de-fat the material. The de-fatted material was then extracted with Benzene, Chloroform, Acetone, ethanol and water to get respective extract¹. The extracts were concentrated for further studies at reduced pressure and temperature in a rotary evaporator and tested for the presence of secondary metabolites by different phytochemical tests¹. Different concentrations of extract were prepared by dissolving the fine powder of extract in 10% aqueous dimethylsulfoxide (DMSO) for further study²

Preliminary Phytochemical Analysis

The Petroleum, Benzene, Chloroform, Acetone, ethanol and aqueous extract were screened for the phytochemical constituents using the standard method^{1,3}

The phytochemical components analyzed were alkaloids, steroids, starch, proteins, anthraquinone glycosides, saponins, flavonoids, tannins, and cardiac glycosides.

Preparation of bacteria

The bacteria *Staphylococcus aureus*, *Bacillus cereus*, *Pseudomonas aeruginosa*, *Escherichia Coli* were purchased from M.T.C.C Institute of Microbial Technology, Chandigarh, India (Invoice No. 9/7/5790). The ability of the various extracts to inhibit growth of clinical bacteria and fungi isolates was determined using the Agar disc diffusion method. Sterile filter paper discs, 11 mm in diameter were impregnated with each extract at different concentration and dried at 30° C in the static incubator. They were then carefully placed aseptically with a forceps on the surface of the Mueller-Hinton (MH) agar plates⁴ that were pre-inoculated with the 24 hr culture of bacteria and 0.1 ml spore suspension (1×10^5 spores/ml). The control antibiotics disc containing gentamicin (40µg/ml) was placed on each of the inoculated plates of nutrient agar. The plates were left on the bench undisturbed for few minutes, after which the bacterial culture plates were incubated at 37° C for 24h. The external diameters of visible zones of growth inhibition were measured after incubation⁵.

with petroleum ether (60-80 °C) to de-fat the material. The de-fatted material was then extracted with Benzene, Chloroform, Acetone, ethanol and water to get respective extract¹. The extracts were concentrated for further studies at reduced pressure and temperature in a rotary evaporator and tested for the presence of secondary metabolites by different phytochemical tests¹. Different concentrations of extract were prepared by dissolving the fine powder of extract in 10% aqueous dimethylsulfoxide (DMSO) for further study²

Preliminary Phytochemical Analysis

The Petroleum, Benzene, Chloroform, Acetone, ethanol and aqueous extract were screened for the phytochemical constituents using the standard method^{1,3}

The phytochemical components analyzed were alkaloids, steroids, starch, proteins, anthraquinone glycosides, saponins, flavonoids, tannins, and cardiac glycosides.

Preparation of bacteria

The bacteria *Staphylococcus aureus*, *Bacillus cereus*, *Pseudomonas aeruginosa*, *Escherichia Coli* were purchased from M.T.C.C Institute of Microbial Technology, Chandigarh, India (Invoice No. 9/7/5790). The ability of the various extracts to inhibit growth of clinical bacteria and fungi isolates was determined using the Agar disc diffusion method. Sterile filter paper discs, 11 mm in diameter were impregnated with each extract at different concentration and dried at 30° C in the static incubator. They were then carefully placed aseptically with a forceps on the surface of the Mueller-Hinton (MH) agar plates⁴ that were pre-inoculated with the 24 hr culture of bacteria and 0.1 ml spore suspension (1×10^5 spores/ml). The control antibiotics disc containing gentamicin (40µg/ml) was placed on each of the inoculated plates of nutrient agar. The plates were left on the bench undisturbed for few minutes, after which the bacterial culture plates were incubated at 37° C for 24h. The external diameters of visible zones of growth inhibition were measured after incubation⁵.

STATISTICAL ANALYSIS

Data collected in the study are expressed as the mean \pm standard error of mean (S.E.M.) and the statistical analysis was carried out by using one-way analysis of variance (ANOVA) method. P value of less than 0.05 was considered to be statistically significant. All groups were compared with dimethyl sulfoxide treated control group.

Analgesic Activity of Rasonapinda on Swiss albino mice

Animals

For the experiment Swiss albino mice of either sex, 3-4 weeks of age, weighing between 20-25 g, were procured from Mahaveer Enterprises, Hyderabad, India were used in the studies. Animals were maintained under standard environmental conditions (temperature: $24.0 \pm 1.0^\circ$), relative humidity: 55-65% and 12 h light/12 h dark cycle) and had free access to feed and water ad libitum. The animals were acclimatized to laboratory condition for one week prior to experiments. All protocols for animal experiment were approved by the Institutional Animal Ethical Committee (IAEC,), Shri Vishnu College of Pharmacy, Bhimavaram Andhra Pradesh.

Acute oral toxicity studies

Administration of doses

The Rasona panda was administered in a single dose by gavage using a stomach tube or a suitable intubation canula.

Animals should be fasted prior to dosing (e.g. in mouse, food but not water should be withheld for 3-4 hours). Following the period of fasting, the animals should be weighed and the test substance administered. After the substance has been administered, food may be withheld for 1-2 hours in mice. Where a dose is administered in fractions over a period of time, it may be necessary to provide the animals with food and water depending on the length of the period.

Groups of animals of a single sex are dosed in a stepwise procedure using the fixed doses of 5, 50, 300 and 2000 mg/kg (exceptionally an additional fixed dose of 5000 mg/kg may be considered. The initial dose level is selected on the basis of a sighting study as the dose expected to produce some signs of toxicity without causing severe toxic effects or mortality. Clinical signs and conditions associated with pain, suffering, and impending death, are described in detail in a separate OECD Guidance Document (8). Further groups of animals may be dosed at higher or lower fixed doses, depending on the presence or absence of signs of toxicity or mortality. This

procedure continues until the dose causing evident toxicity or no more than one death is identified, or when no effects are seen at the highest dose or when deaths occur at the lowest dose. Exceptionally, and only when justified by specific regulatory needs, the use of an additional upper fixed dose level of 5000 mg/kg may be considered. For reasons of animal welfare concern, testing of animals in GHS Category 5 ranges (2000-5000mg/kg) is discouraged and should only be considered when there is a strong likelihood that results of such a test have a direct relevance for protecting human or animal health or the environment. period of at least 24 hours will be allowed between the dosing of each animal. All animals should be observed for at least 14 days ⁶.

Analgesic screening:

Hot plate method

The animals were divided into five groups with five mice in each group. Group I animals received vehicle (normal saline), animals of Group II the animals were administered a 22.8 mg/kg (body weight i.p route) dose of standard drug (Tramadol HCl)⁷. While animals of Group III, group IV and group V were treated with 100, 300 and 500mg/ kg body weight (p.o.) of the crude extract of *Rasona pinda* respectively. The animals were placed on Eddy's hot plate kept at a temperature of 55±0.5°C. A cut off period of 15sec, was observed to avoid damage to the paw.⁸ Reaction time was recorded when animals licked their fore or hind paws, or jumped prior to and 0, 30, 60 and 90 min after oral administration of the samples^{9,10}

Statistical analysis

Statistical analysis for animal experiments was carried out using one-way ANOVA followed by Dunnet's multiple comparisons. The results obtained were compared with the vehicle control group. P- value < 0.05, 0.001 were considered to be statistically significant.

Formalin induced arthritis inflammation

Formalin (2% v/v) induced acute inflammatory model [12] the volume of the hind paw of the animals was measured initially using plethysmograph. After taking the initial reading, 0.1 ml of formalin (2% v/v in water) was injected into sub-plantar aponeurosis of the left hind foot. The paw volume was measured at 0, 30, 60, 90,120, 150,180 min after injection. Drugs were given orally 1 hr before formalin injection. The difference between the initial and subsequent reading gave the actual edema volume which was compared with control. The difference of average

values between treated animals and control group is calculated for each time interval and evaluated statistically.

Male wistar rats (150-190 g) were divided into five groups of five animals each. Inflammation was produced by subaponeurotic injection of 0.1 mL of 2 % w/v formalin in normal saline in the right hind paw of the rats on the first and third day. The extract (100, 300 and 500mg/kg) and distilled water (3 mL/kg) were administered orally. Indomethacin (5 mg/kg) given orally, was used as standard. Paw volume was measured by using plethysmograph (Glass model)

Statistical analysis

Data were expressed as the mean \pm SEM. The data were analyzed using one way analysis of variance (ANOVA) followed by Dunnet's test. Data were considered different at significance level of $p < 0.05$.

Table 1: Phytochemical Screening of Polyherbal formulation

Test	Name of the extract					
	Petroleum Ether	Benzene	Chloroform	Acetone	Ethanol	Aqueous
Alkaloids	+	+	+	+	+	+
Steroids	+	-	-	-	-	-
Carbohydrates	-	-	-	-	+	+
Starch	-	-	-	-	-	-
Proteins	-	-	-	-	-	-
Glycosides	-	-	-	+	+	+
Tannins & Phenolics	-	-	-	+	+	+
Test for flavonoids	-	-	-	-	+	+

Note: '+' Indicates Presence, '-' Indicates Absence

Table:8 Effect of *Rasona pinda* extract on latency to hot plate test.

Treatment group	Post drug Reaction time in sec (Mean \pm SEM)				
	0min	15 min	30 min	60 min	90 min
Control	4.73 \pm 0.38	5.67 \pm 0.361	7.26 \pm 0.428	7.38 \pm 0.470	7.18 \pm 0.354
Standard (Tramadol Hcl 22.8 mg/kg i.p)	7.96 \pm 0.985**	12.04 \pm 0.269***	12.32 \pm 0.304***	12.63 \pm 0.386***	13.18 \pm 0.226***
100mg/kg Rasona pinda (p.o)	5.24 \pm 0.688	7.37 \pm 0.563	7.03 \pm 0.504	8.414 \pm 0.795	12.12 \pm 0.611***
300 mg/kg Rasona pinda(p.o)	5.98 \pm 0.921	7.752 \pm 0.585	10.13 \pm 0.742**	11.57 \pm 0.688***	13.18 \pm 0.228***
500 mg/kg Rasona pinda(p.o)	5.58 \pm 0.845	8.19 \pm 0.952*	11.04 \pm 0.423***	11.95 \pm 0.534***	12.94 \pm 0.265***

All values are expressed as Mean \pm SEM, n= 5, One way Analysis of Variance (ANOVA) followed by Dunnet's test. The minimum value of $p < 0.05$ was considered as significant. * $p < 0.05$, ** $p < 0.01$, *** $P < 0.001$ as compared with control group, both standard and extract treated group.

Table:9 Anti inflammatory activity of Rasona Pinda on formalin induced rat paw edema

Treatment group	Paw Volume in ml (Mean ± SEM)						
	0min	30 min	60 min	90 min	120 min	150 min	180 min
Control	0.062±0.0074	0.206± 0.048	0.354± 0.030	0.299±0.0677	0.407± 0.061	0.392±0.369	0.624±0.074
Standard (Indomethacin)	0.0346±0.0038***	0.0516±0.0105***	0.097±0.018***	0.062±0.0223***	0.086±0.0060***	0.1177±0.0368***	0.351±0.9417**
100mg/kg Rasona pinda (p.o)	0.0841±0.0026**	0.084±0.0165**	0.170±0.039**	0.070±0.0108**	0.148±0.0579**	0.310±0.0183	0.700±0.0242
300 mg/kg Rasona pinda(p.o)	0.0816±0.0017*	0.0577±0.0111**	0.0102±0.019***	0.118±0.0377*	0.183±0.066*	0.223±0.0483*	0.545±0.0566
500 mg/kg Rasona pinda(p.o)	0.042±0.0030*	0.075±0.0041**	0.103±0.0592***	0.079±0.0244**	0.078±0.013***	0.209±0.0543*	0.414±0.066*

All values are expressed as Mean ± SEM, n= 5, One way Analysis of Variance (ANOVA) followed by Dunnet's test. The minimum value of $p < 0.05$ was considered as significant. * $p < 0.05$, ** $p < 0.01$, *** $P < 0.001$ as compared with control group, both standard and extract treated group.

Results

From table-2, In Vitro Antimicrobial activity of polyherbal formulation benzene extract has shown significant *zone of inhibition* (ZOI) with 500mg($p < 0.01$) and 1000mg($p < 0.001$) on *S.aureus*. All doses of benzene has shown significant effect $p < 0.001$ on *E.coli*, Benzene extract has shown effect at 250mg($p < 0.05$), 500mg($p < 0.01$), 1000mg($p < 0.001$) on *B.cereus*, extract has also shown significant effect at 250mg($p < 0.01$), 500mg($p < 0.001$) and 1000mg ($p < 0.001$).

From table-3 $CHCl_3$ has shown significant effect at 500mg/kg ($p < 0.001$) and 1000 mg/kg ($p < 0.001$) on *S.aureus*. $CHCl_3$ has shown significant effect on 250mg/kg ($p < 0.01$) 500mg/kg ($p < 0.001$) 1000mg/kg ($p < 0.001$) on *E.coli*. $CHCl_3$ has shown significant effect at a dose of 500mg/kg ($p < 0.01$) 1000mg/kg ($p < 0.001$) on *B.cereus*. $CHCl_3$ has shown significant effect at a dose of 500mg/kg ($p < 0.001$) 1000mg/kg ($p < 0.001$).

From table-4, acetone extract has shown a significant effect on *S.aureus* at 250mg/kg($p < 0.05$) 500mg/kg($p < 0.01$) 100mg/kg(0.001). on *E.coli* shown significant effect doses at doses of

250,500,1000mg/kg($p<0.001$), on *B.cereus* has shown significant effect at 500mg($p<0.05$) &1000mg/kg ($p<0.001$) on *P.aeruginosa* at 500mg($p<0.01$) & 1000mg/kg ($p<0.001$).

From table-5 Ethanolic extract has shown significant effect on *S.aureus* at 250mg/kg ($p<0.05$), 500mg/kg($p<0.001$) & 1000mg/kg ($p<0.001$).on *E.coli* all doses has shown significant effect ($p<0.001$) on *B.cereus* has shown significant at a dose of 500mg/kg ($p<0.05$) &1000mg/kg ($p<0.001$).on *P.aeruginosa* 500mg &1000 mg/kg ($p<0.001$).

From table-6 Aqueous extract is against all microorganisms at 500&1000mg/kg

From table-7, We can conclude that *Rasona pinda* a Polyhedral Formulation has shown decrease in *time of paralysis* and *time of death* as the dose is increased. Standard mebendazole has shown time of paralysis at 8 min 30 sec and time of death 15min 35 sec.1000mg/ml of rasona pinda has shown decrease time of paralysis i.e. 10min29 sec and time of death 17min 30seconds.

From table- 8, *Rasona pinda* has significant effect at 500mg/kg($p<0.05$) after 5 min time interval after dosing the animal group .After 30min of treatment with *Rasona pinda* has Increase in post during reaction time in sec at 300mg/kg($p<0.001$) and 500 mg/kg ($p<0.001$).After 60min of during the animal group 300 and 500mg/kg has shown increase post during reaction time in sec ($p<0.001$).After 90 min after dosing at all doses 100,300,500mg/kg has shown significant($p<0.001$).

Discussion

The analgesic property of *Rasona pinda* can also probably be due to the blockade of the effects or the synthesis and /or release of PGs and /or other endogenous substances that excite pain nerve endings¹¹

The hotplate method test are considered to be selective to examine compounds acting through opioid receptor; the extract increased mean basal latency which indicates that it may act via centrally mediated analgesic mechanism. Narcotic analgesics inhibit both peripheral and central mechanism of pain, while non steroidal anti-inflammatory drugs inhibit only peripheral pain^{12,13}. Based on the results of the present study, we conclude that the plant extract possesses strong analgesic potential. However, further studies are necessary to examine underlying mechanisms of analgesic and antioxidant effects and to isolate the active compound (s) responsible for these pharmacological activities. The presence of some of the phytochemical components like saponins, tannins and phenolic

Table 2: Invitro Antimicrobial activity of Polyherbal Formulation Benzene extract

Treatment	<i>Staphylococcus Aureus</i> (Zone of inhibition in mm)	<i>E-Coli</i> (Zone of inhibition in mm)	<i>B.Cereus</i> (Zone of inhibition in mm)	<i>P.Aerugenosa</i> (Zone of inhibition in mm)
Control (DMSO)	13.67±1.202	13±0.577	13.67±0.66	18±0.577
40µg/ml Gentamicin	36±3.055***	44±0.577***	38.67±3.84***	42.67±2.404***
250 mg/ml	21.67±1.453	29±2.64***	23±2.082*	23±1.00**
500 mg/ml	26.33±2.603**	36±0.577***	29±1.732**	35.67±0.881***
1000 mg/ml	35.33±0.881***	39±0.577***	32.33±1.202***	42.33±0.881***

Values are expressed as mean + SEM. and analyzed by One way Analysis of variance (ANOVA) followed by Dunnet's t test, *P< 0.05, **P<0.01, ***P<0.001.

Table 3: Invitro Antimicrobial activity of Polyherbal Formulation CHCl₃ Extract

Treatment	<i>Staphylococcus Aureus</i> (Zone of inhibition in mm)	<i>E-Coli</i> (Zone of inhibition in mm)	<i>B.Cereus</i> (Zone of inhibition in mm)	<i>P.Aerugenosa</i> (Zone of inhibition in mm)
Control (DMSO)	13.67±1.202	13±0.577	13.67±0.66	18±0.577
40µg/ml Gentamicin	36±3.055***	44±0.577***	38.67±3.84***	42.67±2.404***
250 mg/ml	20.33±0.881	20.33±1.202**	21.67±1.45	22.33±2.028
500 mg/ml	33.67±1.45***	27.33±1.202***	26.17±1.59**	32.67±2.404***
1000 mg/ml	33.67±3.712***	34±1.155***	34.33±1.85***	34±1.155***

Values are expressed as mean + SEM. and analyzed by One way Analysis of variance (ANOVA) followed by Dunnet's t test, *P< 0.05, **P<0.01, ***P<0.001.

Table 4: Invitro Antimicrobial activity of Polyherbal Formulation Acetone Extract

Treatment	<i>Staphylococcus Aureus</i> (Zone of inhibition in mm)	<i>E-Coli</i> (Zone of inhibition in mm)	<i>B.Cereus</i> (Zone of inhibition in mm)	<i>P.Aerugenosa</i> (Zone of inhibition in mm)
Control (DMSO)	13.67±1.202	13±0.577	13.67±0.667	18±0.577
40µg/ml Gentamicin	36±3.055***	44±0.577***	38.67±3.84***	42.67±2.404***
250 mg/ml	27±1.155*	26±1.155***	21±3.215	25±1.528
500 mg/ml	21.67±4.372**	28.67±1.453***	29.67±2.33*	30±3.055**
1000 mg/ml	34.33±0.881***	34.33±1.202***	35.33±3.383***	37.33±1.667***

Values are expressed as mean + SEM. and analyzed by One way Analysis of variance (ANOVA) followed by Dunnet's t test, *P< 0.05, **P<0.01, ***P<0.001.

Table 5: Invitro Antimicrobial activity of Polyherbal Formulation Ethanolic Extract

Treatment	<i>Staphylococcus Aureus</i> (Zone of inhibition in mm)	<i>E-Coli</i> (Zone of inhibition in mm)	<i>B.Cereus</i> (Zone of inhibition in mm)	<i>P.Aerugenosa</i> (Zone of inhibition in mm)
Control (DMSO)	13.67±1.202	13±0.577	13.67±0.667	18±0.577
40µg/ml Gentamicin	36±3.055***	44±0.577***	38.67±3.84***	42.67±2.404***
250 mg/ml	22±1.732*	23.33±0.881***	19.33±1.453	17±0.5774
500 mg/ml	28±0.577***	27.67±0.881***	23±0.577*	24.33±1.202*
1000 mg/ml	32.67±0.881***	34.33±2.028***	32.33±1.333***	37.67±1.453***

Values are expressed as mean + SEM. and analyzed by One way Analysis of variance (ANOVA) followed by Dunnet's t test, *P< 0.05, **P<0.01, ***P<0.001.

Table 6: Invitro Antimicrobial activity of Polyherbal Formulation Aqueous Extract

Treatment	<i>Staphylococcus Aureus</i> (Zone of inhibition in mm)	<i>E-Coli</i> (Zone of inhibition in mm)	<i>B.Cereus</i> (Zone of inhibition in mm)	<i>P.Aerugenosa</i> (Zone of inhibition in mm)
Control (DMSO)	13.67±1.202	13±0.577	13.67±0.667	18±0.577
40µg/ml Gentamicin	36±3.055***	44±0.577***	38.67±3.84***	42.67±2.404***
250 mg/ml	20.67±1.764	19.67±1.202	19±1.528	17.67±0.881
500 mg/ml	26±1.155**	25.33±1.764*	26.33±1.453**	25.67±1.856*
1000 mg/ml	36±1.155***	29.67±4.631**	35.67±1.764***	34.67±0.881***







Values are expressed as mean + SEM. and analyzed by One way Analysis of variance (ANOVA) followed by Dunnet's t test, *P< 0.05, **P<0.01, ***P<0.001.

Table: 7 Effect of different extracts of Polyherbal formulation on *Pheretima posthuma* (earth worms).


Treatment Groups	Concentration in mg/ml	<i>Pheretima posthuma</i>	
		Time of paralysis(min)	Time of death(min)
Standard	250mg/ml	8.30	15.35
Rasona pinda	100 mg/ml	22.50	26.36
	250 mg/ml	18.38	25.50
	500mg/ml	16.42	19.20
	1000mg/ml	10.20	17.30

As mentioned in the above table readings are the effect of *Rasona pinda* on five earth worms i.e. Time of paralysis and time of death.


compounds have been attributed to the antibacterial activity of the crude drugs observed. Tannins and alkaloids were demonstrated to inhibit the growth of *E.coli*, *P.aeruginosa*, *B.cereus* and *S.aureus*. The presence of these bioactive components in the crude drugs have been linked to their activities against disease causing microorganisms and also offering the plants to protect themselves against infection by pathogenic micro-organisms¹⁴.




Chloroform extract *B.Cereus*




Chloroform extract *P.aerugenosa*




Acetone *S.aureus*




Acetone *E-coli*











Acetone *B.Cereus*





Acetone *P.aerugenosa*












Statistical analysis Graphs of analgesic activity







Anti inflammatory Activity of Rasona pinda (Polyherbal formulation)




60 min Anti inflammatory




90 min Anti inflammatory




120 min anti inflammatory



150 min Anti Inflammatory



180 min Anti Inflammatory



References

1. Kokate C.K. Practical pharmacognosy. Vallabh prakashan New Delhi. Preliminary phytochemical screening, Chapter 6, pp106-111.
2. Shailendra S. Gurav, Vijay D. Gulkari, Nandkishore J. Duragkar and Aarun T. Patil IJPT January 2008 7 (1) P.No 21-24
3. Khandelwal K.R. Practical pharmacognosy. Nirali prakashan Pune. Techniques and experiments, Chapter 40, 17thed. pp 149-153.
4. National Committee for Clinical Laboratory Standards. Protocols for evaluating Dehydrated Mueller-Hinton agar. Approved Standard M6- A. Wayne, PA: NCCLS, 1996.
5. M. A. Ekpo* and P. C. Etim. 'Antimicrobial activity of ethanolic and aqueous extracts of *Sida acuta* on microorganisms from skin infections' Journal of Medicinal Plants Research Vol. 3(9), pp. 621-624, September, 2009 Available Online at <http://www.academicjournals.org/JMPR>.
6. OECD GUIDELINE FOR TESTING OF CHEMICALS Acute Oral Toxicity – Fixed Dose Procedure OECD-420
7. Sharma MC, Smita Sharma. Some Plant extracts used in pharmacologically activity of Anxiolytics, Antidepressant, Analgesic, and Anti-inflammatory activity. Digest Journal of Nanomaterials and Biostructures. March 2010; 5 (1): 223 – 227.
8. Franzotti EM, Santos CVF. Anti-inflammatory, analgesic activity and acute toxicity of *Sida cordifolia* (L). (*Malva-branca*). J. Ethnopharmacol. 2000; 72:273-278.
9. Eddy NB, Leimback D. Synthetic analgesic. II. Dithienyl butenyl and dithienyl butyl amines. J. Pharmacol. Exp. Ther. 1953; 107: 385-393
<http://jpet.aspetjournals.org/cgi/reprint/107/3/385>.
10. Toma W, Graciosa JS. Evaluation of the analgesic and antiedematogenic activities of *Quassia amara* barks extract. J. Ethnopharmacol 2003; 85: 19-23.
11. Priyanka Vijay, Rekha Vijay vergia. Analgesic, anti-inflammatory and antipyretic activity of *Cissus quadrangularis*. Journal of Pharmaceutical Science and Technology 2010; 2 (1):111-118)
12. Elisabetsky E, Amador TA. Analgesic activity of *psychotria colorata* (Willd.ex R. and S.). Muell. Arg. Alkaloids. J. Ethnopharmacol.1995; 48: 77-83.

13. (Pal S, Sen T, A.K. Chaudhuri AK. Neuropsychopharmacological profile of the methanolic fraction of *bryophyllum pinnatum* leaf extract. J. Pharm. Pharmacol. 1999;51: 313-18.)

14. El-Mahmood, A. M, Doughari, J. H. and Chanji, F. J. In vitro antibacterial activities of crude extracts of *Nauclea latifolia* and *Daniella oliveri*. Scientific Research and Essay 2008; 3(3), pp.102-105.





Date: 19-05-2018.

CERTIFICATE

This is to certify that Ms. **DIVYA SNEHA** (HT.NO.15DH1S0307) pursuing her M. Pharmacy in **VISHNU INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH** has carried out her project work in our Organization entitled "**DEVELOPMENT AND EVALUATION OF NARATRIPTAN ORODISPERSIBLE TABLETS**" in the department of pharmaceuticals from **18TH DECEMBER, 2017 TO 19TH MAY, 2018.**

During her tenure she was sincere, hardworking and Punctual in her Project work.

We wish her to success in her future career.

Authorized Signature


Mrs. Kajini Sura
Managing Director





Date: 19-05-2018.

CERTIFICATE

This is to certify that **Mr. HYDERABOINI ABHILASH (HT.NO.15DH1S0309)** pursuing his M.Pharmacy in **VISHNU INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH** has carried out his project work in our organization entitled **“FORMULATION DEVELOPMENT AND INVITRO EVALUATION OF FAMCICLOVIR MICROBEADS FOR SUSTAINED DRUG DELIVERY SYSTEM”** in the department of pharmaceutics from **18TH DECEMBER, 2017 TO 19TH MAY, 2018.**

During this tenure he was sincere, hard working and punctual in his project work.

We wish him success in his future career.

Authorized Signature


Mrs. Rajini Sara
Managing Director



Ref:APL/Project/P.Sampath Kumar/0211/2017

07th August, 2017

TO WHOM SO EVER IT MAY CONCERN

This is to certify that **Mr.P.Sampath Kumar, H.T.No: 15DH1S0316** is a bonafide student of **Vishnu Institute of Pharmaceutical Education and Research, Vishnupur,Narsapur,Medak Telangana**. Has undergone project work in our organization from **21-01-2017 to 07-08-2017**, as a part of *partial fulfillment* of his M-Pharmacy course.

The title of the project is "**Formulation and Evaluation of Transdermal Patches of Pioglitazone**".

During the aforesaid period, we found his hard working, sincere and learning attitude.

With Best Wishes.

For **ACTIVE PHARMA LABS**



Authorized Signatory